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Chapter 1 – General Introduction
Brain aging: demographic and biological perspectives
With a rapid rise in the number of old and very old individuals, the need for a
comprehensive understanding of brain aging is growing1. Current data indicate
that age-related disorders such as dementia and stroke impose a great burden
on patients, families and health care systems2,3. The term “Brain Aging” denotes
a constellation of morphological and neurophysiological alterations in the brain
that ultimately leads to impairments in motor, cognitive and social skills4. A pro-
gressive accumulation of damaged molecules and impaired energy metabolism,
in the absence or failure of healing mechanisms, has been implicated in the
pathogenesis of brain aging4,5. Neuronal loss and diminished neuronal activity
and connectivity are among the key features in an aging brain6. While these
changes appear in many older individuals, recognition of factors that accelerate
the process is crucial. Unique features of the brain like its metabolic demand
and circulation might provide us with some clues for better understanding of
the mechanisms leading to the accelerated brain aging. Strategies to slow down
the process of brain aging might have implications in the treatment of age re-
lated disorders of the brain and contribute in better regulation of homeostasis
which is a main function of the brain.
The brain: a vascular organ
Although the brain accounts for about 2% of body weight, it consumes about
20% of total body oxygen and 25% of total body glucose. High metabolic de-
mand of the brain necessitates a remarkable fraction of cardiac output as well as
a relatively constant level of blood flow7. Cerebral blood flow is tightly regulated
by a harmonized function of the systemic and cerebrovascular circulations8.
The heart provides a driving force for cerebral perfusion, extra-cranial vessels
serve as a conduit for blood flow and send regulatory signals to the brain
stem and intra-cranial vessels act in concert to maintain adequate cerebral blood
flow despite fluctuations in systemic blood pressure9. In addition, there is a
tight coordination between neuronal activity and blood flow within the brain
parenchyma, known as functional hyperemia10. After a long-lasting exposure
to cardiovascular risk factors, these regulatory mechanisms may fail to func-
tion properly which ultimately results in cerebral hypoperfusion11. Ultimately,
chronic hypoperfusion might lead to neuronal energy crisis and impairs struc-
tural and functional integrity of the brain12.
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Cardiovascular and hemodynamic contribution to brain aging:
missing links
Different lines of evidence from epidemiological, pathological and neuroimaging
studies show that midlife cardiovascular risk factors are associated with im-
paired brain structure and function in old age13,14. Whether similar risk factors
in late life have similar influence on the brain is a matter of debate. For instance,
midlife hypertension has a well-established link with cerebrovascular events,
cerebral small vessel disease and cognitive impairment15. Nevertheless, it is
controversial whether all old and very old subjects benefit from lowering blood
pressure for preservation of their brain function16. On one hand systemic hyper-
tension might be seen as a risk factor that promotes brain vascular pathologies
and on the other hand in older people who carry a great load of brain vas-
cular pathologies higher blood pressure might be needed to overcome critical
threshold for brain perfusion17. Cerebral perfusion is dependent on the normal
function of the heart-brain axis9. During last couple of years several reports have
shown that heart failure is closely linked with structural and functional features
of brain aging18. Patients in advance stages of heart failure suffer from brain
hypoperfusion and it has been shown that restoration of cardiac function, for
example with cardiac transplantation, improves level of cerebral blood flow and
cognition19. Whether older people free of heart failure but with sub-optimal car-
diac function are also at a high risk for structural brain changes and cognitive
impairment is yet to be determined20. Decline in cognitive performance is one
of the key aspects of brain aging21. Cognitive impairment is common in old age
and is strongly associated with covert brain vascular pathologies such as white
matter hyperintensities, lacunar infarcts and cerebral microbleeds22. In line with
this evidence, previous studies reported that about 10% of patients with first-
time stroke suffer from pre-existing dementia23. Furthermore, it is frequently
reported that subjects with dementia and cognitive impairment have lower cere-
bral blood flow which may predispose them to develop cerebral infarcts24. Fur-
ther studies are needed to confirm whether assessment of cognitive performance
in old age can be a tool to identify subjects at high risk for developing stroke.
The brain acts as a central regulator of homeostasis by coordinating the physiol-
ogy of extraneural tissues4. Therefore, it is possible that accelerated brain aging
has detrimental effects not only on the brain function but also on the whole body
and might affect survival of older people. Accordingly, it has been shown that
structural and functional brain changes such as white matter hyperintensities,
brain atrophy and cognitive impairment associate with shorter survival in old
age25-27. However, role of cerebral perfusion, which is closely related to brain
aging, in the maintenance of health and survival remained unknown.
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Outline of this thesis
In the second chapter of this thesis, association between blood pressure and
cognitive decline in a general population of the oldest old people is tested. The
aim of chapter three is to answer the question whether the association between
higher blood pressure and cerebrovascular events in very old people is depen-
dent on the level of disability. Chapter four presents independent relationship
of visit-to-visit blood pressure variability with cognitive impairment and mani-
festations of cerebral small vessel disease. Chapters five, six and seven are ded-
icated to the link between cardiac functioning and features of brain aging in two
general populations of older people as well as in older subjects at high risk for
cardiovascular disease. In a systematic review and meta-analysis (chapter eight),
alterations of cerebral hemodynamics in patients with Alzheimers disease and
vascular dementia were evaluated. Chapter nine compares the predictive value
of cognitive impairment with Framingham stroke risk score in relation to future
risk of stroke in the oldest old. Chapter ten expands current knowledge on the
role of endothelial cells in regulation of cerebral blood flow. Chapter eleven
presents new evidence on the relationship between level of cerebral blood flow
and survival in old age. Chapter twelve summarizes key findings of this thesis
and discusses them in the context of current knowledge about cardiovascular
aspects of brain aging.
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High Blood Pressure and
Resilience to Physical and
Cognitive Decline
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Summary
The aim of this chapter is to evaluate the association of various blood pressure
measures at age 85 years with future decline in physical and cognitive function
in the oldest old. From the Leiden 85-plus Study, five hundred and seventy
two community-dwelling individuals aged 85 years were included. Blood pres-
sure was measured at age 85 years during home visits. Activities of daily living
(ADL) and Mini Mental State Examination (MMSE) were assessed at age 85 years
and annually thereafter up to age 90 years. On average, participants were fol-
lowed for 3.2 years. Cross-sectional and longitudinal analyses were performed
using linear regression models. Systolic, diastolic, mean arterial blood pressure
and pulse pressure were considered as the determinants. All analyses were ad-
justed for socio-demographic and cardiovascular factors. At age 85 years, higher
systolic blood pressure and pulse pressure were associated with lower ADL dis-
ability scores (both p =0.01). Similarly, higher systolic blood pressure, diastolic
blood pressure and mean arterial pressure were associated with higher MMSE
scores (all p<0.05). From age 85 years onward, higher systolic blood pressure
(p<0.001), mean arterial pressure (p=0.01) and pulse pressure (p=0.003) at age
85 years were associated with lower annual increases in ADL disability scores.
Likewise, both higher systolic (p=0.03) and pulse pressure (p=0.008) at age 85
years were associated with lower annual declines in MMSE scores. Additional
analyses showed that the association between high blood pressure and lower
annual decline in MMSE score was most pronounced in subjects with high ADL
disability. In the oldest old, higher systolic blood pressure and pulse pressure
are associated with resilience to physical and cognitive decline, especially in
those with pre-existing physical disability.
8
Introduction
Although high blood pressure is highly prevalent in the oldest old1, the rela-
tionship between high blood pressure and adverse medical outcomes remains
ambiguous2. In contrast to general expectation, it has been shown that low
blood pressure, rather than high blood pressure carries the greatest mortality
risk among the oldest old3. Low blood pressure may be a consequence of im-
minent heart failure, drug treatment or both4. On the other hand, high blood
pressure may be reactive and can have a survival benefit while ensuring per-
fusion in critical organs5. High blood pressure in middle age has detrimen-
tal effects on physical and cognitive disabilities in later life6,7. Paradoxically,
it has been suggested that in older people with physical disability, low blood
pressure may lead to cerebral hypoperfusion and accelerated cognitive decline8.
Since a considerable proportion of the oldest old individuals with physical dis-
abilities have widespread vascular damage9,10, high blood pressure might be a
compensatory mechanism to maintain organ perfusion, function of body and
brain, and ultimately prevention of physical and cognitive decline. Large ran-
domized clinical trials such as Hypertension in the Very Elderly Trial (HYVET)
showed no increased risk of cognitive impairment in very old subjects treated
for hypertension11. However, these clinical trials generally included healthy par-
ticipants, with low levels of co-morbidities and physical disability12. Therefore,
observational studies are needed to address the trajectories of cognitive function
dependent on blood pressure in unselected oldest old subjects with different
levels of disability.
In the Leiden 85-plus Study, we have recruited a population-based sample of
the oldest old with a wide variety of functional disability at age 85 years who
were prospectively followed for five years for clinical outcomes. This allowed
us to investigate the association between various blood pressure measures at
age 85 years with future physical and cognitive decline in the oldest old. The
underlying hypothesis under scrutiny is that older people with higher physical
disability may benefit from higher blood pressure to preserve perfusion of the
brain and to protect their cognitive function.
Methods
Study design and participants
The Leiden 85-plus Study is a population-based prospective follow-up study of
inhabitants of Leiden, the Netherlands. Between 1997 and 1999, all inhabitants of
1912-1914 birth cohort (n = 705) were contacted in the month of their 85th birth-
9
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day. There were no selection criteria on demographic features or health status. A
total of 599 (397 women and 202 men) subjects agreed to participate (85%) and
572 of them for whom blood pressure and functionality measures were avail-
able, were included in this study. As described earlier, there was no significant
difference between the demographic features and health status of those who par-
ticipated and those who did not13. Participants were visited within one month
after their 85th birthday at their homes where face-to-face interviews and neu-
ropsychological testing were done. After age 85 years, all subjects were revisited
annually until age 90 years for physical and cognitive assessment. On average,
participants were followed for 3.2 years. The Medical Ethical Committee of the
Leiden University Medical Centre approved the study, and informed consent
was obtained from all the subjects.
Blood pressure
Blood pressure was measured at baseline in the seated position, using a mercury
sphygmomanometer. During the home visits, two blood pressure measurements
were done two weeks apart. Blood pressure measurements were recorded after
at least 5 min of rest and no vigorous exercise in the preceding 30 min. The sys-
tolic blood pressure (SBP) was measured at Korotkoff sound 1, and the diastolic
blood pressure (DBP) was measured at Korotkoff sound 5. The mean value of
two measurements was calculated and used in further analyses. Mean arterial
pressure (MAP) and pulse pressure (PP) were calculated as 1/3(SBP) + 2/3(DBP)
and (SBP) - (DBP) respectively.
Physical and cognitive disability
To evaluate level of physical disability we used Groningen Activity Restriction
Scale (GARS) which is a non-disease-specific instrument to measure disability
in activities of daily living (ADL)14. In the GARS nine questions refer to ADL.
Using four-category response for each question, a score of 9 indicates no disabil-
ity while a score of 36 indicates highest disability in ADL. Based on the median
of ADL scores, participants were categorized into two groups with high (ADL
score ≥ 10) and low (ADL score < 10) physical disability. Disability in cognitive
function was assessed in all participants using Mini-Mental State Examination
(MMSE).
Demographic and clinical characteristics
Level of education was dichotomized into primary education and less versus
more than primary education. All participants were interviewed about their
10
smoking habits and alcohol intake. Use of antihypertensive medication was ex-
tracted from pharmacy records. Antihypertensive medications were categorized
into classes of calcium channel blockers, ACE inhibitors, beta blockers and di-
uretics. All participants were interviewed about their smoking habits and alco-
hol intake. Diabetes mellitus was considered present if diagnosed by the primary
care physician, if the non-fasting glucose level was greater than 11 mmol/L or if
a participant was taking antidiabetic medication. History of cardiovascular dis-
eases including ischemic heart disease and peripheral vascular disease as well
as stroke was obtained from general practitioners or nursing home physicians.
Statistical analysis
Since distribution of ADL and MMSE scores was skewed, summary statistics of
them are reported as median and inter quartile range (IQR). In cross-sectional
and longitudinal analyses, various measures of blood pressure were divided into
three strata and baseline or changes in physical and cognitive scores were calcu-
lated in each stratum. Change in physical and cognitive disability were defined
as the last ADL and MMSE scores minus first ADL and MMSE scores divided by
observed years of follow up. To determine the p value for the trend over strata
of blood pressure measures, linear regression analyses were performed using
tertiles of blood pressure measures as determinants. We did our cross-sectional
and longitudinal analyses in two steps. First, analyses were adjusted for sex and
then we did further adjustment for level of education, smoking status, alcohol in-
take, history of stroke, types of antihypertensive medications, diabetes mellitus
and history of cardiovascular diseases (including myocardial infarction, angina
pectoris, intermittent claudication, vascular Surgery, congestive heart failure, ar-
rhythmia). All longitudinal analyses were adjusted for baseline physical and
cognitive scores in both steps. Finally, in a stratified analysis, we tested whether
the association between blood pressure and cognitive decline was different in
subjects with low and high physical disability at baseline. Interaction between
level of physical disability and tertiles of blood pressure measures was tested
by adding an interaction term in linear regression models. All analyses were
carried out using SPSS software (version 17.0.0, SPSS Inc., Chicago, IL).
Results
A total of 382 (66.8%) participants were female. Sixty four percent had low ed-
ucation. Mean values of systolic blood pressure, diastolic blood pressure, mean
arterial pressure and pulse pressure were 155mmHg, 77 mmHg, 103 mmHg and
78 mmHg respectively. The median ADL and MMSE scores were 10 and 26
11
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respectively, reflecting low physical and cognitive disabilities in a considerable
proportion of the participants. Table 1 shows the characteristics of participants
at age 85 years in tertiles of systolic blood pressure. Subjects in lowest tertile of
systolic blood pressure were more diabetic (p=0.05) and had lowest prevalence
of alcohol consumption (p=0.04).
Table 1. Characteristics of the Study Participants at Age 85 Years in Tertiles of Systolic Blood
Pressure.
Tertiles of systolic blood pressure
110-146 mmHg 147-161 mmHg 162-215 mmHg pValue†
(n= 186) (n= 193) (n= 193)
Demographic factors
Female, n (%) 125 (67.2) 125 (64.8) 132 (68.4) 0.79
Low education∗, n (%) 107 (65.6) 122 (65.6) 113 (60.8) 0.32
Cardiovascular risk factors
Ever smoking, n (%) 83 (45.6) 98 (52.4) 89 (46.6) 0.86
Regular alcohol use∗∗, n (%) 77 (42.1) 105 (55) 101 (52.6) 0.04
BMI, mean (SD) 27.2 (4.6) 27 (4.0) 27.4 (4.6) 0.77
Diabetes mellitus, n (%) 32 (18.6) 32 (16.6) 23 (11.9) 0.05
Antihypertensive medication, n (%) 81 (43.5) 82 (42.7) 87 (45.3) 0.63
Co-morbidities
Cardiovascular diseases∗∗∗, n(%) 81 (45.3) 86 (46.5) 82 (43.9) 0.22
Stroke, n (%) 23 (12.4) 12 (6.3) 21 (10.9) 0.51
Parkinson, n (%) 6 (3.2) 6 (3.1) 3 (1.6) 0.30
Malignancy 27 (14.7) 40 (20.8) 34 (17.6) 0.46
Arthritis 62 (33.3) 61 (31.8) 61 (31.8) 0.77
Abbreviations: SD: standard deviation, BMI: body mass index
† Indicates p-value for trend over strata of systolic blood pressure
∗ Primary education or less.
∗∗ Self-reported alcohol consumption
∗∗∗ Including myocardial infarction, angina pectoris, intermittent claudication, vascular
Surgery, congestive hear failure, arrhythmia
Table 2 shows cross-sectional findings on the association between various
measures of blood pressure and level of physical and cognitive disability. At age
85 years, higher SBP and PP were associated with lower ADL disability scores
(both p=0.01). Furthermore, higher SBP, DBP and MAP were associated with
higher MMSE scores (all p<0.01).
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Table 2. Physical and Cognitive Disability in Tertiles of Blood Pressure at Age 85 Years.
Tertiles of blood pressure
Low Middle High P for trend∗
SBP (Range, mmHg) (110-146) (147-161) (162-215)
ADL disability score, median [IQR] 11 [9, 17] 9 [9, 12] 9 [9, 14] 0.01
MMSE score, median [IQR] 25 [18, 27] 26 [21, 29] 27 [24, 28] 0.001
DBP (Range, mmHg) (43-71) (72-80) (81-115)
ADL disability score, median [IQR] 11 [9, 16] 10 [9, 14] 9 [9, 13] 0.57
MMSE score, median [IQR] 25 [19, 27] 26 [22, 29] 27 [24, 28] 0.004
MAP (Range, mmHg) (70-98) (99-107) (108-146)
ADL disability score, median [IQR] 11 [9, 17] 10 [9, 13] 9 [9, 13] 0.08
MMSE score, median [IQR] 25 [18, 27] 26 [22, 29] 27 [24, 29] < 0.001
PP (Range, mmHg) (37-71) (72-83) (84-131)
ADL disability score, median [IQR] 10 [9, 16] 9 [9, 14] 9 [9, 13] 0.01
MMSE score, median [IQR] 26 [19, 28] 26 [22, 28] 26 [24, 28] 0.06
Abbreviations: ADL: activities of daily living, SBP: systolic blood pressure, DBP: di-
astolic blood pressure, MAP; mean arterial pressure, PP: pulse pressure, IQR; inter
quartile range, MMSE: mini mental state examination
∗ Analyses were adjusted for sex, education, smoking status, alcohol intake, history
of stroke, types of antihypertensive medications, diabetes mellitus and history of car-
diovascular diseases
Table 3 presents longitudinal analyses from age 85 years onwards. Higher
SBP (p<0.001), MAP (p=0.01) and PP (p=0.003) were associated with lower an-
nual increases in ADL disability scores. Likewise, higher SBP (p=0.03) and PP
(p=0.008) at age 85 years were associated with lower annual declines in MMSE
scores.
To further explore our findings, we performed a stratified analysis that showed
the association between high blood pressure and lower annual decline in MMSE
scores to be most pronounced in subjects with high physical disability (figure
1). Among participants with high physical disability (ADL score ≥ 10) increase
in tertile of SBP and PP was associated with a 0.39 and 0.41 point lower annual
decline in MMSE scores respectively (p=0.04, p=0.03 respectively). Tests for in-
teraction between blood pressure measures and physical disability were not sta-
tistically significant (all p> 0.05). In addition, we repeated the cross-sectional,
longitudinal and stratified analyses in subjects who were not on antihyperten-
sive medication. This sensitivity analysis showed findings similar to what we
observed in the whole population (data not shown).
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Table 3. Annual Change in Physical and Cognitive Disability from Age 85 Years Onwards in
Tertiles of Blood Pressure
Tertiles of blood pressure
Low Middle High P for trend∗
SBP (Range, mmHg) (110-146) (147-161) (162-215)
∆ ADL disability score, median [IQR] 1.8 [0.4, 3.7] 1.0 [0, 2.4] 0.5 [0, 1.6] < 0.001
∆ MMSE score, median [IQR] -1.0 [-2.0, 0] -0.6 [-1.5, 0] -0.4 [-1.2, 0] 0.03
DBP (Range, mmHg) (43-71) (72-80) (81-115)
∆ ADL disability score, median [IQR] 1.2 [0.4, 3.0] 1.0 [0, 2.7] 0.6 [0, 2.0] 0.13
∆ MMSE score, median [IQR] -0.7 [-2.0, 0] -0.6 [-1.6, 0] -0.5 [-1.4, 0] 0.86
MAP (Range, mmHg) (70-98) (99-107) (108-146)
∆ ADL disability score, median [IQR] 1.4 [0.4, 3.6] 0.8 [0, 2.4] 0.6 [0, 2.0] 0.01
∆ MMSE score, median [IQR] -0.8 [-2.0, 0] -0.6 [-1.5, 0] -0.4 [-1.4, 0] 0.83
PP (Range, mmHg) (37-71) (72-83) (84-131)
∆ ADL disability score, median [IQR] 1.6 [0.2, 3.7] 1.0 [0, 2.2] 0.7 [0, 2.0] 0.003
∆ MMSE score, median [IQR] -0.8 [-2.2, 0] -0.6 [-1.6, 0] -0.3 [-1.0, 0] 0.008
Abbreviations: ADL: activities of daily living, SBP: systolic blood pressure, DBP: diastolic
blood pressure, MAP; mean arterial pressure, PP: pulse pressure, IQR; inter quartile range
∆: Indicates annual change in physical and cognitive scores calculated as (Last measure-First
measure/Years of follow up)
∗ Analyses were adjusted for sex, education, smoking status, alcohol intake, history of
stroke, types of antihypertensive medications, diabetes mellitus, history of cardiovascular
diseases and baseline physical and cognitive scores
Discussion
In this study, we showed that higher levels of various blood pressure measures
are associated with less physical and cognitive disabilities at age 85 years. Fur-
thermore, in longitudinal analyses, we observed that higher SBP and PP at age
85 years are associated with lower physical and cognitive decline. The relation
between high blood pressure and lower cognitive decline was most pronounced
in those with preexisting physical disability. These associations were indepen-
dent of cardiovascular risk factors and co-morbidities such as smoking, diabetes
mellitus, coronary artery diseases, arrhythmias, peripheral vascular diseases and
heart failure.
Our findings are consistent with previous observational studies in the oldest-
old. In a recent study by Molander et al, among individuals aged 85 years and
older, higher PP was associated with better cognition15. Furthermore, a simi-
lar study in Australian centenarians reported that higher SBP is associated with
14
Figure 1. Annual change in MMSE (mini mental state examination) score for increase
in tertiles of systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial
pressure (MAP) and pulse pressure (PP) in two groups of low and high physical dis-
ability measured by activities of daily living (ADL). † and ‡ show significant difference
from unity (p=0.04 and p=0.03 respectively). Analyses were adjusted for sex, education,
smoking status, alcohol intake, history of stroke, types of antihypertensive medications,
diabetes mellitus, history of cardiovascular diseases and baseline mini mental state ex-
amination (MMSE) scores.
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lower cognitive and physical disabilities16. In the third national health and nu-
trition examination in the United States, although hypertension was associated
with poorer cognitive performance in younger subjects (aged less than 80 years),
optimally-controlled blood pressure was associated with better cognitive func-
tion in those aged 80 years and older17. Similarly, in a study among individuals
aged 85 years and over, five years follow up did not show a significant asso-
ciation between various measures of blood pressure measures at baseline and
incidence of dementia18.
One reason why the relationship between blood pressure and cognitive func-
tion differs between younger and oldest-old patients has been suggested by other
authors: a higher blood pressure might be needed to overcome advanced arte-
rial stiffness to ensure sufficient perfusion in critical organs19. Another possible
reason for the observed findings is that those subjects that are most vulnerable
to the adverse effects of high blood pressure have died earlier, leaving a subset
who is resistant to these adverse effects. Alternatively, cognitive and physical
disabilities may cause abnormalities in blood pressure regulation and decline in
blood pressure20,21. An overall decline might be confounding both blood pres-
sure and functional or cognitive decline. Although our longitudinal study helps
to address some reverse causality, further controlled interventions in older pa-
tients with baseline disability are needed to fully answer questions posed by our
results.
Clinical trials on the benefit of antihypertensive medication in very old sub-
jects have shown mixed findings22. A recent meta-analysis by Bejan-Angoulvant
et al shows that antihypertensive treatment in subjects 80 years and older re-
duces risk of cardiovascular events; however, it has no benecial effects on all
cause or cardiovascular mortality23. This meta-analyses also showed that the
mortality rate in trials were heterogeneous which might be explained by the
heterogeneity in the population under study and/or an increase in mortal-
ity in trials where the participant received maximal allowable blood pressure
lowering24-26. A limited number of studies evaluated the effect of antihyperten-
sive treatment on cognitive function in very old subjects. In the hypertension
in the very elderly trial (HYVET), antihypertensive treatment showed no signifi-
cant benefit in reducing incidence of dementia11. However, the HYVET findings,
when combined in a meta-analysis of other placebo-controlled, double-blind,
trials of antihypertensive treatment in younger elderly people27-29, a significant
reduction in incident dementia was observed. It is worth pointing out that par-
ticipants in HYVET were generally healthier than normal for their age, as shown
by a low number of cardiovascular risk factors and co-morbidities which limits
the extrapolation of these findings to the general population of the oldest old
where physical and cognitive disability is common12.
Physical disability has been linked to cerebrovascular pathologies in the brain30.
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In the presence of hypotension, regulatory mechanisms in the brain cannot ef-
fectively safeguard brain blood flow leading to decline in cerebral perfusion31.
Consistent with this mechanism, in our study, those with poorest baseline phys-
ical function showed the strongest association between hypotension and greater
cognitive decline.
In the coming years, the increasing number of the oldest old subjects with
various levels of functional disability32 highlights the necessity of an individu-
alized approach for treatment of hypertension in this age group33. Further ex-
perimental and interventional studies, combined with imaging techniques, are
warranted to further explore and substantiate the impact of physical disability
on the association between systemic blood pressure and cognitive function. We
also propose that future trials should test whether relaxation of blood pressure
control in elderly with low or normal blood pressure can contribute in preven-
tion of further physical and cognitive decline especially in elderly with advanced
physical disability. This study has certain strengths. A relatively large group of
the oldest old subjects, a long term follow up, low attrition rate and annual
home visits to assess physical and cognitive disability can be put forward as
the strengths of this study. However, there are limitations which are necessary
to be considered when interpreting the results. First, our findings can be due
to the fact that subjects who had lower blood pressure at age 85 years were al-
ready on the way down because of long histories of exposure to hypertension
and co-morbidities. This decline in blood pressure could be concomitant with
decline in physical and cognitive function after age 85 years raising the issue
whether confounding by overall decline can explain our results. Nevertheless,
our analyses show that subjects with low systolic blood pressure did not have
higher prevalence of cardiovascular risk factors or co-morbidities except for di-
abetes mellitus. In addition, we performed all cross-sectional and longitudinal
analyses adjusted for cardiovascular risk factors and co-morbidities at baseline
which did not essentially change our estimates. As a second limitation, we used
only ADL and MMSE to estimate physical and cognitive disability. Since there
are no single criteria or definition for physical and cognitive disability, ADL and
MMSE may not fully reflect the level physical and cognitive disabilities respec-
tively. Furthermore, lack of information on neuroimaging and cardiac function
of our participants, did not allow us to add further details on the causal inter-
pretation of our findings.
In conclusion, our results show that higher systolic blood pressure and pulse
pressure are associated with resilience to physical and cognitive decline in the
oldest old. Subjects with preexisting physical disability may benefit most from
high blood pressure to preserve cognitive function.
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Summary
Epidemiological studies have shown mixed findings on the association between
hypertension and stroke in the oldest-old. Heterogeneity of the populations
under study may underlie variation of outcomes. The aim of this chapter is
to examine whether level of physical and cognitive function moderates the as-
sociation between blood pressure and stroke. We included 513 subjects aged
85 years old from the population based Leiden 85-plus Study. Systolic blood
pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP)
and pulse pressure (PP) were measured at baseline. Activities of daily living
and Mini Mental State Examination were assessed to estimate level of physical
and cognitive function, respectively. Five-year risk of stroke was estimated with
Cox-regression analysis. In the entire cohort, there were no associations between
various measures of blood pressure and risk of stroke except for the inverse re-
lation between PP and stroke risk (HR: 0.80, 95 % CI: 0.66-0.98). Among subjects
with impaired physical functioning, higher SBP (HR: 0.74, 95 % CI: 0.59-0.92),
MAP (HR: 0.68, 95 % CI: 0.47-0.97) and PP (HR: 0.71, 95 % CI: 0.55-0.93) were
associated with reduced risk of stroke. Likewise, among subjects with impaired
cognitive functioning higher SBP was associated with reduced risk of stroke
(HR: 0.80, 95 % CI: 0.65-0.98). In subjects with unimpaired cognitive functioning,
higher DBP (HR: 1.98, 95 % CI: 1.21-3.22) and MAP (HR: 1.70, 95 % CI: 1.08-2.68)
were associated with higher risk of stroke. Our findings suggest that impaired




Clinical trials have shown mixed findings on the benefit of antihypertensive
treatment in lowering risk of stroke in very old age1. It has been suggested that
heterogeneity of the populations under study underlies variety of outcomes, but
the explanatory biological variables have as yet remained uncertain2, 3.
Inherent mechanisms in brain vessels keep cerebral blood flow constant de-
spite variations in blood pressure4. Once advanced cerebrovascular damage is
present, these mechanisms cannot effectively regulate level of cerebral blood
flow5, 6. Therefore, low systemic blood pressure in the presence of cerebrovas-
cular damage may lead to decline in cerebral blood flow which renders brain
tissue vulnerable to ischemic events7. Both physical and cognitive impairment
are common in very old age and are strongly associated with cerebrovascular
pathologies and cerebral hypoperfusion8-11. Hence, low systemic blood pres-
sure in subjects with physical and cognitive impairment might reduce cerebral
blood flow and increase risk of ischemic stroke.
In the Leiden 85-plus Study, we have recruited a population-based sample
of the oldest-old with a wide variety of functional impairments at age 85 years
who were prospectively followed for clinical outcomes. This allowed us to ex-
amine whether very old subjects with different levels of physical and cognitive
impairment show different associations between high blood pressure and risk of
stroke. We hypothesized that higher blood pressure in the presence of physical
and cognitive impairment is associated with lower risk of stroke.
Material and methods
Study design and participants
The Leiden 85-plus Study is a population-based prospective follow-up study of
inhabitants of Leiden, the Netherlands. Between 1997 and 1999, all inhabitants
of 1912-1914 birth cohort (n = 705) were contacted in the month of their 85th
birthday. There were no selection criteria on demographic features or health
status. A total of 599 (397 women and 202 men) subjects agreed to participate
(85%). As described previously, there was no significant difference between the
demographic features and health status of those who participated and those
who did not12. Blood pressure measures and clinical data were available for
571 subjects. We excluded 58 subjects who had a clinically recognized stroke at
baseline, leaving 513 subjects for this analysis. Participants were visited within
one month after their 85th birthday at their homes where face-to-face interviews
and clinical examinations were done. The Medical Ethical Committee of the Lei-
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den University Medical Centre approved the study, and informed consent was
obtained from all the subjects.
Blood pressure
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured
at baseline, using a mercury sphygmomanometer, in seating position. During
two home visits at age 85 years, two blood pressure measurements were done
in two weeks apart. Blood pressure measurements were recorded after at least
5 min of rest and no vigorous exercise in the preceding 30 min. The mean value
of the two measurements was calculated and used in further analyses. Mean
arterial pressure (MAP) and pulse pressure (PP) were calculated as 1/3(SBP) +
2/3(DBP) and (SBP) - (DBP), respectively, using the mean blood pressure of the
two visits.
Stroke
The primary outcome of this study was fatal plus non-fatal stroke. In the Nether-
lands detailed information on health status, emergency events and patients’ hos-
pitalizations are recorded with general practitioners. Occurrence of clinically
recognized stroke during five years of follow up was assessed by annually in-
terviewing general practitioners (for subjects living independently) or nursing
home physicians (for subjects living in a nursing home). We used the World
Health Organization definition of stroke of “rapidly developing clinical signs of
focal (at times global) disturbance of cerebral functioning lasting >24 hours” to
identify subjects with stroke events13. To assess fatal stroke, we obtained dates
of deaths from the Dutch civic registry and specific data on causes of death from
Statistics Netherlands, which assigns codes for all national death certificates ac-
cording to the International Classification of Diseases and Related Disorders,
10th revision (ICD-10). Death due to stroke was classified as ICD-10 codes I60-
I6914.
Physical and cognitive function
To evaluate level of physical impairment in the participants we used Groningen
Activity Restriction Scale (GARS) which is a non-disease-specific instrument to
measure impairment in activities of daily living (ADL)15. In the GARS, nine
questions refer to ADL. Using four-category response for each question, a score
of 9 indicates no impairment while a score of 36 indicates highest impairment in
ADL. Based on the median ADL scores (10 points), participants were categorized
into two groups of impaired (ADL score ≥ 10) and unimpaired (ADL score = 9)
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physical function. Impairment in cognitive function was assessed in all partici-
pants using Mini-Mental State Examination (MMSE)16. Similarly, based on the
median MMSE scores (26 points), participants were categorized into two groups
of impaired (MMSE score ≤ 26) and unimpaired (MMSE score > 26) cognitive
function.
Demographic and clinical characteristics
Level of education was dichotomized into primary education and less versus
more than primary education. Use of antihypertensive medication was extracted
from pharmacy records. All participants were interviewed about their smoking
habits and alcohol intake. Diabetes mellitus was considered present if diagnosed
by the primary care physician, if the nonfasting glucose level was greater than
11 mmol/L or if a participant was taking antidiabetic medication. History of
cardiovascular diseases, including ischemic heart disease, intermittent claudica-
tion, vascular surgery, arrhythmia and heart failure, was obtained from general
practitioners or nursing home physicians.
Statistical analysis
Since distribution of ADL and MMSE scores was skewed, summary statistics of
them are reported as median and inter quartile range (IQR). Cox regression mod-
els were fitted with time-to-stroke as the outcome variable and each 10 mmHg
increase in various blood pressure measures as the determinants. First, we per-
formed our analyses adjusted for sex and then we did further adjustments for
history of cardiovascular diseases, diabetes mellitus, smoking and use of antihy-
pertensive medication in multivariate models. These variables were selected for
multivariable analysis since they were correlated with level of blood pressure
(data not shown) and have a well-established association with stroke17. Outputs
of the Cox regression analyses were checked for violation of the proportional
hazards and linearity assumptions. Furthermore, we performed a stratified anal-
ysis to test whether subjects with different levels of physical and cognitive func-
tion show different associations between blood pressure and stroke. Interaction
between the level of physical and cognitive function with various blood pressure
measures regarding the risk of stroke was tested by adding an interaction term
in Cox regression models. All analyses were carried out using SPSS software
(version 17.0.0, SPSS Inc., Chicago, IL).
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Results
Table 1 summarizes the clinical characteristics of participants at age 85 years.
Mean values of SBP, DBP, MAP and PP were 155mmHg, 77mmHg, 102mmHg
and 78mmHg respectively. Median ADL and MMSE scores were 10 and 26, re-
spectively. Clinical characteristics of the subjects with different levels of physical
and cognitive function are separately presented in the supplement data (Table
S-1 and Table S-2, http://stroke.ahajournals.org/content/44/1/15/suppl/
DC1). Subjects with physical and cognitive impairment had lower levels of blood
pressure measures in comparison to those with unimpaired physical and cogni-
tive function (all p<0.05). In addition, subjects with cognitive impairment had
higher prevalence of myocardial infarction (p=0.03) and heart failure (p=0.04) in
comparison to those with unimpaired cognitive function.




Female, n (%) 344 (67.1)
Low education∗, n (%) 312 (63.9)
Ever smoking, n (%) 242 (48.2)
Regular alcohol intake†, n (%) 262 (51.6)
Cerebrovascular risk factors
History of CVD‡, n (%) 218 (44)
Heart failure, n (%) 63 (12.3)
History of DM, n (%) 79 (16)
BMI, mean (SD) 27.2( 4.5)
Total cholesterol, mmol/L mean (SD) 5.7 (1.1)
Triglycerides, mmol/L mean (SD) 1.6 (0.8)
Systolic blood pressure, mmHg mean (SD) 155 (18)
Diastolic blood pressure, mmHg mean (SD) 77 (10)
Pulse pressure, mmHg mean (SD) 78 (15)
Mean arterial pressure, mmHg mean (SD) 102 (11)
Antihypertensive medication, n (%) 222 (43.3)
Functionality measures
ADL, median [IQR] 10 [9,13]
MMSE, median [IQR] 26 [23,28]
∗ Primary education and less.
†Self-reported alcohol consumption
‡ Including myocardial infarction, angina pectoris, in-
termittent claudication, congestive heart failure and ar-
rhythmia
Abbreviations: CVD: cardiovascular diseases, DM: di-
abetes mellitus, BMI: body mass index, SD: standard
deviation, IQR: interquartile range, ADL: activities of
daily living, MMSE: mini mental state examination
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During five years of follow up, 58 of the 513 (11.3%) subjects developed
stroke, of which 27 (46.5%) cases were fatal. Risk of stroke per each 10 mmHg in-
crease in various blood pressure measures in the whole population is presented
in table 2. The proportional hazards and linearity assumptions of the Cox re-
gression analyses were confirmed after checking the outputs. In the sex adjusted
models, there was no association between different measures of blood pressure
and risk of stroke (all p>0.05). Further adjustment for socio-demographic and
cardiovascular factors did not essentially change the estimates except for the
association between higher PP and lower risk of all stroke (Hazard ratio [HR]:
0.80, 95 % CI: 0.66-0.98). In a sensitivity analysis, we tested the association be-
tween blood pressure measures and risk of stroke in subjects who were not on
antihypertensive medication. In this sensitivity analysis we also found no asso-
ciation between different measures of blood pressure and risk of stroke (Table
S-3 http://stroke.ahajournals.org/content/44/1/15/suppl/DC1).
Table 2. Risk of stroke for each 10mmHg increase in systolic blood pressure, dias-
tolic blood pressure, mean arterial pressure and pulse pressure
Crude model Adjusted model
HR (95% CI) P-value HR (95% CI) P-value
Fatal and non-fatal stroke
SBP 0.91 (0.78-1.06) 0.21 0.86 (0.73-1.02) 0.09
DBP 1.03 (0.78-1.37) 0.82 1.04 (0.76-1.40) 0.81
MAP 0.93 (0.73-1.19) 0.57 0.89 (0.68-1.17) 0.41
PP 0.86 (0.72-1.03) 0.10 0.80 (0.66-0.98) 0.03
Crude Model: Adjusted for sex
Adjusted Model: Analyses were adjusted for sex, cardiovascular diseases, diabetes
mellitus, antihypertensive medication, smoking
Abbreviations: HR: Hazard ratio, SBP: systolic blood pressure, DBP: diastolic blood
pressure, MAP: mean arterial pressure, PP: pulse pressure
Figure 1 shows the associations between various measures of blood pressure
and risk of stroke dependent on level of physical and cognitive function. Sig-
nificant interactions were present between SBP, DBP, MAP and PP and level of
physical function regarding the risk of stroke (all p for interaction <0.05). Simi-
larly, we observed significant interactions between SBP, DBP and MAP and level
of cognitive function regarding the risk of stroke (all p for interaction <0.05).
Interactions were most pronounced for those subjects who had both impaired
physical and cognitive function (n=144) when compared to those who had nei-
ther of these disabilities (n=180). To explore whether use of more than one blood
pressure value in our analyses changed our results, we performed a sensitivity
analysis in which the association of mean blood pressure measures at age 85 and
86 years with stroke events from age 86 years onwards was investigated. This
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sensitivity analysis did not change the effect estimates (data not shown).
Table 3 shows multivariable adjusted analyses on the associations between
various measures of blood pressure and risk of all strokes, stratified for level of
physical and cognitive function at baseline. In subject with unimpaired physical
functioning, no significant association was found between various measures of
blood pressure and risk of stroke (all p>0.05), albeit virtually all HRs were above
unity, indicating higher risk of stroke with increasing blood pressure. Con-
versely, in subjects with impaired physical functioning, higher SBP (HR: 0.74,
95 % CI: 0.59-0.92), MAP (HR: 0.68, 95 % CI: 0.47-0.97) and PP (HR: 0.71, 95
% CI: 0.55-0.93) were associated with reduced risk of stroke. In subjects with
unimpaired cognitive functioning, higher measures of blood pressure were as-
sociated with increased risk of stroke, which was statistically significant for DBP
and MAP (HR: 1.98, 95% CI: 1.21-3.22 and 1.70, 95% CI: 1.08-2.68, respectively).
In contrast, in subjects with impaired cognitive function, higher measures of
blood pressure were associated with lower risk of stroke, which was statistically
significant for SBP (HR: 0.80, 95 % CI: 0.65-0.98). To test whether the outcomes of
this stratified analysis were dependent on specific MMSE cut-offs, we repeated
our analyses using a MMSE cut-off at 20 points and found similar outcomes
(data not shown).
Table 3. Risk of stroke for each 10mmHg increase in systolic blood pressure,
diastolic blood pressure, mean arterial pressure and pulse pressure stratified
for level of physical and cognitive function
Unimpaired Impaired
HR (95% CI) P-value HR (95% CI) P-value
Physical function n= 251 n= 262
SBP 1.11 (0.88-1.41) 0.38 0.74 (0.59-0.92) 0.007
DBP 1.45 (0.94-2.25) 0.07 0.81 (0.53-1.22) 0.31
MAP 1.32 (0.91-1.93) 0.14 0.68 (0.47-0.97) 0.03
PP 1.00 (0.73-1.35) 0.98 0.71 (0.55-0.93) 0.01
Cognitive function n= 247 n= 266
SBP 1.21 (0.90-1.61) 0.21 0.80 (0.65-0.98) 0.03
DBP 1.98 (1.21-3.22) 0.006 0.83 (0.57-1.21) 0.33
MAP 1.70 (1.08-2.68) 0.02 0.74 (0.52-1.03) 0.08
PP 0.96 (0.66-1.39) 0.82 0.80 (0.63-1.01) 0.06
Hazard ratio (HR) was measured for each 10 mmHg increase in blood pres-
sure measures
Abbreviations: HR: Hazard ratio, SBP: systolic blood pressure, DBP: dias-
tolic blood pressure, MAP: mean arterial pressure, PP: pulse pressure
Analyses were adjusted for sex, cardiovascular diseases, diabetes mellitus,
antihypertensive medication, smoking
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Figure 1. Hazard ratios (HRs) and 95% confidence interval on the associations between
blood pressure and risk of stroke dependent on level of physical and cognitive function.
Unimpaired physical function was defined as ADL score = 9 and impaired physical func-
tion as ADL score ≥ 10. Unimpaired cognitive function was defined as MMSE score > 26
and impaired cognitive function as MMSE score ≤ 26. Subjects with unimpaired physical
and cognitive function had both ADL score = 9 and MMSE score > 26. Whereas subjects
with impaired physical and cognitive function had both ADL score ≥ 10 and MMSE score
≤ 26. HRs were estimated for each 10 mmHg increase in blood pressure adjusted for sex,
cardiovascular diseases, diabetes mellitus, antihypertensive medication, smoking.
Abbreviations: SBP: systolic blood pressure, DBP: diastolic blood pressure, MAP: mean
arterial pressure, PP: pulse pressure, ADL: activities of daily living, MMSE: mini mental
examination.
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Discussion
The main findings of this study are twofold. First, high blood pressure is not
associated with increased risk of stroke in a general population of the oldest-
old. Second, in subjects with physical and/or cognitive impairment, high blood
pressure might be paradoxically associated with lower risk of stroke.
Although hypertension has been recognized as a strong risk factor for stroke,
current evidence shows that the predictive value of high blood pressure for
stroke attenuates with age18. In line with this evidence, we found that high
blood pressure is not associated with increased risk of stroke in the oldest-old.
Furthermore, our observations suggest that in very old age high blood pressure
in the presence of physical and cognitive impairment, reflecting high load of
brain vascular pathologies, may preserve cerebral perfusion and lower risk of
stroke. This observation might be explained in different ways. First, lower blood
pressure in subjects with physical and cognitive impairment might be related to
better treatment of hypertension in high risk subjects. Furthermore, low blood
pressure related risk of stroke in subjects with previous functional impairment
can be due to the fact that structural heart disease and/or poor cardiac function-
ing are associated with both low blood pressure and risk of stroke19. This might
partially explain different associations between blood pressure measures and
stroke in subjects with different levels of cognitive function, since subjects with
cognitive impairment had higher prevalence of myocardial infarction and heart
failure. However, subjects with physical impairment did not have more cardio-
vascular pathologies at age 85 years compared to the subjects with unimpaired
physical function. Additionally, the observed associations in this study did not
essentially change after adjustment for antihypertensive medications and most
known risk factors for cardiovascular disease, such as sex, smoking, diabetes
mellitus and history of cardiovascular diseases.
The alternative explanation can be that low blood pressure may lead to insuf-
ficient cerebral perfusion, particularly in the presence of advance cerebrovascu-
lar damage20. It is well-established that both physical and cognitive impairment
are associated with structural and functional alterations in the brain vascula-
ture leading to impaired cerebral perfusion21, 22. In this setting, our findings
may imply that higher blood pressure in the presence of advanced brain vas-
cular damage can play a compensatory role to improve cerebral perfusion and
thereby lower risk of ischemic events, especially low-flow infarcts23. However,
we are not able to make a causal inference solely from our observational data
and further experimental and interventional studies are needed to examine this
hypothesis.
Although the number of oldest-old subjects is rapidly increasing and preva-
lence of hypertension as well as functional impairment is high in this age group24,
clinical guidelines on antihypertensive therapy in very old subjects with different
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co-morbidities and functional impairment are not clear25. This ambiguity might
stem from the fact that clinical trials have generally enrolled healthy and com-
petent older participants while very old individuals with multiple morbidities
and cognitive impairment have participated less in such studies26. Previously,
it has been shown that results of the published trials are not always applicable
to the treatment of older frail patients with multiple co-morbid conditions and
concomitant functional impairment27. Findings of current study may support
further investigations to optimize benefits of blood pressure control in very old
patients based on level of functional impairment.
Our study has certain strengths and major limitations. As a strength, this
study was conducted in a relatively large population of the oldest-old people
with long-term follow-up period. As a major limitation, we did not have neu-
roimaging data to identify subjects with unrecognized cerebrovascular patholo-
gies at baseline. Similarly, we were not able to determine type, load and location
of stroke events during follow-up period. However, it has been reported that
the majority of strokes in subjects aged 80 years and older are of the ischemic
type28, 29. Another limitation of this study is that we used only ADL and MMSE
to estimate level of physical and cognitive impairment. Since there is no single
criterion or definition for physical and cognitive impairment, ADL and MMSE
may not fully reflect level of physical and cognitive impairment, respectively.
Detection of outcomes by interviewing general practitioners might be the other
potential limitation of this study. This method could result in detection bias ex-
plaining the differential blood pressure effect in subjects with different levels of
functional impairments. In addition, it was possible that general practitioners
had different diagnostic sensitivity in patients with and without physical and
cognitive impairment.
In conclusion, our findings suggest that impaired physical and cognitive
functioning moderates the traditional association between higher blood pres-
sure and increased risk for stroke. We found that in subjects with physical and
cognitive impairment, a higher blood pressure was associated with lower risk of
stroke. Given the observational design of this study and the mentioned limita-
tions, caution should be used in interpretation of our results as we cannot make
a causal inference from our findings. However, these findings merit further in-
terventional and experimental studies, combined with imaging techniques, to
test whether less intensive control of blood pressure in patients with physical
and cognitive impairment, can contribute to better cerebral perfusion and pre-
vention of subsequent cerebrovascular events.
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Summary
The aim of this chapter is to investigate the association between visit-to-visit
blood pressure variability and cognitive function in elderly subjects. In this
prospective cohort study, 5461 participants at risk of cardiovascular disease with
mean age of 75.3 years were included. Blood pressure was measured every
three months during an average period of 3.2 years. Blood pressure variabil-
ity was defined as the standard deviation of visit-to-visit blood pressure mea-
surements. Four domains of cognitive function including selective attention,
processing speed, immediate and delayed memory were assessed. In an MRI
substudy of 553 participants, structural brain volumes, cerebral microbleeds, in-
farcts and white matter hyperintensities were measured. Subjects with higher
visit-to-visit systolic blood pressure variability had worse performance on all
cognitive tests, including attention (mean difference high vs. low thirds) 3.08
seconds (95% confidence interval (CI) 0.85; 5.31); processing speed -1.16 digits
coded (95% CI -1.69; -0.63), immediate memory -0.27 pictures remembered (95%
CI -0.41; -0.13) and delayed memory -0.30 pictures remembered (95% CI -0.49;
-0.11). Furthermore, higher systolic and diastolic blood pressure variability was
associated with lower hippocampal volume and cortical infarcts, and higher di-
astolic blood pressure variability was associated with cerebral microbleeds (all
p<0.05). All associations were adjusted for average blood pressure and cardio-
vascular risk factors. Higher visit-to-visit blood pressure variability independent
of average blood pressure associates with impaired cognitive function in old age.
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Introduction
Visit-to-visit blood pressure variability independent of average blood pressure is
related to cerebrovascular damage1. It has been shown that higher visit-to-visit
blood pressure variability increases risk of stroke and antihypertensive medica-
tions which decrease both blood pressure variability and mean blood pressure
more effectively reduce risk of stroke2. In addition, observational studies have
demonstrated associations of blood pressure variability, independent of average
blood pressure, with white matter hyperintensities, carotid artery intima media
thickness and atherosclerosis in elderly subjects3-5.
There is a well-established relationship between increased blood pressure
variability and end organ damage6. Recent evidence indicates that higher visit-
to-visit blood pressure variability is linked with microvascular damage, endothe-
lial injury and disturbances in vascular smooth muscle functioning7 8. Indica-
tors of cerebral small vessel disease including white matter hyperintensities, cor-
tical microinfarcts and cerebral microbleeds are implicated in the pathogenesis of
cognitive impairment9-11. Several pathological, observational and experimental
studies showed that disruption of the blood brain barrier due to microvascu-
lar damage results in neuronal injury and accelerates neuronal loss and brain
atrophy12. Hence, higher blood pressure variability might potentially lead to
cognitive impairment through changes in the brain structures and development
of cerebral small vessel disease.
The aim of this study was to investigate the association of visit-to-visit blood
pressure variability independent of average blood pressure with cognitive func-
tion in older subjects at high risk of cardiovascular disease. Possible explanations
behind this association were additionally investigated in an MRI substudy.
Methods
Study design and participants
The data in this study were obtained from the PROSPER study, a random-
ized, double-blind, placebo-controlled trial designed to investigate the effect of
pravastatin in prevention of vascular events in elderly men and women with
pre-existing cardiovascular disease or risk factors thereof. This trial included
5,804 individuals aged 70-82 years old who were enrolled from three collaborat-
ing centers in Ireland, Scotland and the Netherlands. Approximately 50% of the
participants showed evidence of cardiovascular disease including stable angina,
intermittent claudication, stroke (type of stroke, hemorrhagic or ischemic, was
unknown), transient ischemic attack, myocardial infarction and vascular surgery.
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The rest of participants had one or more major cardiovascular risk factors, de-
fined as hypertension, cigarette smoking or diabetes mellitus. The primary out-
come of the PROSPER study was the combined endpoint of definite or suspect
death from coronary heart disease, non-fatal myocardial infarction and fatal or
non-fatal stroke during a mean follow-up period of 3.2 years. In the present
study we included 5,461 participants for whom data on blood pressure variabil-
ity and cognitive function were available. Additionally, participants from the
Netherlands were invited to participate in an MRI substudy. Participants were
included from both pravastatin and placebo groups as we previously reported
that treatment with pravastatin did not influence cognitive function, structural
brain volumes or indicators of cerebral small vessel disease13-15. The institu-
tional ethics committees of the three collaborating centers approved the study
and all participants gave written informed consent.
Blood pressure measurements
Systolic and diastolic blood pressure were measured at baseline and repeated
every three months. Blood pressure was measured in sitting position using a
fully automatic electronic sphygmomanometer (Omron M4 R⃝). All measure-
ments were performed in the same clinical setting. The average values of these
blood pressure measurements were calculated and used in the analyses. Visit-to-
visit blood pressure variability was defined as the standard deviation of blood
pressure measurements during the study period. We only report the blood
pressure variability by using the standard deviation. Variance and coefficient
of variation, which are two other measures of variability, are strongly corre-
lated with the standard deviation (data are presented in supplemental table S-
1 http://www.bmj.com/content/suppl/2013/07/29/bmj.f4600.DC1) and they
showed similar associations with cognitive and MRI outcomes (data not shown).
Cognitive function
The Mini-Mental State Examination (MMSE) was used to evaluate global cogni-
tive function at baseline; a cutoff score of 24 points or more (out of 30) was used
as an inclusion criterion to exclude subjects with poor cognitive function at base-
line. In the present study we used data on cognitive function assessed at the end
of the study, after a mean follow up time of 3.1 years, by a cognitive test battery
consisting of four different tests. The Stroop-Colour-Word-Test was used to test
selective attention and reaction time of the participants. The participants were
asked to read a color name which was displayed in a color different from the
color it actually names. The outcome parameter was total number of seconds to
complete the test; a higher score therefore indicates worse performance. General
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cognitive speed was tested by the Letter-Digit Coding Test. The participants had
to match certain digits with letters according to a provided key. The outcome
variable was the total number of correct entries in 60 seconds, and therefore
higher scores represented better performance. The Picture-Word Learning Test
was used to assess immediate and delayed memory performance. Fifteen pic-
tures were presented at the participants, and they were asked to recall as many
pictures as possible in three trials. After 20 minutes they were asked to repeat
the test to measure their delayed recall. The outcome parameter is the accu-
mulated number of correct recalled pictures, immediate and after 20 minutes.
Higher scores thus indicate better performance. A detailed description of the
cognitive tests and the procedures has been published previously16.
MRI substudy
Of the 1,100 Dutch participants in the PROSPER study, 646 consented to par-
ticipate in the MRI substudy. Forty of the 646 original study participants died
during follow-up period. From the remaining 606 participants, an MRI was
performed at the end of follow up period. Visit-to-visit blood pressure measure-
ments and MRI data were available for a total number of 553 subjects. Details of
individually MRI scan parameters have been published previously13.
All imaging was performed on an MR system operating at field strength of
1.5 Tesla (Philips Medical Systems, Best, the Netherlands). Gray and white mat-
ter volumes were calculated by SIENAX technique. In short, SIENAX starts by
extracting brain and skull images from the single whole-head input data. The
brain image is then afne-registered to Montreal Neurological Institute (MNI) 152
space (by using the skull image to determine the registration scaling), done pri-
marily to obtain the volumetric scaling factor to be used as normalization for
head size. Next, tissue-type segmentation with partial volume estimation is car-
ried out to calculate total volume of brain tissue (including separate estimates
of volumes of gray matter, white matter, peripheral gray matter, and ventricu-
lar cerebrospinal fluid)17. The algorithm FIRST (FMRIBs Integrated Registration
and Segmentation Tool) was applied to estimate the volume of hippocampus.
In addition, volume of six other subcortical regions including nucleus accum-
bens, globus pallidus, amygdala, putamen, caudate nucleus and thalamus were
estimated. FIRST is part of FSL (FMRIB’s Software Library) and performs both
registration and segmentation of the mentioned subcortical regions18. To as-
sess cerebral microbleeds, all MRI scans were read in consensus by two expe-
rienced raters who were blinded to subjects’ clinical history. Cerebral microb-
leeds were defined as focal areas of signal loss on T2∗-weighted gradient echo
pulse sequence (“blooming effect”) that are invisible or smaller on T2-weighted
MRI 19. For each subject the number and location (cortical, subcortical, and in-
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fratentorial) of the cerebral microbleeds were recorded. Segmentation of white
matter hyperintensities volume was performed automatically using software for
Neuro-Image Processing in Experimental Research (SNIPER), an in-house de-
veloped program for image processing20. This segmentation was based on the
T2-weighted and FLAIR images. Cerebral infarcts were defined as parenchymal
defects seen on FLAIR images with the same signal intensity as CSF and a sur-
rounding rim of high signal intensity following a vascular distribution.
Demographic and clinical characteristics
Demographic, medical and anthropometric data of the participants were recorded
at baseline. A fasting venous blood sample was taken for biochemical and hema-
tological assessment. Apolipoprotein E phenotype was determined on plasma
samples by Western blotting 21.
Statistical analysis
Characteristics of the study participants are reported as mean (standard devi-
ation) for continuous variables and frequency (percentage) for categorical vari-
ables. The correlation between blood pressure variability and average blood
pressure was assessed by calculating the Pearson’s Correlation Coefficient. Lin-
ear regression models were used to assess the association of blood pressure
variability and average blood pressure with cognitive function. Dependent vari-
ables were the mean scores of the cognitive tests. In the tables these scores are
presented in thirds of systolic and diastolic blood pressure and blood pressure
variability. In the MRI substudy, we used logistic regression models to estimate
the odds ratio and 95% confidence interval of the presence of microbleeds or
infarcts in different thirds of blood pressure variability as well as average blood
pressure. Multivariable linear regression models were used to test the associa-
tion between blood pressure variability and average blood pressure with volume
of white matter hyperintensities and structural brain volumes. P-values in all the
analyses were calculated using systolic and diastolic blood pressure variability
as continuous variables. We performed our analyses in three steps. In the first
step, crude analyses were performed, in which we only adjusted for cognitive
test version where appropriate. In the second step, we added age, sex, education
and country as covariates to investigate the potential influence of these factors
on the associations (model 1). In the final model (model 2), we further adjusted
the analyses for the following potential confounders: cardiovascular diseases
and risk factors (history of vascular disease, history of hypertension, history of
diabetes mellitus, smoking status, cholesterol levels, body mass index), average
blood pressure, statin treatment and apo E genotype. We adjusted the analyses
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of systolic blood pressure variability with cognitive function and MRI outcomes
for average systolic blood pressure. The analyses of diastolic blood pressure
variability with cognitive function and MRI outcomes were adjusted for average
diastolic blood pressure. Since the associations did not essentially change in dif-
ferent models, results of the second model are presented in the manuscript and
results from the other models are presented as supplementary data (tables S-
2 and S-3 http://www.bmj.com/content/suppl/2013/07/29/bmj.f4600.DC1).
All analyses were performed using SPSS software (version 20.0.0, SPSS Inc.,
Chicago, IL).
Results
Table 1 shows the characteristics of participants in the whole group and MRI
substudy. Blood pressure was measured in an average number of 12.7 and 12.9
visits in the whole group and MRI substudy respectively. Average systolic and
diastolic blood pressure over the period of blood pressure measurements was
153.1 mmHg and 82.5 mmHg respectively. Mean values of standard deviation
of systolic and diastolic blood pressure during this period were 14.8 mmHg
and 7.1 mmHg respectively. There was a weak but statistically significant cor-
relation between average systolic blood pressure and standard deviation of sys-
tolic blood pressure measurements (r=0.20, p<0.001). Similarly, average diastolic
blood pressure was weakly but statistically significantly correlated with stan-
dard deviation of diastolic blood pressure measurements (r=0.12, p<0.001).
Table 2 shows the association of systolic and diastolic visit-to-visit blood
pressure variability with cognitive function. Higher systolic and diastolic blood
pressure variability was associated with worse performance on the Stroop test
(both p<0.001), Letter-Digit Coding test (both p<0.001), immediate Picture-
Word Learning test (both p<0.001) and delayed Picture-Word Learning test (both
p=0.001). All associations were independent of average blood pressure and car-
diovascular diseases and risk factors, as all analyses were adjusted for these
factors. Mean cognitive scores (95% confidence intervals) in each third of sys-
tolic and diastolic blood pressure variability are presented in Figure 1. Data on
the association of blood pressure variability with cognitive function from crude
and minimally adjusted models are shown in supplemental material (table S-
2 and S-3 http://www.bmj.com/content/suppl/2013/07/29/bmj.f4600.DC1).
Furthermore, we found a significant association of higher average systolic and
diastolic blood pressure with worse performance in different domains of cog-
nitive function (all p<0.05), except for the association between higher aver-
age systolic blood pressure and performance on the Picture-Word Learning
tests (p>0.05) (data presented in the supplemental material table S-4 http:
//www.bmj.com/content/suppl/2013/07/29/bmj.f4600.DC1).
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Number of visits, mean (SD) 12.7 (2.4) 12.9 (1.5)
Age, years, mean (SD) 75.3 (3.3) 74.9 (3.2)
Female, n (%) 2,822 (51.7) 241 (43.6)
Age left school, years, mean (SD) 15.1 (2.1) 15.5 (2.9)
Vascular risk factor
History of hypertension, n (%) 3,399 (62.2) 341 (63.1)
History of diabetes mellitus, n (%) 576 (10.5) 91 (16.5)
History of stroke or TIA, n (%) 606 (11.1) 89 (16.1)
History of myocardial infarction, n (%) 714 (13.1) 67 (12.1)
History of vascular disease, n (%) 2,404 (44.0) 240 (43.4)
Current smoker, n (%) 1,433 (26.2) 115 (20.8)
Body mass index , kg/m2, mean (SD) 26.9 (4.2) 26.7 (3.6)
Total cholesterol, mmol/L, mean (SD) 5.7 (0.9) 5.7 (0.8)
Blood pressure, mean (SD)
Systolic blood pressure, mmHg∗ 153.1 (16.1) 156.1 (16.4)
Diastolic blood pressure, mmHg∗ 82.5 (7.5) 85.1 (7.3)
Variability in systolic blood pressure, mmHg∗∗ 14.8 (5.0) 13.9 (4.6)
Variability in diastolic blood pressure, mmHg∗∗ 7.1 (2.9) 7.4 (2.3)
Cognitive function, mean (SD)∗∗∗
Stroop test score, seconds 69.4 (31.6) 56.9 (23.3)
Letter-Digit Coding test score, digits coded 21.8 (8.0) 26.3 (7.4)
PLTi score, pictures remembered 9.2 (2.2) 10.1 (2.2)
PLTd score, pictures remembered 9.8 (3.1) 11.1 (3.0)
MRI features
Grey matter, ml, mean (SD) — 590 (44)
White matter, ml, mean (SD) — 768 (38)
Hippocampus, ml, mean (SD) — 7.5 (1.1)
Micro-bleeds, n (%) — 124 (24.0)
Infarcts, n (%) — 180 (33.6)
Cortical — 65 (12.1)
Lacunar — 112 (21.0)
WMH volume, ml, mean (SD) — 7.2 (1.1)
Abbreviations: SD, standard deviation; n, number; TIA, transient ischemic
attack; PLTi, Picture-Word Learning
Test immediate; PLTd, Picture-Word Learning Test delayed; WMH, white
matter hyperintensity.
∗ defined as the mean of all blood pressure measurements during follow-up.
∗∗ defined as the standard deviation of all blood pressure measurements
during follow-up.
∗∗∗ defined as the cognitive test score at the end of follow-up.
∗∗∗∗ defined as the sum of the z-score of each cognitive test, averaged across
all available cognitive tests.
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Table 2. Cognitive function in thirds of visit-to-visit blood pressure variability
Third of visit-to-visit blood pressure variability
Low Middle High P-value
(n=1820) (n=1821) (n=1820)
Systolic blood pressure
Range of SD, mmHg 0.7-12.2 12.3-16.2 16.3-64.4
Stroop, seconds 68.46 (0.79) 68.75 (0.79) 71.54 (0.82) <0.001
LDCT, digits coded 22.40 (0.19) 21.82 (0.19) 21.24 (0.19) <0.001
PLTi, pictures remembered 9.37 (0.05) 9.28 (0.05) 9.10 (0.05) <0.001
PLTd, pictures remembered 10.00 (0.07) 9.89 (0.07) 9.70 (0.08) 0.001
Diastolic blood pressure
Range of SD, mmHg 0-6.5 6.6-8.5 8.6-33.1
Stroop, seconds 68.28 (0.79) 68.89 (0.79) 71.34 (0.80) <0.001
LDCT, digits coded 22.35 (0.19) 21.93 (0.19) 21.27 (0.19) <0.001
PLTi, pictures remembered 9.41 (0.05) 9.22 (0.05) 9.13 (0.05) <0.001
PLTd, pictures remembered 10.01 (0.07) 9.88 (0.07) 9.74 (0.07) 0.001
Abbreviations: SD, standard deviation; n, number; LDCT, Letter-Digit Coding test;
PLTi, Picture-Word Learning Test immediate; PLTd, Picture-Word Learning Test de-
layed.
Data are adjusted values of the mean (standard error) of each cognitive function test.
Adjustments were made for age, sex, body mass index, Statin treatment, apo E geno-
type, country, education, test version where appropriate, smoking, cholesterol level,
history of vascular diseases, history of hypertension, history of diabetes mellitus, and
average blood pressure measures.
Table 3. Structural brain volumes in three groups of visit-to-visit blood pressure vari-
ability
Three groups of visit-to-visit blood pressure variability
Low Middle High P-value
Systolic blood pressure (n = 194) (n = 210) (n = 149)
Range of SD, mmHg 0.7-12.2 12.3 - 16.2 16.3 - 64.4
Grey matter 593 (3) 590 (3) 589 (3) 0.21
White matter 770 (3) 770 (3) 765 (3) 0.19
Hippocampus 7.6 (0.07) 7.6 (0.07) 7.4 (0.08) 0.01
Diastolic blood pressure (n = 178) (n=184) (n=191)
Range of SD, mmHg 0 - 6.5 6.6 - 8.5 8.6 - 33.1
Grey matter 591 (3) 594 (3) 587 (3) 0.18
White matter 768 (3) 772 (3) 764 (3) 0.62
Hippocampus 7.6 (0.07) 7.5 (0.07) 7.4 (0.07) 0.01
Data are structural brain volumes presented in mean (standard error) ml.
Abbreviations: SD, standard deviation.
Analyses were adjusted for age, sex, body mass index, Statin treatment, smoking,
cholesterol level, history of vascular diseases, history of hypertension, history of di-
abetes mellitus, and average blood pressure measures.
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Table 3 shows the association of systolic and diastolic visit-to-visit blood
pressure variability with structural brain volumes. Higher systolic and dias-
tolic blood pressure variability was associated with lower hippocampal volume
(both p=0.01). There was no association between blood pressure variability
and volume of the other brain structures (all p>0.05), except for the associa-
tion between higher systolic blood pressure variability and lower amygdala and
putamen volumes (both p=0.04). Again, all analyses were adjusted for average
systolic and diastolic blood pressure, which themselves did not associate with
structural brain volumes (all p>0.05) (table S-6 http://www.bmj.com/content/
suppl/2013/07/29/bmj.f4600.DC1).
Table 4. Microbleeds, infarcts and white matter hyperintensities in three groups of visit-to-
visit blood pressure variability
Three groups of visit-to-visit blood pressure variability
Low Middle High P-value
Systolic blood pressure (n=207) (n=191) (n=137)
Range of SD, mmHg 0.7-12.2 12.3-16.2 16.3-64.4
Microbleeds, OR (95% CI) 1(ref) 1.13 (0.69-1.85) 1.30 (0.77-2.21) 0.39
Infarcts, OR (95% CI) 1(ref) 0.95 (0.61-1.48) 1.26 (0.78-2.04) 0.40
Cortical 1(ref) 1.34 (0.68-2.64) 2.22 (1.09-4.54) 0.02
Lacunar 1(ref) 0.79 (0.48-1.31) 0.84 (0.48-1.46) 0.97
WMH volume, ml, mean (SE) 8.12 (1.02) 7.34 (1.08) 7.79 (1.19) 0.98
Diastolic blood pressure (n=215) (n=166) (n=154)
Range of SD, mmHg 0-6.5 6.6-8.5 8.6-33.1
Microbleeds, OR (95% CI) 1(ref) 1.75 (1.05-2.91) 1.77 (1.06-2.96) 0.01
Infarcts, OR (95% CI) 1 (ref) 0.99 (0.63-1.56) 1.32 (0.84-2.06) 0.43
Cortical 1(ref) 1.87 (0.93-3.76) 2.19 (1.10-4.37) 0.02
Lacunar 1(ref) 0.95 (0.57-1.60) 1.17 (0.70-1.95) 0.75
WMH volume, ml, mean (SE) 7.65 (1.05) 8.27 (1.11) 7.93 (1.10) 0.55
Abbreviations: SD, standard deviation; n, number; OR: odds ratio, CI: confidence interval,
WMH: white matter hyperintensity, SE: standard error.
Analyses were adjusted for age, sex, body mass index, statin treatment, smoking, cholesterol
level, history of vascular diseases, history of hypertension, history of diabetes mellitus, and
average blood pressure measures.
Data for microbleeds, infarcts and white matter hyperintensities were available for 535 par-
ticipants
Table 4 shows the association between visit-to-visit blood pressure variabil-
ity and cerebral microbleeds, infarcts and white matter hyperintensities. Higher
systolic and diastolic blood pressure variability was associated with higher risk
of cortical infarcts (both p=0.02). Prevalence of cortical infarcts in participants
with low, middle and high systolic blood pressure variability was 9.2%, 12.0%
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and 16.2% respectively. Prevalence of cortical infarcts in participants with low,
middle and high diastolic blood pressure variability was 7.9%, 13.3% and 16.2%
respectively. Furthermore, higher diastolic blood pressure variability was asso-
ciated with higher risk of all type microbleeds (p=0.01) as well as subcortical
microbleeds (p=0.004). Prevalence of microbleeds in participants with low, mid-
dle and high systolic blood pressure variability was 21.2%, 23.9% and 28.4%
respectively. Prevalence of cortical infarcts in participants with low, middle and
high diastolic blood pressure variability was 17.8%, 27.5% and 28.9% respec-
tively. Systolic and diastolic blood pressure variability was not associated with
white matter hyperintensities (both p>0.05). We found no association of av-
erage systolic and diastolic blood pressure with cerebral microbleeds, infarcts
and white matter hyperintensities (all p>0.05) (data presented in the supple-
mental material table S-6). We performed four sensitivity analyses to explore
whether the association between visit-to-visit blood pressure variability and the
studied outcomes could be affected by (1) participants with a history of clinical
stroke/transient ischemic attack (n=606) and cardiovascular disease (n=2404); (2)
participants with new or change in antihypertensive therapy during the study
period (n=2733); (3) participants who developed vascular events (n=872) or ar-
rhythmia (n=506) during the study period; (4) participants with high average
blood pressure (defined as average systolic blood pressure of ≥ 140 mmHg and
diastolic blood pressure of ≥ 80 mmHg during the study period) (n=830). These
sensitivity analyses showed that the results did not materially change. In an
overall sensitivity analysis we excluded all participants with previously men-
tioned conditions (n=4654) and results remained essentially unchanged (data
not shown).
Discussion
The main findings of this study are threefold. First, higher visit-to-visit systolic
and diastolic blood pressure variability is associated with worse performance
in different domains of cognitive function. Second, higher systolic and diastolic
blood pressure variability is associated with lower hippocampal volume and risk
of cortical infarcts, and higher diastolic blood pressure variability is associated
with risk of cerebral microbleeds. Third, these associations are independent of
various cardiovascular risk factors in particular average systolic and diastolic
blood pressure.
Although hypertension is a well-established risk factor for cardiovascular
diseases22, increasing evidence indicates that the predictive value of conven-
tional blood pressure measurement for cardiovascular diseases attenuates with
increasing age23 24. Recent studies have shown that higher visit-to-visit blood
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Figure 1. Stroop test, Letter-Digit Coding Test (LDCT), immediate Picture-Word Learn-
ing Test (PLTi) and delayed Picture-Word Learning Test (PLTd) scores in low, middle and
high thirds of systolic and diastolic visit-to-visit blood pressure variability. Bars represent
mean and 95% confidence interval. All analyses were adjusted for age, sex, body mass
index, Statin treatment, apo E genotype, country, education, test version where appro-
priate, smoking, cholesterol level, history of vascular diseases, history of hypertension,
history of diabetes mellitus, and average blood pressure measures.
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pressure variability increases risk of cardiovascular events25, stroke 1 24 and
carotid artery atherosclerosis 26 in older subjects, independent of average blood
pressure. Given the link between neuro-vascular dysfunction and cognitive im-
pairment 27, a recent study on 201 elderly participants at high risk of cardiovas-
cular disease showed that high visit-to-visit blood pressure variability during 12
months was associated with worse performance in MMSE and global deterio-
ration scale28. Consistent with this finding, by using a population of over five
thousand participants and over three years of blood pressure measurements, we
showed that high visit-to-visit systolic and diastolic blood pressure variability
associates with worse performance in different domains of cognitive function
including selective attention, processing speed, immediate verbal memory and
delayed verbal memory.
The magnitude of associations in this study, reflected as differences in cogni-
tive scores between top and bottom thirds of systolic and diastolic blood pressure
variability, are comparable with the observed differences in cognitive function
between groups of apolipoprotein E (Apo E) genotype on cognitive function29.
Apo E4 genotype is a well-recognized risk factor for development of demen-
tia in later life and it has been shown that subjects who carry this risk factor
have a four times higher risk of developing late onset Alzheimer‘s disease30.
This similar differences in cognitive test scores in Apo E groups and blood pres-
sure variability implies that the observed associations can be considered clini-
cally relevant. Different explanations can be proposed for the observed associ-
ation between high visit-to-visit blood pressure variability and impaired cogni-
tive function. First, both blood pressure variability and cognitive impairment
could stem from a common cause, without being causally related themselves.
Cardiovascular risk factors are the most likely candidate31. Nevertheless, we
reported our analyses adjusted for different cardiovascular risk factors and we
performed a sensitivity analysis, by separately excluding subjects with history
of cardiovascular diseases, which did not change our estimates, although we
accept that residual confounding could remain from unmeasured CVD risk fac-
tors. As a second explanation, high visit-to-visit blood pressure variability might
reflect a long term hemodynamic instability in the systemic circulation which
puts stress on the vascular endothelium7, 32. This hemodynamic stress may lead
to endothelial dysfunction and micro-vascular damage with consequent alter-
ations in brain structure and function33. Thirdly, exaggerated fluctuations in
systemic blood pressure could result in repeated episodes of cerebral hypoper-
fusion causing neuronal injury and cell death particularly in vulnerable brain
regions such as the hippocampus4. In line with latter explanations, we found
that higher visit-to-visit blood pressure variability is related to lower hippocam-
pal volume and presence of cerebral microbleeds and cortical infarcts. Given the
well-described association of hippocampal atrophy 34 and cerebral small vessel
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disease 10 with cognitive impairment, our findings may suggest that decreased
hippocampal volume, cerebral microbleeds and cortical infarcts are potential
pathogenic mechanisms behind the association between visit-to-visit blood pres-
sure variability and cognitive impairment.
Current evidence on the association of blood pressure variability with struc-
tural brain damage and cerebral small vessel disease mainly comes from studies
that focused on ambulatory blood pressure variability rather than visit-to-visit
blood pressure variability. These studies showed that higher ambulatory blood
pressure variability associates with brain atrophy and white matter lesions35-37.
In the present study, we only observed the association of visit-to-visit blood
pressure variability with lower hippocampal volume, cerebral microbleeds and
cortical infarcts. This might imply that different measures of blood pressure
variability carry different predictive values for brain outcomes24. Data on the
association between visit-to-visit blood pressure variability and manifestations
of small vessel diseases are scarce. Consistent with our findings, a recent study
showed that higher visit-to-visit blood pressure variability in subjects with a
history of ischemic stroke was associated with progression of cerebral microb-
leeds but not with white matter lesions38. It is worth pointing out that it is still
unclear whether higher blood pressure variability is a cause or consequence of
brain pathologies. It has been suggested that higher blood pressure variability
itself could originate from previously established brain pathologies disturbing
central autonomic control39. While clinical trials have shown conflicting find-
ings on the benefit of antihypertensive therapy on reducing risk of dementia,
calcium channel blockers, the most effective drug class to reduce blood pressure
variability40, showed significant efficacy in lowering risk of vascular cognitive
impairment41. This might highlight potential clinical implications of blood pres-
sure variability reducing agents in lowering risk of brain vascular pathologies
and cognitive impairment in old age. Collectively, we are not able to make a
causal inference from our observation and future long-term investigations are
warranted to examine whether strategies to reduce blood pressure variability
can effectively decrease risk of cognitive impairment as well as brain vascular
pathologies.
The major strengths of this study include a large sample size and application
of an extended standardized cognitive test battery to assess cognitive function.
In addition, availability of neuroimaging data provided us with a unique oppor-
tunity to investigate potential biological pathways linked to the association be-
tween visit-to-visit blood pressure variability and cognitive function. However,
this study has certain limitations that should be kept in mind when evaluating
the results. First, we included elderly participants at risk of cardiovascular dis-
eases with relatively preserved cognitive function (MMSE ≥ 24 points), which
might limit the extrapolation of our findings to a general population of elderly.
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However, this restriction has likely resulted in a homogeneous study popula-
tion who are among the main target groups for preventing cognitive decline42.
Second, the outcomes of this study were evaluated at one time point and long-
term longitudinal studies are needed to test whether lowering blood pressure
variability could lead to decelerated cognitive decline and lower load of brain
pathologies. Third, due to the limited number of participants in the MRI sub-
study, we had limited power in several outcome measures. This means that
absence of significant associations for several outcome measures should be in-
terpreted with caution. There are reports indicating that higher visit-to-visit
blood pressure variability is related to a higher risk of stroke and cerebrovascu-
lar damage1, however, the exact mechanisms behind these associations are still
unclear. This issue needs to be addressed in future MRI studies with larger
number of participants. Fourth, although we adjusted our analyses for different
potential confounding factors, there still might be some other confounders that
we did not consider in our analyses. Future studies investigating the determi-
nants of visit-to-visit blood pressure variability might help to better understand
the association between visit-to-visit blood pressure variability and neurocogni-
tive outcomes.
In conclusion, our findings suggest that higher visit-to-visit blood pressure
variability independent of average blood pressure is associated with worse cog-
nitive performance in older subjects at high risk of cardiovascular disease. Changes
in hippocampal volume and occurrence of cortical infarcts and cerebral microb-
leeds might be candidate pathogenic mechanisms behind this association. This
observation merits further interventional studies to address whether reducing
blood pressure variability can decrease risk of cognitive impairment in old age.
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Summary
The aim of this chapter is to investigate the association between cardiac hemody-
namics and features of brain ageing in community dwelling older subjects. Data
are from 931 subjects (b. 1907-35) who participated in a sub-study of the Age,
Gene/Environment Susceptibility (AGES)-Reykjavik Study. Cardiac hemody-
namics including left ventricular stroke volume (LVSV) and cardiac output (CO)
were measured using cardiac MRI. We assessed parenchymal brain volumes,
performance in three domains of cognition and presence of mild cognitive im-
pairment or dementia. Each 10 ml lower LVSV was associated with 5.0 ml (95%
CI 2.6-7.4) lower total parenchymal brain volume and 4.4 ml (95% CI 2.5-6.3)
lower gray matter volume. Likewise, each unit (L/min) lower CO was associ-
ated with 4.4 ml (95% CI 1.0-7.9) lower total brain parenchymal volume and 4.5
ml (95% CI 1.8-7.3) lower gray matter volume. Lower LVSV was associated with
worse performance in memory (p=0.040), processing speed (p=0.003) and exec-
utive functioning (p<0.001). Lower CO was associated with worse performance
in processing speed (p=0.014) and executive functioning (p<0.001). A decrease
in each 10 ml of LVSV and each unit of CO associated with higher risk of mild
cognitive impairment or dementia (OR: 1.25, 95% CI 1.02-1.561 and OR: 1.43,
95% CI 1.05-1.96 respectively). All these associations were independent of car-
diovascular diseases and risk factors such as hypertension, diabetes mellitus and
body mass index. Sub-optimal cardiac functioning, as reflected in lower levels of
stroke volume and cardiac output, is associated with structural and functional
features of brain ageing.
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Introduction
Structural and functional integrity of the brain depends on adequate and con-
stant supply of oxygen and nutrient through cerebral blood flow1. Chronic cere-
bral hypoperfusion has been shown to play a key role in development of age-
related brain pathologies in animal models2. Animal models with decreased
cerebral blood flow carry a higher risk for neuronal injury and death, blood
brain barrier disruption, cerebrovascular pathologies, and cognitive deficit3-6.
Congestive heart failure has a well-established association with decline in
cerebral blood flow7. Hence, patients with heart failure have been described as
human models for studying the impact of cerebral hypoperfusion on abnormal
brain ageing8. Different lines of evidence indicate that patients with heart failure
are at a higher risk for structural and functional brain abnormalities and inter-
ventions to improve cardiac functioning might lead to neurocognitive benefits in
these patients9-11. Recently, it has been debated whether early disturbances in
cardiac functioning, as reflected in cardiac hemodynamics, should also be con-
sidered as a risk factor for abnormal brain ageing12. Given the scarcity of data
on the link between suboptimal changes in cardiac functioning and features of
brain ageing in elderly community dwelling subjects, we aimed to investigate
the association of cardiac hemodynamics with structural and functional features
of brain ageing in a community-based cohort of older subjects.
Methods
Study population
Participants were from the ICELAND MI (Imaging Cardiac Evaluation to Lo-
cate Areas of Necrosis and Detect MI) cohort, which is a substudy of the Age,
Gene/Environment Susceptibility (AGES)-Reykjavik Study (n=5764)13. The AGES-
Reykjavik study is a randomly selected population-based cohort of men and
women born between 1907 and 1935 in Iceland. This study was approved by
the National Bioethics Committee in Iceland that acts as the institutional review
board for the Icelandic Heart Association and by the National Institute on Age-
ing intramural institutional review board. Participants in the AGES-Reykjavik
study were enrolled from January 2004 to January 2007. Details of inclusion
procedure for the AGES-Reykjavik study have been reported previously14. To
be eligible for the sub-study participants should be free of contraindications for
MRI scanning and gadolinium contrast injection. All participants gave informed
consent for this sub-study.
The overall study goals and study design of the ICELAND MI study have been
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described previously13. Participants in the ICELAND MI cohort were recruited
in two phases. The first phase involved random recruitment and a second phase
recruited all eligible and willing participants with diabetes. Of those who un-
derwent cardiac MRI (n = 970), 34 participants had nondiagnostic cardiac MRI
scans due to arrhythmia or inability to hold breath (n = 14), claustrophobia (n =
7), inability to gate cardiac images (n = 3), technical issues with reconstruction
and data transfer (n = 9), or artifact from spinal implants (n = 1). For five partic-
ipants data on the brain outcomes was not available leaving a final cohort of 931
participants (including 671 who were randomly selected and 260 with diabetes)
for this analysis.
Cardiac MRI and hemodynamic parameters
Cardiac magnetic resonance scans were performed on a study-dedicated 1.5-T
Signa Twinspeed system (GE Healthcare) using a 4-element cardiac phased array
coil. Typical cine steady-state free precession (SSFP) scan parameters resulted in
pixel dimensions of 1.8 × 2.1 mm, a slice thickness of 8mm with a 3-mm gap, and
30 images per cycle. Standard long-axis and short-axis views were obtained to
evaluate global and regional function. End-systolic phase was determined as the
minimal cross-sectional area of a midventricular slice. Left ventricular end di-
astolic volume (LVEDV) and Left ventricular end systolic volume (LVESV) were
computed by the summation of disks method. Left ventricular stroke volume
(LVSV) in ml was calculated by subtracting LVESV from LVEDV. Left ventricular
ejection fraction (LVEF) in % was calculated as LVSV/LVED × 100 and cardiac
output (CO) in L/min was calculated as LVSV/1000 × heartbeat per minute.
Brain Imaging
All the participants underwent a high-resolution brain MRI on the same 1.5-T
system. The imaging protocol has been described previously14, 15 and included
3D spoiled-gradient recalled T1-weighted, fast spin echo proton density/T2-
weighted, fluid-attenuated inversion recovery (FLAIR) and echo-planar imaging
gradient echo T2∗-weighted sequences. All images were acquired to give full
brain coverage with slices angled parallel to the anterior commissure-posterior
commissure line in order to give reproducible image views in the oblique-axial
plane. Total brain, white and grey matter, and white matter hyperintensity vol-
umes were computed automatically with the AGES-Reykjavik/Montreal Neu-
rological Institute pipeline, which accommodates full brain coverage includ-
ing cerebellum and brainstem, includes multispectral images (T1-weighted 3D
spoiled-gradient recalled sequence, FLAIR and proton density/T2-weighted fast
spin echo sequences), and is high throughput and with minimal editing. Data
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on manifestations of cerebral small vessel disease including white matter hy-
perintensities, infarcts and cerebral microbleeds (CMB) were obtained. The seg-
mentation pipeline, its components and accuracy has been described in detail
elsewhere16. White matter hyperintensities were considered present in regions
where signal intensity was higher than that of normal white and grey matter on
both T2-weighted and FLAIR images. Infarcts and CMB were evaluated qual-
itatively according to a standardized protocol that required a neuroradiologist
to identify the parenchymal defects and radiographers who entered additional
data on slice, location, and image characteristics. Infarcts were defined as a de-
fect of the brain parenchyma with signal intensity equal to cerebrospinal fluid
on all pulse sequences (FLAIR, T2-weighted, proton density weighted). CMB
were defined as focal areas of signal void within the brain parenchyma that (1)
are visible on T2∗-weighted GRE-EPI images, (2) are smaller or invisible on T2-
weighted FSE images (“blooming effect”), (3) are not abutting a parenchymal
defect, and (4) do not show any other structure in the area of signal void. Us-
ing these criteria, CMB can be differentiated from areas of signal void based on
vascular flow voids (which do not show the “blooming effect”), from past larger
hematomas associated with parenchymal defects, and from cavernomas. Areas
of symmetric hypointensities of the globus pallidus and putamen, likely to rep-
resent calcification or nonhemorrhagic iron deposits, were excluded.
Cognitive function and depressive symptoms
A battery of six different neurocognitive tests was administered to all partici-
pants. From these tests, three cognitive domain composite scores were calcu-
lated: (1) the memory composite score included the immediate and delayed re-
call of a modified version of the California Verbal Learning Test17; (2) the speed
of processing composite included the Figure Comparison Test18, the Digit Sym-
bol Substitution Test19, and the Stroop Test20 part 1 and 2; and (3) the executive
function composite included a short version of the Cambridge Neuropsycho-
logical Test Automated Battery Spatial Working Memory test, the Digits Back-
ward test19, and the Stroop test part 3. Composite measures were computed
by converting raw scores on each test to standardized Z-scores and averaging
the Z-scores across the tests in each composite. Inter-rater reliability for all tests
was excellent (Spearman correlations range, 0.96-0.99). Cognitive impairment
was considered to be present if subjects had either mild cognitive impairment
or dementia. Mild cognitive impairment and dementia case ascertainment was
a 3-step process described previously21. Briefly, all subjects were screened on
cognitive function with the Mini-Mental State Examination22 and Digit Symbol
Substitution Test. Those with positive screen results were administered a diag-
nostic battery of neuropsychological tests and, among them, those with positive
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screen results were examined by a neurologist and a proxy interview was admin-
istered. A consensus diagnosis, according to international guideline, was made
by a panel that included a geriatrician, neurologist, neuropsychologist, and neu-
roradiologist. Depressive symptoms were assessed using the 15-item Geriatrics
Depression Scale (GDS-15)23. The GDS-15 is a well-established screening tool to
detect depression in elderly people and consists of yes and no questions. Higher
scores in the GDS-15 indicate greater number of depressive symptoms.
Other covariates
Level of education and smoking status were assessed by questionnaire. Dia-
betes was defined as a history of diabetes, use of glucose-modifying medication,
or fasting blood glucose of 7 mmol/L. Hypertension was defined as measured
systolic blood pressure 140 mm Hg or diastolic blood pressure 90 mm Hg, or
self-reported doctor’s diagnosis of hypertension, or using antihypertensive med-
ications. Prevalent coronary heart disease was defined as self-reported history
of coronary artery disease or coronary artery bypass surgery or angioplasty or
angina pectoris on the Rose Angina Questionnaire, or evidence on ECG of pos-
sible or probable myocardial infarction. The diagnosis of atrial fibrillation was
made by a twelve lead electrocardiogram (ECG) performed during the AGES-
Reykjavik study comprehensive examination. Additionally, hospital discharge
diagnosis codes from all hospitals in Reykjavik from January 1987 till the day
of the study examination were reviewed for the diagnosis of atrial fibrillation
(ICD-9 code 427.9 or ICD-10 code I48).
Statistical analyses
Characteristics of the study participants are reported as mean (standard devia-
tion) for continuous variables and number (percentage) for categorical variables.
GDS score is reported as median (interquartile range) since it was not distributed
normally. The association between hemodynamic parameters and continues out-
comes was estimated with linear regression models, and the association between
hemodynamic parameters and dichotomous outcomes was estimated with logis-
tic regression models. We performed our analyses in two steps. In the first step
all the analyses were adjusted for age and sex. In the second step all analyses
were adjusted for age, sex, education, smoking status, hypertension, diabetes
mellitus, prevalent coronary heart disease, total cholesterol, body mass index,
atrial fibrillation and systolic blood pressure. For the association between hemo-
dynamic parameters and brain volumes, analyses were additionally adjusted for
intracranial volume. All the probability values were calculated by using car-
diac hemodynamics as continuous variables. Analysis of covariance was used
58
to calculate the adjusted means and standard errors for the brain volumes and
cognitive scores in the tertiles of hemodynamic parameters. All analyses were
carried out using SPSS software (version 20.0.0, SPSS Inc., Chicago, IL).
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Results
Mean age of participants was 75.9 years and 47.7% of them were male. Average
values for LVEF, LVSV and CO were 60.5%, 62.1 ml and 4.0 L/min respectively
(Table 1).
Table 1. Characteristics of the study participants: AGES-RS ICELAND-MI
Characteristics Values
Number of participants 931
Socio-demographics
Age, mean (SD) 75.9 (5.2)
Male, n (%) 444 (47.7)
Low education∗, n (%) 206 (22.2)
Current smoker, n (%) 105 (11.3)
Cardiovascular risk factors
Hypertension, n (%) 770 (82.7)
Diabetes mellitus, n (%) 330 (35.4)
Coronary heart disease, n (%) 208 (22.3)
Atrial fibrillation, n (%) 138 (14.8)
Systolic blood pressure, mmHg, mean (SD) 143.4 (19.7)
Diastolic blood pressure, mmHg, mean (SD) 74.0 (9.5)
Total cholesterol, mmol/L, mean (SD) 5.5 (1.2)
Body mass index, kg/m2, mean (SD) 27.6 (4.3)
Cardiac hemodynamics
Left ventricular end diastolic volume, ml, mean (SD) 105.0 (29.8)
Left ventricular end systolic volume, ml, mean (SD) 43.0 (23.3)
Left ventricular ejection fraction, %, mean (SD) 60.5 (9.8)
Left ventricular stroke volume, ml, mean (SD) 62.1 (15.2)
Cardiac output∗∗, L/min, mean (SD) 4.0 (1.0)
Brain outcomes
Total brain tissue volume, ml, mean (SD) 1082.0 (104.8)
Grey matter volume, ml, mean (SD) 678.0 (64.8)
White matter volume, ml, mean (SD) 384.3 (48.2)
Memory composite score, point, mean (SD) 0.07 (0.9)
Processing speed composite score, point, mean (SD) 0.10 (0.8)
Executive function composite score, point, mean (SD) 0.04 (0.7)
Geriatric depression scale score, point, median (IQR) 2 (1-3)
Cognitive impairment∗∗∗, n (%) 81 (8.8)
White matter lesion volume, ml, mean (SD) 19.7 (18.2)
Infarcts, n (%) 311 (33.4)
Microbleeds, n (%) 110 (11.9)
∗ Primary school education or less
∗∗ Data for cardiac output was available for 922 participants.
∗∗∗ Presence of mild cognitive impairment or dementia
Abbreviations: SD; standard deviation, n; number, IQR; inter quartile
range,
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As presented in table 2, multivariate analyses showed that each 10 ml lower
LVSV was associated with 5.0 ml (95% CI 2.6-7.4) lower total brain parenchymal
volume and 4.4 ml (95% CI 2.5-6.3) lower gray matter volume. Likewise, each
unit (L/min) lower CO was associated with 4.4 ml (95% CI 1.0-7.9) lower total
brain parenchymal volume and 4.5 ml (95% CI 1.8-7.3) lower gray matter volume.
Lower LVSV and CO were not associated with white matter volume and we
found no association between LVEF and any of the brain volumes we examined
(all p<0.05). Figure 1 shows adjusted mean values of the brain volumes in
tertiles of LVEF, LVSV and CO.
In multivariate analyses lower LVEF was associated with worse performance
in executive function (p<0.001) (Table 3). Lower LVSV was associated with
worse performance on memory (p=0.04), processing speed (p=0.003) and ex-
ecutive function (p<0.001) tests. Likewise, lower CO was associated with worse
scores in processing speed (p=0.014) and executive function (p<0.001). Figure
2 shows adjusted mean values of the cognitive scores in tertiles of LVEF, LVSV
and CO.
In age and sex adjusted analyses, lower LVEF, LVSV and CO were associated
with depressive symptoms (Table 4). However, further adjustment for cardio-
vascular risk factors attenuated the significance of the associations. We observed
that each 10 ml lower LVSV was associated with 1.25-fold (95% CI 1.02-1.51)
higher risk of cognitive impairment and each unit lower CO was associated with
1.43-fold (95% CI 1.05-1.96) higher risk of cognitive impairment. All these as-
sociations were independent of socio-demographic and cardiovascular factors.
We found no associations between cardiac hemodynamic parameters and man-
ifestations of cerebral small vessel disease. To test whether the association of
cardiac hemodynamic parameters with brain volumes and cognitive functioning
was the same in the groups of randomly selected subjects and diabetic patients,
we performed a stratified analysis and found similar associations (all p for in-
teractions <0.05). In a sensitivity analysis, to test whether observed associations
were not dependent on subjects with very low cardiac functioning, we excluded
subjects in the lowest decile of the cardiac hemodynamic parameters and the
associations did not essentially change (data not shown).
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Figure 1: Brain tissue volumes in tertiles of left ventricular ejection fraction (LVEF), left
ventricular stroke volume (LVSV) and cardiac output (CO). Bars represent adjusted means
and standard errors. Analyses were adjusted for age, sex, education, current smoker,
intracranial volume, history of hypertension, diabetes mellitus, systolic blood pressure,
prevalent coronary heart disease, total cholesterol, body mass index and atrial fibrillation.
Ranges for tertiles of LVEF are low: 15.2-58.4%, middle: 58.5-65.2% and high: 65.3-85.3%.
Ranges for tertiles of LVSV are low: 20.3-55.3ml, middle: 55.4-66.5ml and high: 66.6-
166.9ml. Ranges for tertiles of CO are low:1.6-3.4L/min, middle: 3.5-4.2L/min and high:
4.3-11.7L/min.
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Figure 2: Cognitive function in tertiles of left ventricular ejection fraction (LVEF), left
ventricular stroke volume (LVSV) and cardiac output (CO). Bars represent adjusted means
and standard errors. Analyses were adjusted for age, sex, education, current smoker,
history of hypertension, diabetes mellitus, systolic blood pressure, prevalent coronary
heart disease, total cholesterol, body mass index and atrial fibrillation. Ranges for tertiles
of LVEF are low: 15.2-58.4%, middle: 58.5-65.2% and high: 65.3-85.3%. Ranges for tertiles
of LVSV are low: 20.3-55.3ml, middle: 55.4-66.5ml and high: 66.6-166.9ml. Ranges for
tertiles of CO are low:1.6-3.4L/min, middle: 3.5-4.2L/min and high: 4.3-11.7L/min.
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Table 4. Association of cardiac hemodynamics with depression and cog-
nitive impairment: AGES-RS ICELAND-MI
Depression Cognitive impairment†
Beta∗ (95% CI) P value OR∗ (95% CI) P value
LVEF Model 1 0.16 (0.02, 0.30) 0.03 1.16 (0.99, 1.47) 0.09
Model 2 0.08 (-0.06, 0.23) 0.25 1.07 (0.84, 1.37) 0.56
LVSV Model 1 0.10 (0.00, 0.19) 0.05 1.28 (1.06, 1.59) 0.004
Model 2 0.07 (-0.03, 0.17) 0.16 1.25 (1.02, 1.51) 0.033
CO Model 1 1.5 (0.15, 2.90) 0.029 1.56 (1.18, 2.08) 0.003
Model 2 1.1 (-0.33, 2.50) 0.13 1.43 (1.05, 1.96) 0.025
Model 1- Adjusted for age and sex
Model 2- Adjusted for age, sex, education, current smoker, history of
hypertension, diabetes mellitus, systolic blood pressure, prevalent coro-
nary heart disease, total cholesterol, body mass index, atrial fibrillation
† Defined as mild cognitive impairment or dementia
∗ Betas and odds ratios are presented for each 10% lower LVEF, 10 ml
lower LVSV and one L/min lower CO
Abbreviation: LVEF; Left ventricular ejection fraction, LVSV: Left ven-
tricular stroke volume, CO; Cardiac output
Discussion
Findings of this study suggest that sub-optimal cardiac functioning, as reflected
in cardiac hemodynamics, is associated with lower brain volumes and cognitive
performance. We observed that community-dwelling older subjects with low
stroke volume and cardiac output are at a higher risk for brain parenchymal
loss and cognitive impairment. The associations between cardiac hemodynamics
and brain outcomes were independent of socio-demographic and cardiovascular
factors.
Increasing body of evidence indicates that patients with advanced heart fail-
ure carry a higher risk for manifestations of brain ageing including gray matter
loss, white matter hyperintensities, infarcts, and cognitive impairment9, 24-26. Re-
cently, it has been proposed that not only subjects with advanced heart failure
but also those with suboptimal cardiac functioning might be at higher risk for
accelerated brain ageing8. This hypothesis was tested in a limited number of
studies based on community-dwelling older adults. In a cohort of individuals
from the Framingham Offspring Study with a mean age of 61 years, Jefferson
et al showed that higher cardiac index was associated with higher total brain
volume but they could not demonstrate a clear association with most of the
neuropsychological measures in the whole study population12. However, the
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interpretation of those findings is hampered because brain outcomes were as-
sessed about four years before cardiac MRI measurements. On average, this
cohort is also younger than our study population. In an another study, middle
aged to elderly subjects in the lowest and highest quintile of the LVEF showed
worse performance in memory and executive functioning as well as visuoper-
ceptual abilities compared to the reference groups27. In our cohort, with a mean
age of 76 years, we showed that decreased cardiac hemodynamic parameters,
in particular stroke volume and cardiac output, was strongly associated with
structural brain changes including lower total brain volume and gray matter
volume as well as functional brain abnormalities including worse performance
in processing speed and executive functioning. Moreover, we showed that lower
stroke volume and cardiac output associates with higher risk of mild cognitive
impairment or dementia. Different mechanisms may explain a link between
impaired cardiac functioning and brain ageing. One possibility is shared co-
morbidities and vascular risk factors28. That could, on the one hand, impair car-
diac functioning and on the other hand, lead to brain structural and functional
abnormalities29. Available evidence for the importance of early recognition and
management of vascular risk factors such as hypertension in prevention of car-
diovascular and cerebrovascular events support this notion30. However, we ob-
served that correction of the analyses for established vascular risk factors did not
essentially change our findings except for depressive symptoms. It is also pos-
sible the decline in cardiac functioning and brain ageing are an epiphenomenon
and not causally related. While this possibility cannot be totally excluded, pre-
vious population-based cohort studies on older people free of dementia showed
that subjects with heart failure are at a significantly higher risk for developing
dementia26. As an alternative explanation, impaired cardiac functioning could
result in a decreased cerebral blood flow and consequently long-standing cere-
bral hypoperfusion, via neuronal loss and injury, put the brain at higher risk
for structural and functional abnormalities31. In line with this hypothesis, it has
been shown that interventions to enhance left ventricular functioning improve
cognitive performance in patients with heart failure10. In this study we observed
that lower cardiac functioning was not related with markers of brain small vessel
pathologies. This finding might indicate that long-term decreased cardiac func-
tioning mainly influences neuronal energy homeostasis which ultimately results
in neuronal cell death and brain tissue loss. Although a role for cerebral hy-
poperfusion as a mediator in the association between cardiac functioning and
brain ageing seems plausible, further research is needed to confirm this hypoth-
esis and we are not able to establish a causal relationship only based on our
observational data.
This study has certain strengths and limitations. A relatively large cohort of
community-dwelling older individuals with available data on cardiac function-
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ing assessed by cardiac MRI, which is a reliable method and less operator depen-
dent modality compared to conventional echocardiography32, can be marked as
the main strengths of this study. In addition, we had an extended set of data
on structural and functional features of brain ageing. A possible limitation is
that our study population consists of randomly selected individuals as well as
a group of individuals with diabetes. However, the stratified analyses showed
that the association between cardiac hemodynamics and brain outcomes was
similar in both groups. As another limitation, due to the cross-sectional design
of this study, it is not clear whether changes in cardiac hemodynamics preceded
changes in brain outcomes. This highlights a need for future longitudinal studies
to investigate whether disturbances in cardiac hemodynamics are also associated
with progression of the structural and functional brain pathologies.
In conclusion, our findings suggest that suboptimal cardiac functioning, in-
dependent of conventional cardiovascular risk factors, is associated with struc-
tural and functional features of brain ageing in community-dwelling older sub-
jects. The cross-sectional associations suggest that elderly patients presenting
with cardiac or cognitive signs and symptoms may have both cardiac and cere-
bral disease and should be evaluated accordingly. Further, since there is a wider
formulary for treating cardiac problems than there is for cognitive problems,
clinicians treating cardiac problems should monitor a patient’s cognition along
with cardiac function. This is consistent with recent recognition and recommen-
dations by the AHA that cardio-vascular risk factors lead to vascular cognitive
impairment33. Future longitudinal and experimental studies will unravel the
temporality and pathogenic mechanisms behind this association.
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Summary
Hypertension in middle age is a risk factor for dementia, whereas in old age
cognitive impairment is associated with lower blood pressures. Heart failure
may play a role in this reversal of associations. In this chapter, we studied the
relation between N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, a
marker of heart failure, blood pressure, and cognitive function over time in the
oldest old. In the Leiden 85-plus Study, we measured NT-proBNP levels at base-
line and annually global cognitive function (MMSE) and blood pressure (BP) in
560 subjects aged 85 years at baseline, who were followed for 5 years. Subjects
in the highest tertile of NT-proBNP levels scored 1.8 points lower on the MMSE
than subjects in the lowest tertile (p=0.004), and had a 0.7 point stronger decline
in MMSE score per year (p=0.006). Subjects in the category highest tertile of NT-
proBNP and the lowest tertile of systolic BP had a 3.7 point lower MMSE score
at baseline (p<0.001) and a 0.6 point additional annual decline in MMSE score
(p=0.040) compared to subjects in any other category. In the oldest old high
NT-proBNP levels are associated with lower MMSE scores and with stronger
declines in MMSE score. The combination of high NT-proBNP levels and low
systolic BP is most detrimental for global cognitive function. Possibly, a failing




Cardiovascular diseases, such as myocardial infarction, generalized atheroscle-
rosis, and stroke have been associated with increased risk of dementia and with
steeper declines in cognitive function1-4. Hypertension on the contrary seems to
be a risk factor for dementia only when present in middle age, whereas most
studies show that dementia and cognitive decline in the oldest old associate
with lower blood pressures5. In the oldest old blood pressures decrease over
time6,7, and stronger declines are related to the presence of dementia and cogni-
tive decline8,9. One possible explanation for the decline in blood pressure in the
oldest old might be the presence of (subclinical) congestive heart failure, with a
failing pump function resulting in lower blood pressures10.
Congestive heart failure has been associated with cognitive impairment in
several studies. In two hospital-based studies, patients with heart failure had
an increased risk of cognitive impairment, and with increasing severity of heart
failure patients had worse cognitive performance11,12. Moreover, another study
showed that lower left ventricular ejection fractions in elderly patients with heart
failure associated with reduced verbal memory function13. A commonly used
serum marker of heart failure is the N-terminal pro-brain natriuretic peptide
(NT-proBNP), the inactive fragment of the proBNP hormone14. NT-proBNP has
proven to be a quantitative marker of acute heart failure, with high sensitiv-
ity and reasonable specificity, and is also a useful tool to monitor (treatment
of) heart failure15. Several cross-sectional studies have shown that higher NT-
proBNP levels associate with lower cognitive function16,17, and one follow-up
study showed that higher NT-proBNP levels at baseline associated with worse
cognitive function five to eight years later18. The relation between NT-proBNP
levels, blood pressure, and cognitive function over time in the oldest old, has not
been studied yet.
Here, we studied the association between NT-proBNP levels, blood pressure
and cognitive function over time in the Leiden 85-plus Study, a population based
follow-up study amongst subjects aged 85 years at baseline. We hypothesize that
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Between September 1, 1997, and September 1, 1999, a total of 705 inhabitants of
the community of Leiden, the Netherlands, reached the age of 85 years. Among
these 85-year-old persons, we initiated a follow up study to investigate determi-
nants of successful aging. There were no selection criteria on health or demo-
graphic characteristics. Fourteen inhabitants died before they could be enrolled.
The response rate was 87%; a total of 599 subjects (397 women and 202 men)
participated19. Of the 599 participants in the cohort, 38 refused to provide a
blood sample, and NT-proBNP measurement failed in one participant, yielding
a total number of 560 participants for the present study. Participants were visited
within one month after their 85th birthday at their home for face-to-face inter-
views and neuropsychological testing. They were revisited annually until age
90 years. The Medical Ethical Committee of the Leiden University Medical Cen-
tre approved the study, and informed consent was obtained from all participants.
Plasma levels of NT-proBNP
Non-fasted blood samples were taken at the first visit early in the morning.
Blood samples were kept frozen at -80oC. In 2011 citrated plasma levels of NT-
proBNP were measured in one batch using the NT-proBNP assay of Roche Diag-
nostics (Mannheim, Germany) on a Roche Modular E-170 automated immuno-
analyser.
Blood pressure
Annually, blood pressure was measured, using a mercury sphygmomanome-
ter, in seated position. During each home visit two blood pressure measurements
were done, the first after at least five minutes of rest and no vigorous exercise
in the preceding thirty minutes, the second after approximately 90 minutes at
the end of the visit. The systolic value was measured at Korotkoff sound 1, and
the diastolic value was measured at Korotkoff sound 5. For each year, the mean
value of the two measurements was calculated and used in further analyses.
Mean arterial pressure was calculated as 1/3(systolic blood pressure) + 2/3(di-
astolic blood pressure).
Global cognitive function
At age 85 years and then annually, global cognitive function was assessed in
participants using the Mini-Mental State Examination (MMSE)20. The MMSE
examines five areas of cognitive function: orientation, registration, attention and
calculation, recall, and language. Possible scores on the MMSE range from 0 to
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30 points, with lower scores indicating worse global cognitive functioning.
Other covariates
The level of education of each participant was determined by the number of
years a subject went to school. Information was obtained at the first visit us-
ing a questionnaire. Low education was defined by six or less than six years
of schooling, whereas high education was defined by seven or more years of
schooling. The burden of vascular disease at baseline was determined by the
number of cardiovascular and cerebrovascular pathologies (myocardial infarc-
tion, angina pectoris or myocardial ischemia, claudicatio intermittens, arterial
surgery, stroke, and transient ischemic attack). Information on use of antihy-
pertensive medication was obtained from pharmacist records, or from a ques-
tionnaire, filled out by the treating physician for institutionalized participants.
Participants were classified as having diabetes when they met at least one of the
following criteria: (a) history of type 2 diabetes obtained from the general prac-
titioner or the subject’s treating physician; (b) use of antidiabetic medication,
based on information obtained from the subject’s pharmacist; or (c) nonfasting
glucose of 11.1 mmol/L or higher. Information on smoking was obtained from
questionnaires, which were filled out by each participant at baseline. BMI was
calculated by dividing the weight in kilograms by the square of length in meters
(kg/m2). Creatine clearance was estimated with the Cockroft-Gault formula.
Prevalence of atrial fibrillation was determined by automated Minnesota Cod-
ing (Minnesota Code 8-3-1) of ECGs, which were recorded on a Siemens Sicard
440 (Erlangen, Germany), and were transmitted to the ECG Core Laboratory in
Glasgow Royal Infirmary.
Statistical analyses
Characteristics of the study participants are reported as mean (standard devia-
tion) for continuous variables and number (percentages) for categorical variables
in tertiles of NT-proBNP levels. The associations of both NT-proBNP levels and
systolic blood pressure with MMSE score at baseline and during follow up were
analyzed using two different methods. First, linear mixed models were used
for graphically representing the associations. Linear mixed models use all avail-
able data during follow-up and account for repeated measurements, thereby
handling missing data more appropriately than traditional models21. For more
accurate analyses using all available data, but without imputation methods for
missing data, the associations of NT-proBNP levels and systolic blood pressure
with MMSE score were analyzed using linear regression analysis. In these analy-
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ses baseline associations were tested and for the longitudinal associations regres-
sion coefficients of change in MMSE score per year were calculated per subject,
yielding new outcome variables used as the determinant. In the primary anal-
yses categorical NT-proBNP levels and systolic blood pressure were the inde-
pendent variable, whereby NT-proBNP levels and systolic blood pressure were
divided in tertiles. For continuous analyses log-transformed NT-proBNP lev-
els were used. In a multivariate model all analyses were corrected for level
of education, use of antihypertensives, smoking status, prevalence of diabetes,
body mass index, renal function, prevalence of atrial fibrillation, and, finally, the
number of cardiovascular and cerebrovascular pathologies at baseline. In a final
analysis a new variable consisting of four categories, using combinations of the
lowest and highest tertile of NT-proBNP levels and the lowest and highest ter-
tile of systolic blood pressure, was used as an independent variable with MMSE
scores as the determinant. All calculations were performed using SPSS software
(version 20.0.1, SPSS Inc, Chicago, Ill).
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Results
Table 1 shows baseline characteristics of all 560 study participants in tertiles of
NT-proBNP levels. Compared to subjects in the lowest tertiles, subjects in the
highest tertile of NT-proBNP had a lower educational level, had lower blood
pressures, had a lower body mass index, and a lower renal function, were more
likely to use antihypertensives, and to have a history of smoking, and had a
higher prevalence of cardiovascular pathologies and atrial fibrillation.
Table 1. Baseline characteristics of study population.
Serum MT-proBNP
Low Middle High
Characteristics (n=186) (n=187) (n=187) p-value
Male (%) 62 (33%) 54 (29%) 71 (38%) 0.176c
Low education (%)a 115 (62%) 112 (60%) 134 (72%) 0.030c
SBP, mmHg (SD)b 156.8 (17.6) 155.9 (18.1) 152.9 (20.0) 0.045d
DBP, mmHg (SD)b 79.0 (9.0) 77.2 (9.4) 74.1 (9.6) <0.001d
MAP, mmHg (SD)b 104.9 (10.5) 103.4 (11.0) 100.4 (11.4) <0.001d
PP, mmHg (SD)b 77.8 (14.3) 78.7 (14.6) 78.8 (17.1) 0.553d
Body mass index, kg/m2 (SD)b 28.1 (4.2) 27.4 (4.9) 26.1 (4.0) < 0.001d
GFR, ml/min (SD)b 48.7 (11.0) 46.2 (10.6) 40.7 (11.5) <0.001d
Use of antihypertensives (%) 66 (36%) 87 (45%) 96 (51%) 0.007c
Current smoking (%) 30 (16%) 24 (13%) 35 (19%) 0.307c
Former smoking (%) 90 (49%) 76 (42%) 99 (54%) 0.048c
Prevalence of DM type II (%) 30 (16%) 27 (14%) 35 (19%) 0.531c
Prevalence CVD (%) 49 (27%) 65 (36%) 111 (62%) <0.001c
Prevalence of atrial fibrillation (%) 3 (2%) 4 (2%) 49 (27%) <0.001c
a Level of education was dichotomized by six years of schooling
b Normally distributed continuous data are presented as means with standard
deviations
c Statistical significance of the difference in number of subjects per tertile, using
Chi2 testing
d Statistical significance of the trend over the tertiles, using linear regression anal-
ysis
Abbreviations: SBP: systolic blood pressure, DBP: diastolic blood pressure, MAP:
mean arterial pressure, PP: pulse pressure
Figure 1a graphically shows the association between NT-proBNP levels and
MMSE scores from age 85 to 90 years. At age 85 years, subjects in the highest
tertile of NT-proBNP had a 1.8 point lower MMSE score than subjects in the
lowest tertile (p=0.002). Moreover, during the five year follow-up, subjects in the
highest tertile of NT-proBNP had a 0.24 point steeper decline in MMSE score
per year compared to subjects in the lowest tertile (p=0.008). There was also an
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association between systolic blood pressure and MMSE score (figure 1b). Sub-
jects in the lowest tertile of systolic blood pressure had a 2.8 point lower MMSE
score at age 85 years than subjects in the highest tertile (p<0.001). They also had
a 0.39 point steeper decline in MMSE score per year compared to subjects in the
highest tertile of systolic blood pressure (p<0.001).
When analyzing these associations with NT-proBNP levels and systolic blood
pressure as continuous variables similar associations were found. An increase in
log-transformed NT-proBNP levels associated both with lower MMSE scores as
baseline (difference in MMSE score at age 85 years per 1 ln-NT-proBNP increase:
-0.57, 95% CI, -0.98 to -0.16, p=0.007) and with stronger declines in MMSE score
from age 85 to 90 years (additional annual change in MMSE score from age 85
to 90 years per 1 ln-NT-proBNP increase: -0.08, 95% CI, -0.15 to -0.02, p=0.012).
An increase in systolic blood pressure associated with higher MMSE scores at
baseline (difference in MMSE score at age 85 years per 10 mmHg increase in
systolic blood pressure: +0.68, 95% CI, 0.43 to 0.93, p<0.001) and with weaker
declines in MMSE score from age 85 to 90 years (additional annual change in
MMSE score from age 85 to 90 years per 10 mmHg increase in systolic blood
pressure: 0.08, 95% CI, 0.01 to 0.04, p<0.001).
When using linear regression analyses for analyzing the association between
tertiles of NT-proBNP levels and MMSE scores at baseline and during follow-
up, similar results were found as in the linear mixed models analyses (table 2).
Subjects in the highest tertile of NT-proBNP had lower MMSE scores at age 85
years and had stronger declines in MMSE score from age 85 to 90 years. Also for
the baseline association between systolic blood pressure and MMSE score simi-
lar results were found, with the lowest MMSE scores at age 85 years in subjects
in the lowest tertile of systolic blood pressure. However, subjects in the lowest
tertile of systolic blood pressure did not have a significant stronger decline in
MMSE score from age 85 to 90 years compared to subjects in the highest tertile.
In continuous multivariate analyses, with further correction for possible con-
founders, similar associations were found. After correction for sex, education,
smoking, prevalence of diabetes mellitus and atrial fibrillation, use of antihyper-
tensives, BMI, and renal function, higher ln-NT-proBNP levels associated with
lower MMSE scores at age 85 years (difference in MMSE score at age 85 years
per 1 ln-NT-proBNP increase: -0.49, 95% CI, -0.94 to -0.04, p=0.032), and with
stronger declines in MMSE score from age 85 to 90 years (change in MMSE
score from age 85 to 90 years: -0.19, 95% CI, -0.37 to -0.02, p=0.030). With fur-
ther correction for the prevalence of cardiovascular pathologies the association
was no longer significant for the baseline analysis (p=0.131), but stayed for the
longitudinal analysis (p=0.043). In the multivariate analyses there was a strong
association between systolic blood pressure and MMSE score at baseline (dif-
ference in MMSE score at age 85 years per 10 mmHg increase in systolic blood
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Figure 1. NT-proBNP and systolic blood pressure were divided in tertiles, based on
the medians. Data points represent estimates and their standard errors, calculated us-
ing linear mixed models, with adjustment for sex and level of education. Number of
subjects and range of values per tertile: low NT-proBNP, n=186, 20.8-200.9 pg/ml; high
NT-proBNP, n=187, 552.9-28,362.7 pg/ml; low systolic blood pressure, n=186, 110.0-146.5
mmHg; high systolic blood pressure, n=193, 162.0-215.0 mmHg.
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pressure: +0.49, 95% CI, 0.24 to 0.75, p<0.001), but not with MMSE score from
age 85 to 90 years (change in MMSE score from age 85 to 90 years per 10 mmHg
increase in systolic blood pressure: +0.08, 95% CI, -0.02 to 0.18, p=0.138).
Table 2. MMSE score at age 85 years and change in MMSE score from
age 85 to 90 years dependent on tertiles of NT-proBNP and tertiles of
systolic blood pressure.
Tertiles of the determinant
Low Middle High P-value
NT-proBNP
Cross-sectional 25.8 (0.4) 24.6 (0.4) 24.0 (0.4) 0.004
Longitudinal -0.9 (0.2) -1.0 (0.2) -1.6 (0.2) 0.006
SBP
Cross-sectional 23.1 (0.4) 25.3 (0.4) 25.9 (0.4) <0.001
Longitudinal -1.4 (0.2) -1.0 (0.2) -1.1 (0.2) 0.139
Tertiles of NT-proBNP and tertiles of systolic blood pressure were cre-
ated on the median. Estimates with their standard errors were calcu-
lated, with correction for sex and level of education. P-values represent
the statistical significance of the trend over the tertiles of NT-proBNP
and tertiles of systolic blood pressure (SBP), calculated using linear re-
gression analysis, with adjustment for sex and level of education. Num-
ber of subjects per tertile NT-proBNP: lowest, n=186; medium, n=187;
highest, n=187. Number of subjects per tertile systolic blood pressure:
lowest, n=186; medium, n=181; highest, n=193.
Finally, to test for the combined effect of NT-proBNP levels and systolic blood
pressure on MMSE scores, a new variable was created, consisting of combina-
tions of the lowest and highest tertiles of NT-proBNP levels and systolic blood
pressure. Figure 2 shows that subjects in the categor ‘high NT-proBNP & low
systolic blood pressure’ had the lowest MMSE score at baseline and had the
strongest decline in MMSE score from age 85 to 90 years. Compared to the other
three categories, subjects in the category ‘high NT-proBNP & low systolic blood
pressure’ had a 3.7 point lower MMSE score at age 85 years (95% CI, 2.1 to 5.3,
p<0.001), and a 0.49 point annual additional decline in MMSE score from age 85
to 90 years (95% CI, 0.24 to 0.75, p<0.001). When using diastolic blood pressure,
mean arterial pressure, and pulse pressure in the models, similar associations
were found at baseline (all p≤0.001) and during follow up for pulse pressure
(p<0.001), but not for diastolic blood pressure (p=0.580) and mean arterial pres-
sure (p=0.089).
When analyzing the associations between NT-proBNP levels, systolic blood
pressure and MMSE scores with linear regression analysis instead of linear
mixed models, similar results were found for baseline associations, and results
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Figure 2. MMSE score from age 85 to 90 years dependent on categories of tertiles of
NT-proBNP and tertiles of systolic blood pressure. Categories of NT-proBNP and sys-
tolic blood pressure were created by making tertiles, based on the medians, and using
the highest and the lowest tertile of each parameter. Data points represent estimates,
calculated using linear mixed models, with adjustment for sex and level of education.
were less outspoken for the longitudinal associations. When comparing the cat-
egory ‘high NT-proBNP & low systolic blood pressure’ with the other three
categories the difference in MMSE score at age 85 years was 3.7 points (95% CI,
2.1 to 5.3, p<0.001), and the additional annual decline in MMSE score from age
85 to 90 years was 0.6 points (95% CI, 0.0 to 1.3, p=0.040).
Discussion
The main finding of our study is that higher NT-proBNP levels are associated
with worse global cognitive function at baseline and with stronger cognitive
decline during follow-up in the oldest old. Moreover, lower systolic blood pres-
sures associated with worse global cognitive function at baseline, but not clearly
with stronger cognitive decline during follow-up. When combining NT-proBNP
levels and systolic blood pressures in a new variable, subjects with both high NT-
proBNP levels and low systolic blood pressures had the worst global cognitive
83
Chapter 6 – Serum NT-proBNP, Blood Pressure and Cognitive Function
function and the strongest cognitive decline compared to all other subjects.
Our finding of higher NT-proBNP levels associating with worse cognitive
function is in accordance with previous studies. In the Rancho Bernardo Study,
a population-based study amongst 950 subjects with a mean age of 77 years,
subjects with high NT-proBNP levels had worse cognitive test scores compared
to subjects with low NT-proBNP levels16. A recently published study amongst
elderly patients with type 2 diabetes also showed that higher NT-proBNP lev-
els associated with lower cognitive function17. However, these studies reported
on cross-sectional associations and lack follow up data. In the Hoorn Study,
higher NT-proBNP levels at baseline associated with worse cognitive perfor-
mance, which was measured after a follow up period of five to eight years18.
There was no information on cognitive performance at baseline, and therefore
conclusions on cognitive decline could not be drawn from these results. The
only study reporting on prospective associations was performed in 464 subjects
aged 75 years and over22. In this study, high NT-proBNP levels associated with
both higher declines in MMSE score, measured at baseline and after five years of
follow up, and with an increased risk of dementia. Information on blood pres-
sure was not reported. Only one study has shown the absence of an association
between NT-proBNP levels and cognitive function, despite the clear association
between high NT-proBNP levels and vascular disease in the population of el-
derly patients with mental illness23.
NT-proBNP has emerged as an important biomarker of cardiac function and
is commonly used in clinical practice for the evaluation of congestive heart
failure24. NT-proBNP is the biologically inactive N-terminal fragment of the pro-
hormone proBNP, which is evenly split into the active BNP and NT-proBNP25.
ProBNP is secreted predominantly by cardiac myocytes of the ventricles in re-
sponse to stretching and distension of the cardiac wall and has a natriuretic
and diuretic effect26,27. An experimental study amongst healthy male volun-
teers showed that infusion of low-dose BNP resulted in natriuresis and the in-
hibition of plasma renin activity28. Moreover, in animals, sustained infusion of
natriuretic peptides resulted in a lower blood pressure29. Additionally, genetic
variation in the natriuretic peptide precursor B gene was shown to associate
with both lower NT-proBNP levels and higher blood pressures30. These find-
ings might explain the observed association between high NT-proBNP levels
and lower blood pressures in our study. However, this contradicts with results
from previously published studies, in which high NT-proBNP levels associated
with higher blood pressures, albeit in younger populations31,32. An explanation
for these opposing results might be that initially, as a consequence of hyperten-
sion, higher filling pressures of the ventricles result in an increased release of
NT-proBNP. However, with longer standing hypertension ventricular enlarge-
ment and dysfunction may develop. This leads to heart failure with lower car-
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diac output and persisting NT-proBNP release with increased natriuresis and
diuresis, subsequently resulting in lower blood pressures.
Since low NT-proBNP levels reliably exclude heart failure and high NT-
proBNP levels are related to heart failure, our results may suggest that heart
failure associates with worse cognitive function and with stronger cognitive de-
cline in the oldest old. The relation between cognitive function and heart failure,
irrespective of NT-proBNP levels, has been reviewed before33,34. The authors
conclude that there is a strong cross-sectional association between heart fail-
ure and cognitive impairment, but that there are very few longitudinal data
available. Possible pathophysiological mechanisms explaining for the associa-
tion between heart failure and cognitive impairment may be found in direct and
indirect pathways. An indirect pathway may be the presence of common risk
factors that associate with both heart failure and cognitive impairment. Hyper-
tension at midlife for instance is a risk factor for late-life cognitive impairment5,
but is also a well-known risk factor for heart failure up to old age35. Similar
common risk factors are a history of smoking and prevalence of atherosclerotic
disease, which all associate with both an increased risk of heart failure and an
increased risk of cognitive impairment36-38. Specifically the latter one may ex-
plain the found associations for a substantial part, because correction for the
prevalence of cardiovascular pathologies in the multivariate model diminished
the cross-sectional association between NT-proBNP levels and MMSE scores at
age 85 years. However, these indirect pathways may only explain part of the
observed association between NT-proBNP levels and cognitive function in our
study, since correction for all these risk factors in our analyses did not materi-
ally change the longitudinal results. Another likely pathophysiological expla-
nation might be found in the direct effect of heart failure on cerebral perfusion.
Heart failure is characterized by a decreased cardiac pump function, with resul-
tant lower cardiac output. This eventually may result in cerebral hypoperfusion
with concomitant decreased cerebral function. In an older population of pa-
tients with heart failure, ejection fractions below 30% were indeed associated
with worse memory function compared to ejection fractions over 30% 39. In
further support of this possible pathophysiological mechanism we showed in a
recently performed meta-analysis that both patients with Alzheimer’s disease
and patients with vascular dementia have lower cerebral blood flow velocities
than age-matched controls40. Other explanatory factors that associate with both
NT-proBNP levels and cognitive function, such as atrial fibrillation and renal
function, are less likely to play a substantial role, since correction for these vari-
ables did not materially change the associations.
In cross-sectional analyses low systolic blood pressure associated with worse
global cognitive function. However, results from the longitudinal analyses are
less clear. When using linear mixed models low systolic blood pressure associ-
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ated with stronger declines in MMSE score. This could however not be replicated
when using linear regression analyses, using regression coefficients of change in
MMSE scores over the years as outcome variable. A possible explanation may
be found in the handling of missing values. Linear mixed models uses impu-
tation techniques for missing values of MMSE scores, whereas the regression
coefficients of change in MMSE score are created using available data points
only, without imputation of missing values. Likely, the imputation of missing
values in the linear mixed models gave a slight overestimation of the effect ob-
served when using linear regression analysis. Worst global cognitive function
and strongest cognitive decline was observed in subjects who had both high NT-
proBNP levels and low systolic blood pressures, as opposed to all other subjects.
This suggests that only the combination of the two is detrimental. A possi-
ble explanation for this finding might be that high NT-proBNP levels reflect
a different pathomechanism in the group of subjects with low blood pressure
compared to the group with high blood pressure. In subjects with low blood
pressure high NT-proBNP levels may be the result of longer existing heart fail-
ure, which results in cardiac dysfunction, lower cardiac output and low blood
pressure. This then eventually may result in cerebral hypoperfusion. In subjects
with high blood pressure high NT-proBNP levels may be the result of cardiac
stress caused by the hypertension, which does not necessarily have a direct neg-
ative impact on cerebral function. In other words, the latter group may reflect
subjects with better cardiac function, and possibly better general health than
the former group. This reasoning corresponds with previous findings, in which
lower diastolic blood pressure in old age was shown to associate with increased
mortality risk41. In the Leiden 85-plus Study we previously showed that in the
oldest old declines in blood pressure during follow up associate with increased
mortality risk6,42. Within the context of this reasoning low blood pressure and
possibly high NT-proBNP levels in old age could also be a marker of underlying
disease, such as general wasting, explaining for these findings.
A limitation of our study is that information on cardiac output, and cere-
bral perfusion is not available. Echocardiograhy was only performed in a conve-
nience sample of 90 year olds, and unfortunately not at baseline. With additional
information of these two parameters the possible pathophysiological mecha-
nisms could have been further elucidated. Another limitation of our study is
that these results cannot be extrapolated to younger populations, since the study
was performed in the oldest old only.
In conclusion, high NT-proBNP levels in the oldest old associate with worse
global cognitive function and with stronger cognitive decline. The combination
of high NT-proBNP levels and low systolic blood pressure is specifically detri-
mental for cognitive function.
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Summary
N-terminal pro-brain natriuretic peptide (NT-proBNP) has been related with
cognitive impairment, which might be explained by clinical heart failure. Whether
NT-proBNP associates with cognitive decline independent of clinical heart fail-
ure has not been studied. We investigated the association of NT-proBNP with
cognitive decline in older subjects without advanced stages of clinical heart fail-
ure. We studied 5205 men and women (mean age 75 years) at high cardiovas-
cular risk without prevalence or incidence of advanced stages of clinical heart
failure (defined as New York Heart Association functional class III/IV at base-
line or heart failure hospitalization during follow-up) of the PROspective Study
of Pravastatin in the Elderly at Risk (PROSPER). Four domains of cognitive func-
tion were tested at baseline and repeated during a follow-up period of 3.2 years.
Participants with higher NT-proBNP levels (≥ 450 ng/L) had a worse baseline
cognitive function on all tests, including reaction time (mean difference high
vs. low group (95% CI)) 2.84 seconds (0.60; 5.08); processing speed -0.94 dig-
its coded (-1.57; -0.31); immediate memory -0.11 pictures remembered (-0.28;
0.06); and delayed memory -0.13 pictures remembered (-0.36; 0.11). Longitudi-
nally, participants with higher NT-proBNP levels had a steeper cognitive decline
during follow-up, including reaction time (mean annual change high vs. low
group (95% CI)) 0.61 seconds (0.15; 1.07); processing speed -0.15 digits coded (-
0.25; -0.05); immediate memory -0.05 pictures remembered (-0.09; 0.00); delayed
memory -0.05 pictures remembered (-0.11; 0.01). Higher NT-proBNP levels asso-
ciate with a steeper cognitive decline in older subjects without advanced stages
of clinical heart failure. Although the exact underlying mechanism is unclear,
NT-proBNP may serve as a biomarker of suboptimal left ventricular function,
resulting in cognitive decline.
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Introduction
Higher levels of N-terminal pro-brain natriuretic peptide (NT-proBNP), a hor-
mone produced by cardiomyocytes in response to ventricular stretch, have been
associated with cognitive impairment1-4. Evidence comes from several cross-
sectional studies, which show that among community-dwelling older subjects,
higher NT-proBNP levels were associated with worse cognitive function, in par-
ticular memory1-4. There are a limited number of longitudinal studies with
relatively small sample sizes, which demonstrate that higher NT-BNP levels are
also associated with steeper declines in Mini-Mental State Examination (MMSE)
scores and higher incidence of dementia5. A potential mechanism behind the
relationship between higher NT-proBNP levels and cognitive function is clinical
heart failure, resulting in left ventricular dysfunction with subsequent reduced
cardiac output. It is hypothesized that reduced cardiac output causes inade-
quate cerebral perfusion, leading to a higher risk of cognitive impairment6-8.
Improvements in cognitive function in patients following cardiac transplanta-
tion suggests that impaired cardiac function might be a reversible risk factor for
cognitive impairment9,10.
Recent evidence demonstrates that higher NT-proBNP levels in older subjects
without clinical heart failure are strongly associated with cardiovascular dis-
eases and risk factors and predict an increased risk of atrial fibrillation, stroke,
transient ischemic attack, myocardial infarction and mortality11-14. In addition,
higher NT-proBNP levels have been related to left ventricular hypertrophy and
systolic and diastolic dysfunction in subjects without clinical heart failure15,16.
The relationship of cardiovascular diseases and risk factors with cognitive im-
pairment is well-established17,18. Hence, cognitive impairment might already
be present in asymptomatic subjects at early stages of reduced cardiac function.
However, the association of higher NT-proBNP levels with cognitive impairment
and decline in subjects without advanced stages of clinical heart failure has not
been studied yet.
We hypothesized that elevated levels of NT-proBNP are associated with a
steeper cognitive decline, even in subjects without the prevalence or incidence of
advanced stages of clinical heart failure. Therefore, we studied the association
of NT-proBNP with cognitive function cross-sectionally and longitudinally in a
cohort of older men and women from the PROspective Study of Pravastatin in
the Elderly at Risk (PROSPER), in which participants with advanced heart fail-
ure, defined as New York Heart Association (NYHA) functional class III/IV at
baseline or heart failure hospitalization during follow-up, were not included.
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Methods
Study design
Data in this study were obtained from the PROspective Study of Pravastatin in
the Elderly at Risk (PROSPER), a randomized, double-blind, placebo-controlled
trial designed to investigate the effect of pravastatin in prevention of vascu-
lar events in older men and women with pre-existing cardiovascular disease or
risk factors thereof. This trial included 5,804 individuals aged 70-82 years old
who were enrolled from three collaborating centers in Ireland, Scotland and
the Netherlands. Approximately 50% of the participants showed evidence of
cardiovascular disease including stable angina, intermittent claudication, stroke,
transient ischemic attack, myocardial infarction and vascular surgery. The rest of
participants had one or more cardiovascular risk factor, defined as hypertension,
smoking or diabetes mellitus. Primary outcome of the trial was the combined
endpoint of definite or suspect death from coronary heart disease, non-fatal my-
ocardial infarction and fatal or non-fatal stroke during a mean follow-up period
of 3.2 years. The institutional ethics committees of the three collaborating cen-
ters approved the study and all participants gave written informed consent19,20.
Study participants
Participants with congestive heart failure, defined as New York Heart Associa-
tion functional class III or IV, were excluded from PROSPER19. For the present
study, we additionally excluded participants with heart failure hospitalization
during follow-up (n=205).
Serum NT-proBNP
Blood samples were taken at 6 months after follow-up in EDTA tubes. NT-
proBNP was determined using electrochemiluminescence immunoassay on a
Roche Modulator E170. A number of 394 participants had missing NT-proBNP
measurements. In keeping with existing literature on cutoff values in this age
group, we defined three groups of NT-proBNP: low (<100 ng/L), middle (100-
450 ng/L) and high NT-proBNP (≥ 450 ng/L)1.
Cognitive function
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The MMSE was used to evaluate global cognitive function; participants with a
baseline score below 24 points were excluded from PROSPER. Cognitive func-
tion was tested at baseline and at 9, 18, 30 months and at the end of the study.
The time-point of the measurement at the end of the study varied between 36
and 48 months; therefore, we performed the analysis with their individually
varying time point, but report the results for the mean of these time points (at 42
months). Four different neuropsychological tests were used to assess executive
function, attention, immediate and delayed memory. The Stroop-Colour-Word-
Test was used to test selective attention and reaction time of the participants.
The participants were asked to read a color name which was displayed in a
color different from the color it actually names. The outcome parameter was
total number of seconds to complete the test; a higher score therefore indicates
worse performance. General cognitive speed was tested by the Letter-Digit Cod-
ing Test. The participants had to match certain digits with letters according to
a provided key. The outcome variable was the total number of correct entries
in 60 seconds, and therefore higher scores represented better performance. The
Picture-Word Learning Test was used to assess immediate and delayed mem-
ory performance. Fifteen pictures were presented at the participants, and they
were asked to recall as many pictures as possible in three trials. After 20 min-
utes they were asked to repeat the test to measure their delayed recall. The
outcome parameter is the accumulated number of correct recalled pictures, im-
mediate and after 20 minutes. Higher scores thus indicate better performance.
A detailed description of the cognitive tests and the procedures has been pub-
lished previously21. Since treatment with pravastatin did not influence cognitive
function during follow-up, we included participants from both pravastatin and
placebo groups22.
Statistical analysis
Baseline characteristics of the study participants are reported as mean (stan-
dard deviation) for continuous variables and number (percentage) for categori-
cal variables for each group of NT-proBNP. Differences in continuous variables
were tested with linear regression models, in which p-values were calculated us-
ing log-transformed NT-proBNP levels. Differences in categorical variables were
tested by Chi-squared tests.
To investigate the cross-sectional association of NT-proBNP with cognitive func-
tion, we used linear regression models. Log transformed NT-proBNP levels
were included as independent variable; outcome variable was the mean baseline
score on each of the four cognitive function tests. Linear mixed models were
used to examine the association between NT-proBNP and cognitive decline over
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time. The models included log transformed NT-proBNP levels, time (in years)
and the interaction term between time and log transformed NT-proBNP levels.
We performed our analyses in three steps. In the first step, crude analyses were
performed, in which we only adjusted for cognitive test version where appropri-
ate. In the second step, we added the variables age, sex, education, country and
apolipoprotein E genotype to the model to investigate the potential influence
of these factors on the associations (minimally adjusted model). Furthermore,
in a fully adjusted model we also added the following potential confounders:
cardiovascular diseases and risk factors at baseline (history of cerebrovascular
and cardiovascular disease, history of hypertension, history of diabetes melli-
tus, smoking status, HDL and LDL cholesterol levels, triglycerides, systolic and
diastolic blood pressure, body mass index), statin treatment and serum creati-
nine level. Since the associations did not essentially change in different mod-
els, results of the minimally and fully adjusted models are presented in the
manuscript. To further explore the influence of cardiovascular diseases and risk
factors, additional analyses were performed in which we stratified for history
of cardiovascular diseases and risk factors. To test whether the difference be-
tween participants with or without a history of cardiovascular disease or risk
factor was significant, we calculated a p-value for interaction by using linear re-
gression models. Furthermore, we performed additional sensitivity analyses in
which we excluded 1) participants taking pravastatin treatment during follow-
up; 2) participants with incident stroke and/or transient ischemic attack during
follow-up; 3) participants with incident myocardial infarction during follow-up;
4) participants with incident atrial fibrillation during follow-up; 5) participants
with vascular events, including coronary heart disease death, nonfatal myocar-
dial infarction, nonfatal and fatal stroke and/or TIA during follow-up; and 6)
participants taking loop diuretics, beta blockers or ACE-inhibitors at baseline.
Results
Table 1 shows baseline characteristics of study participants grouped by NT-
proBNP levels. Participants with higher NT-proBNP levels were older and had
a higher prevalence of hypertension, myocardial infarction, vascular disease and
smoking (all p-values <0.001). Body mass index was lower in participants with
higher NT-proBNP levels (p-value <0.001). Systolic blood pressure, pulse pres-
sure and mean arterial blood pressure were higher among participants with
higher NT-proBNP levels (p-values <0.001, p<0.001 and p=0.001 respectively).
Furthermore, use of loop diuretics, beta blockers and ace-inhibitors was higher
in participants with higher NT-proBNP levels (p-values <0.001, p<0.001 and
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p=0.031 respectively). Participants with higher NT-proBNP levels had higher
creatinine levels (p <0.001).
Table 2 shows the association of NT-proBNP levels with cognitive function at
baseline. In the minimally adjusted model, participants with higher NT-proBNP
levels had a worse performance on Stroop test (p=0.004) and Letter-Digit Cod-
ing test (p<0.001). The same trend was observed for immediate and delayed
Picture-Word Learning tests, showing that participants with higher NT-proBNP
levels had worse performance, albeit these associations were not significant (p-
value=0.062 and p=0.065 respectively). When further adjusting for prevalent
cardiovascular diseases or risk factors at baseline, we found similar differences
in cognitive function between the groups. The association of NT-proBNP lev-
els with Stroop test and Letter-Digit Coding test in the fully adjusted model
remained significant (p-value=0.005 and p<0.001 respectively), whereas for im-
mediate and delayed Picture-Word Learning tests the associations did not sig-
nificantly differ (p-value=0.115 and p=0.083 respectively). Results from adjusted
models did not materially differ from crude models.
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Table 1. Baseline characteristics of study participants grouped by NT-proBNP
NT-proBNP (ng/L)
Low Middle High
N=1818 N=2698 N=689 P-value
<100 ng/L 100-450 ≥450 ng/L
Demographics
Age, years 74.42 (3.04) 75.53 (3.37) 76.59 (3.40) <0.001
Female, n (%) 850 (46.8) 1490 (55.2) 360 (52.2) <0.001
Age left school, years 15.17 (2.06) 15.15 (2.06) 15.10 (2.08) 0.083
Vascular risk factors
Hypertension, n (%) 1056 (58.1) 1736 (64.3) 444 (64.4) <0.001
Diabetes mellitus, n (%) 245 (13.5) 245 (9.1) 57 (8.3) <0.001
Stroke or TIA, n (%) 189 (10.4) 301 (11.2) 85 (12.3) 0.371
Myocardial infarction, n (%) 120 (6.6) 369 (13.7) 177 (25.7) <0.001
Vascular disease, n (%) 630 (34.7) 1246 (46.2) 393 (57.0) <0.001
Current smoker, n (%) 536 (29.5) 667 (24.7) 175 (25.4) 0.001
Body mass index, kg/m2 27.22 (4.02) 26.69 (4.21) 26.17 (4.20) <0.001
Total cholesterol, mmol/L 5.68 (0.90) 5.68 (0.91) 5.70 (0.93) 0.461
Systolic blood pressure, mmHg 152.60 (20.25) 155.11 (21.75) 158.75 (23.50) <0.001
Diastolic blood pressure, mmHg 84.02 (10.95) 83.73 (11.33) 83.38 (12.01) 0.158
Pulse pressure, mmHg 68.58 (0.42) 71.38 (0.35) 75.37 (0.68) <0.001
Mean Arterial Pressure, mmHg 106.88 (0.30) 107.53 (0.25) 108.51 (0.49) 0.001
Antihypertensive medications, n (%)
Diuretics 650 (35.8) 1067 (39.5) 269 (39.0) <0.001
Loop 153 (8.4) 327 (12.1) 107 (15.5) < 0.001
Other 497 (27.3) 740 (27.4) 162 (23.5)
Calcium channel blockers 459 (25.2) 692 (25.6) 151 (21.9) 0.125
Beta blockers 241 (13.3) 831 (30.8) 273 (39.6) < 0.001
Ace-inhibitors 279 (15.3) 421 (15.6) 134 (19.4) 0.031
Creatinine level, Umol/L 97.92 (19.35) 100.76 (22.22) 108.58 (25.08) < 0.001
Values presented as mean (standard deviation) except as noted.
Abbreviations: SD, standard deviation; n, number; TIA, transient ischemic attack. P-values
were calculated using log-transformed NT-proBNP levels for continuous variables and Chi-
squared tests for categorical variables.
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Cognitive tests (mean, SE) <100 ng/L 100-450 ≥450 ng/L P-value∗
Stroop, seconds
Minimally adjusted model 64.37 (1.46) 64.13 (1.42) 67.36 (1.63) 0.004
Fully adjusted model 66.28 (1.56) 66.12 (1.53) 69.26 (1.72) 0.005
LDCT, digits coded
Minimally adjusted model 23.94 (0.41) 23.54 (0.40) 23.03 (0.46) <0.001
Fully adjusted model 23.29 (0.44) 22.85 (0.43) 22.29 (0.48) <0.001
PLTi, pictures remembered
Minimally adjusted model 9.58 (0.11) 9.52 (0.11) 9.44 (0.12) 0.062
Fully adjusted model 9.49 (0.12) 9.44 (0.12) 9.37 (0.13) 0.115
PLTd, pictures remembered
Minimally adjusted model 10.43 (0.16) 10.40 (0.15) 10.29 (0.17) 0.065
Fully adjusted model 10.21 (0.17) 10.18 (0.16) 10.08 (0.18) 0.083
Data represent mean (standard error) score of each cognitive function test.
∗ P-values were calculated using the continuous value of log-transformed NT-
proBNP levels.
Abbreviations: SE, standard error; n, number; LDCT, Letter-Digit Coding test;
PLTi, Picture-Word Learning test, immediate; PLTd, Picture-Word Learning
test, delayed.
Minimally adjusted model: adjusted for age, sex, country, education, apoe
genotype, test version for LDCT and PLT.
Fully adjusted model: Minimally adjusted model + adjustments for history of
cerebrovascular and cardiovascular disease, history of hypertension, history
of diabetes mellitus, current smoking, baseline systolic and diastolic blood
pressure, HDL and LDL cholesterol, triglycerides, body mass index and serum
creatinine.
Table 3 and Figure 1 show the association of NT-proBNP levels with changes
in cognitive function during follow-up. Participants with higher NT-proBNP
levels had a steeper cognitive decline on Stroop test, Letter-Digit Coding test
and immediate and delayed Picture-Word Learning tests (all p-values < 0.001).
Again, further adjustments for prevalent cardiovascular diseases or risk factors
at baseline did not alter the observed associations (all p-values <0.001). The
association of NT-proBNP levels with cognitive decline from crude models did
not materially differ from adjusted models.
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Table 3. Association of NT-proBNP with cognitive decline during follow-up
NT-proBNP
Low Middle High
Cognitive tests N=1818 N=2698 N=689
(mean annual change, SE) <100 ng/L 100-450 ≥450 ng/L P-value∗
Stroop, seconds
Minimally adjusted model 0.46 (0.11) 0.71 (0.09) 1.04 (0.26) 0.001
Fully adjusted model 0.47 (0.11) 0.72 (0.09) 1.04 (0.26) 0.001
LDCT, digits coded
Minimally adjusted model -0.32 (0.02) -0.36 (0.02) -0.46 (0.04) 0.001
Fully adjusted model -0.32 (0.02) -0.35 (0.02) -0.47 (0.04) <0.001
PLTi, pictures remembered
Minimally adjusted model -0.00 (0.01) -0.03 (0.01) -0.05 (0.02) <0.001
Fully adjusted model 0.00 (0.00) -0.02 (0.01) -0.04 (0.02) <0.001
PLTd, pictures remembered
Minimally adjusted model -0.05 (0.01) -0.06 (0.01) -0.10 (0.03) 0.001
Fully adjusted model -0.03 (0.01) -0.05 (0.00) -0.10 (0.03) 0.001
Data represent mean annual change (standard error) in each cognitive func-
tion test. *P-values were calculated using the interaction term of time x log
transformed NT-proBNP levels.
Abbreviations: SE, standard error; n, number; LDCT, Letter-Digit Coding test;
PLTi, Picture-Word Learning test, immediate; PLTd, Picture-Word Learning
test, delayed.
Minimally adjusted model: adjusted for age, sex, country, education, apoe
genotype, treatment group, test version for LDCT and PLT.Fully adjusted
model: Minimally adjusted model + adjustments for history of cerebrovas-
cular and cardiovascular disease, history of hypertension, history of diabetes
mellitus, current smoking, baseline systolic and diastolic blood pressure, HDL
and LDL cholesterol, triglycerides, body mass index and serum creatinine.
To further explore the influence of cardiovascular diseases and risk factors,
we performed additional analyses in which we stratified for history of various
cardiovascular diseases and risk factors, and tested for interaction. Figure 2
shows the association of NT-proBNP levels with cognitive decline, stratified by
history of cardiovascular diseases and risk factors. There was no significant
difference in change in cognitive function during follow-up between participants
with and without cardiovascular diseases or risk factors, except for participants
with a history of stroke and/or transient ischemic attack (TIA) and myocardial
infarction. Participants with previous stroke and/or TIA had a less steep decline
on Letter-Digit Coding test (p-value for interaction=0.003), while participants
with previous myocardial infarction had a steeper decline on Letter-Digit Coding
test (p-value for interaction=0.008). However, no such differences were observed
for participants with previous stroke and/or TIA or myocardial infarction on
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Figure 1. Association of NT-proBNP with cognitive decline during follow-up. Data
represent mean score (95% confidence interval) of each cognitive test during follow-up,
in each group of NT-proBNP. P-values were calculated using the interaction term of time
x log transformed NT-proBNP levels. Adjustments were made for age, sex, country,
education, apoE genotype and test version where appropriate.
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any of the other cognitive tests.
Furthermore, we performed additional sensitivity analyses to investigate wh-
ether the association between NT-proBNP levels and cognitive function and
decline could be affected by 1) participants taking pravastatin treatment dur-
ing follow-up (n=2588); 2) participants with incident stroke and/or TIA during
follow-up (n=355); 3) participants with incident myocardial infarction during
follow-up (n=339); 4) participants with incident atrial fibrillation during follow-
up (n=421); 5) participants with vascular events, including coronary heart dis-
ease death, nonfatal myocardial infarction, nonfatal and fatal stroke and/or TIA
during follow-up (n=648); and 6) participants taking loop diuretics (n=588), beta
blockers (n=1345) or ace-inhibitors (n=834) at baseline. Exclusion of these par-
ticipants did not essentially change our results (data not shown).
Discussion
In this prospective cohort study including over 5000 men and women with mean
age of 75 years, we showed that participants with higher NT-proBNP levels with-
out advanced stages of clinical heart failure had worse cognitive function and
steeper cognitive decline during a mean follow-up period of 3.2 years. These
associations were independent of cardiovascular diseases and risk factors.
Our finding is in line with previous cross-sectional studies investigating
the association of NT-proBNP and cognitive function1-5. The Rancho Bernardo
Study investigated the association in 950 community-dwelling adults of 60 years
and older and found that higher NT-proBNP levels were associated with poor
global and executive function, but not with cognitive flexibility1. Another cross-
sectional study including 1066 men and women aged 60-75 years with type 2 di-
abetes showed that higher NT-proBNP levels were weakly associated with lower
general cognitive function2. Furthermore, The Hoorn study found that baseline
BNP was associated with worse processing speed, memory, attention and exec-
utive function. Besides, they observed that an increase of BNP over time was
associated with reduced attention and executive function4. So far only few other
longitudinal studies investigated the association5. In a prospective study, we
previously found that at age 85, subjects in the highest tertile of NT-proBNP had
a lower baseline MMSE score and a steeper decline in MMSE during a 5-year
follow-up period (unpublished results). This is in line with the study performed
by Kerola et al, who showed that BNP was associated with worse baseline score
on MMSE, a higher decline of MMSE, and a higher incidence of dementia during
a mean follow-up period of 5 years5. To our knowledge, this is the first study
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Figure 2. Association of NT-proBNP with cognitive decline during follow-up, stratified
by cardiovascular diseases and risk factors. Data represent mean annual change (95%
confidence interval) per 1 ng/L increase in log transformed NT-proBNP for each cognitive
test, Stratified by cardiovascular diseases. Adjusted for age, sex, country, education, apoE
genotype and test version where appropriate. P-values show p for interaction.
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reporting on the association of NT-proBNP and cognitive function and decline
in a large cohort of older participants without advanced stages of clinical heart
failure at baseline and during follow-up.
Brain natriuretic peptide (BNP) and the biologically inactive N-terminal pro-
brain natriuretic peptide are secreted by the ventricles of the heart in response
to excessive stretching of cardiomyocytes23. BNP has favorable physiological
properties, including increased natriuresis and diuresis, relaxation of vascular
smooth muscle cells and inhibition of the renin-angiotensin-aldosterone-axis,
eventually causing a reduction in blood pressure and ventricular preload23. Our
results showed that higher NT-proBNP levels, and thus BNP as well, were asso-
ciated with higher systolic blood pressure.
Different explanations can be proposed for the observed association of NT-
proBNP with cognitive decline. First, NT-proBNP and cognitive decline may
both reflect underlying cardiovascular damage and therefore stem from a com-
mon cause, rather than suggesting a causal relationship. Previous studies have
shown that NT-proBNP levels have a prognostic value for the occurrence of
cardiovascular events, such as myocardial infarction, atrial fibrillation, coronary
heart disease, unstable angina, stroke and transient ischemic attack11;14;24;25. This
has also been demonstrated in subjects with elevated NT-proBNP levels, but
without clinical heart failure14. Furthermore, NT-proBNP levels provide predic-
tive information for use of risk stratification in nonfatal cardiac events, stroke
and mortality25;26. Cardiovascular diseases are closely linked to cognitive dys-
function and dementia17;18. This is in line with the finding that high NT-proBNP
levels are associated with an increased prevalence of cardiovascular diseases and
risk factors in the population under study. However, when adjusting and strat-
ifying our analyses for cardiovascular diseases and risk factors, our results did
not essentially change. Furthermore, excluding participants with incident my-
ocardial infarction, stroke and/or TIA showed the same results. Nevertheless,
we cannot totally rule out the possibility that unmeasured cardiovascular risk
factors resulted in both increased NT-proBNP and cognitive decline. Second, im-
paired cardiac function may activate the renin-angiotensin system which in turn
has been associated with cognitive decline27. Recent evidence suggests that the
renin-angiotensin system is important in the regulation of cerebral blood flow:
it impairs cerebrovascular regulation and promotes oxidative stress and amy-
loid protein deposition.28 In line with this evidence, observational studies have
shown that subjects receiving angiotensin receptor blockers have a lower decline
in their cerebral perfusion and have a lower risk of developing dementia29;30.
Therefore, activation of the renin-angiotensin system might be a possible ex-
planation on the observed association between higher NT-proBNP levels and
cognitive decline. Since only a small number of participants used angiotensin
receptor blockers in the population under study (n<100), we could not further
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investigate this issue. Third, since natriuretic peptides have first been identified
in porcine brain extract, one could hypothesize that NT-proBNP could have a
direct effect in the brain. However, filtered by the blood brain barrier, the con-
centration of NT-proBNP in the brain is very low, if not undetectable31. A fourth
explanation might be that high NT-proBNP levels in subjects without advanced
stages of heart failure indicate a suboptimal left ventricular functioning with
subsequent decreased cardiac output and cerebral hypoperfusion8;15. Cerebral
hypoperfusion, which impairs the delivery of oxygen and nutrients to the brain,
has been associated with cognitive dysfunction and dementia6-8. In this sce-
nario, high NT-proBNP levels could serve as a biomarker, reflecting suboptimal
left ventricular function, which may result in cognitive decline. Although this ex-
planation seems plausible, there is a need for interventional studies investigating
the influence of improvement in cardiac function with its subsequent influence
on cerebral perfusion, and eventually the prevention of cognitive decline in old
age. Taken together, we favor the hypothesis that NT-proBNP could serve as a
biomarker, reflecting suboptimal left ventricular function, which may result in
cognitive decline. Major strengths of this study include the large sample size
of over 5000 older participants and the repeated use of an extended standard-
ized cognitive test battery to assess cognitive function over a mean follow-up
period of 3.2 years. Furthermore, in contrast to previous studies, participants
in our study had relatively preserved cardiac function, which gave us the op-
portunity to investigate the independent value of NT-proBNP in relation with
cognitive function and decline. However, this study has several limitations. Our
study population consisted of older participants at risk of cardiovascular dis-
eases with relatively preserved cognitive function (MMSE ≥ 24 points), which
might limit the extrapolation of our findings to a general population of older
subjects. Furthermore, although participants with NYHA functional class III/IV
were excluded from PROSPER, we might still have included participants with
advanced stages of clinical heart failure but without ever being diagnosed with
this condition. In addition, only information on heart failure hospitalization
was available, which could have resulted in the inclusion of participants who
developed clinical heart failure during follow-up, without being admitted to
the hospital. However, excluding participants with NT-proBNP levels of ≥ 450
ng/L showed essentially the same results. In conclusion, higher NT-proBNP
levels associate with worse cognitive function and steeper cognitive decline in
older subjects without advanced stages of clinical heart failure. Although the
exact underlying mechanism is unclear, NT-proBNP may serve as a biomarker
of suboptimal left ventricular function, which through decreased cardiac output
and cerebral hypoperfusion may result in cognitive decline.
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Summary
Alteration in cerebrovascular hemodynamics has been reported in both ageing
and dementia. However, it is still unclear whether this alteration follows sim-
ilar pattern in ageing and in different dementia pathologies. The aim of this
meta-analysis was to investigate changes in cerebral blood flow velocity and
pulsatility index in two most common forms of dementia; Alzheimer’s disease
and vascular dementia, using transcranial doppler studies. A literature search
was conducted in Pubmed, EMBASE and Web of Science. After initial screen-
ing of 304 articles and removing duplicates, a total of 53 articles, published
between 1980 and 2010, were reviewed. Finally 12 articles were included in the
meta-analysis. For each study, effect sizes (ES) indicating the standardized mean
differences of the hemodynamic measures between two groups were calculated.
Using random effect models, pooled estimates of ES were measured. Patients
with Alzheimer’s disease (ES=-1.09, 95% CI -1.77 - -0.44, p=0.004) and vascu-
lar dementia (ES=-1.62, 95% CI -2.26 - -0.98, p<0.001) had significantly lower
cerebral blood flow velocity compared with healthy aged-matched controls. In
addition, pulsatility index was significantly higher in both Alzheimer’s disease
(ES =0.5, 95% CI 0.28 0.72, p<0.001) and vascular dementia patients (ES=2.34,
95% CI 1.39 3.29, p<0.001). Patients with Alzheimer’s disease had lower pul-
satility index (ES= -1.22, 95% CI -1.98 0.46, P=0.002) compared to subjects with
vascular type of dementia. Patients with Alzheimer’s disease and vascular de-
mentia have a pronounced disturbance in their cerebrovascular hemodynamics.
The severity of disturbances in cerebral hemodynamics is significantly lower in
Alzheimer’s disease compared to vascular dementia.
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Introduction
Over the decades, our knowledge regarding the pathogenic pathways behind
dementia and its most common forms, Alzheimer‘s disease and vascular de-
mentia, has changed considerably1. In contrast to previous thoughts about
the pure neurodegenerative nature of Alzheimer‘s disease, it is now well es-
tablished that vascular dysfunction and hemodynamic disturbances play a role
in both Alzheimer‘s disease and vascular dementia2, 3. Several epidemiological
studies have reported an association between vascular risk factors, such as hy-
pertension, hyperlipidemia, diabetes mellitus type 2 and metabolic syndrome,
and Alzheimer‘s disease4. Furthermore, pathologic investigations have shown
that many autopsied brains of patients with Alzheimer‘s disease contain cere-
brovascular pathologies5. In this setting, recently this pathologic condition was
introduced as a vasocognopathy entity6. Although recognition of Alzheimer‘s
disease as a vascular entity can have certain clinical, therapeutic and preven-
tive implications, many issues regarding the mechanisms by which vascular risk
factors initiate or promote cognitive impairment are still unknown7.
While both ageing and Alzheimer‘s pathology have been shown to affect
neurovascular and metabolic regulation of cerebral blood flow8, there are in-
consistent findings on differences in cerebrovascular hemodynamics in patients
with Alzheimer‘s disease compared to healthy elderly subjects. Furthermore, it
is not clear whether alterations in cerebrovascular hemodynamics follow similar
patterns in different types of dementia. Transcranial doppler sonography is a
non-invasive imaging technique widely used for the investigation of cerebrovas-
cular hemodynamics in the major cerebral arteries9. This technique provides two
major hemodynamic measures: mean cerebral blood flow velocity and pulsatil-
ity index. While the mean cerebral blood flow velocity shows a relative measure
of the integrity in arterial perfusion, the pulsatility index reflects cerebrovascular
resistance and intracranial compliance10.
By the introduction of transcranial doppler sonography, the number of in-
vestigations on the changes of cerebral hemodynamic status among demented
patients has increased11-24. However, this growing body of evidence on the cere-
brovascular hemodynamic changes in Alzheimer‘s disease and vascular demen-
tia, if not demonstrated in a systematic way, might lead to complexity of inter-
pretations. We conducted a systematic review and meta-analysis to investigate
changes in the cerebral hemodynamics in patients with Alzheimer‘s disease and
vascular dementia in comparison with healthy aged match subjects. Further-
more, the differences in the cerebral hemodynamic measures were evaluated
between Alzheimer‘s disease and vascular dementia. Since the middle cerebral
artery is the most commonly investigated vessel by transcranial doppler sonog-
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raphy and supplies the main cognitive areas in brain, we focused on changes of
cerebral blood flow velocity and pulsatility index in the middle cerebral arteries
of the included studies participants.
Methods
Search strategy
Pubmed, EMBASE and Web of Science were searched with the key words rep-
resenting Alzheimer’s disease, vascular dementia, transcranial doppler sonog-
raphy, healthy ageing and cerebrovascular hemodynamics (see details in the
appendix 1). The search was restricted to original articles published up to De-
cember of 2010 with English, German, French and Dutch languages (n=304).
Two independent reviewers (BS and SJ) examined titles and abstracts to decide
whether studies could be included. Then the full articles of included studies
were checked for further determination. The reference lists of the key studies
were reviewed for potential relevant articles. In order to avoid inclusion of re-
peated data, the whole final studies were checked for similar authors, patient
characteristics and results. At the end, one study was excluded for this reason.
Study selection/Data extraction
Title and abstracts of 53 articles were screened initially and then a total of 23
studies were reviewed in detail. The following criteria were considered for el-
igibility of articles: (1) participants consisting of Alzheimer‘s disease patients
and/or vascular dementia diagnosed by NINCDS-ADRDA 25, NINCDS-AIREN
26, DSM-III-R 27 or DSM-IV criteria 28 (in those studies that used the term multi-
infarct dementia, criteria were assessed to be compatible with the mentioned
criteria for vascular dementia); (2) transcranial doppler sonography investiga-
tion as the main tool for measurement of cerebral hemodynamics; (3) healthy
and age-matched control subjects who had no history of neurological or psychi-
atric disorders, substance abuse and chronic medical conditions such as anemia;
and (4) assessment of cerebrovascular hemodynamics including cerebral blood
flow velocity (cm/second) or pulsatility index measured in the middle cerebral
artery. In those studies that provided cerebral blood flow velocity and pulsatility
index values in both left and right middle cerebral arteries (n=5), left side mea-
sures were considered for the final analysis. Key information on demographic
and cognitive status of participants, transcranial doppler sonography examina-
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tion procedure and hemodynamic outcomes of each study were extracted by one
reviewer (SJ) and were then checked by another reviewer (BS). When hemody-
namic data were not reported in mean and standard deviation but in mean and
confidence interval, the standard deviation was calculated. In one study where
hemodynamic measures were presented separately in male and female groups,
the mean and standard deviation of the hemodynamic parameters in men and
women were combined.
Data analysis
For each study effect sizes were calculated by the Hedges method which can
be interpreted as standardized mean difference of the hemodynamic measures
between two groups29. The larger the effect size, the greater the differences in
the hemodynamic measures between the two groups. After calculation of the ef-
fect sizes for each study, the meta-analyses were performed by using a random
effects model which computes the pooled effect size. The random effects model
was applied since it takes into account the variability between studies. Further-
more, sensitivity analysis was performed to ensure that no single study biased
the combined results by repeated excluding one study at a time and measuring
of the combined effect size in the remaining studies. To assess heterogeneity, i.e.,
whether the differences between studies were greater than would be expected
by chance alone, the Q method was used30. Possible sources of for heterogeneity
were explored by evaluating the differences in the characteristics of the included
studies. The limited number of studies did not allow us to investigate source
of heterogeneity further by meta-regression analysis. Using weighted regression
and rank correlation methods, we assessed publication bias i.e., the phenomenon
in which small studies with negative results are not published31. All the statisti-
cal analyses were carried out using STATA version 10.
Results
Study population
Among 23 reviewed full-text articles, a total of 12 studies were included in the
meta-analysis 1-12 (Table 1). The studies included a total of 795 participants: 268
with Alzheimer‘s disease, 200 with vascular dementia, and 327 controls. Females
made 56%, 46% and 53% of the participants in Alzheimer‘s disease, vascular de-
mentia and control groups respectively. Average MMSE scores ranged from 13
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to 25 in Alzheimer‘s disease and from 12 to 23 in vascular dementia groups.
Hemodynamic measures
Hemodynamic measures from the individual studies are presented in the ta-
ble 2. After pooling the data, in comparison with healthy aged-matched sub-
jects, significantly lower cerebral blood flow velocity was observed in patients
with Alzheimer‘s disease (effect size=-1.09, p=0.004, figure 1-A) and vascular
dementia (effect size=-1.62, p<0.001, figure 1-B). Pulsatility index was signifi-
cantly higher in both Alzheimer‘s disease (effect size=0.497, p=0.004, figure 2-A)
and vascular dementia patients (effect size=2.34, p<0.001, figure 2-B). When we
compared cerebral blood flow velocity between patients with Alzheimer‘s dis-
ease and vascular dementia, there was no significant difference (effect size=0.24,
p=0.56, figure 3-A). However sensitivity analysis revealed that the outlier study
3 biased the pooled estimate. After excluding the outlier study, patients with
Alzheimer‘s disease showed significant higher cerebral blood flow velocity (ef-
fect size=0.56, p=0.003). Compared to vascular dementia patients, patients with
Alzheimer‘s disease had significantly lower pulsatility index (effect size= -1.22,
P=0.002, figure 3-B).
Source of heterogeneity
Except for the set of studies on pulsatility index in patients with Alzheimer‘s
disease when compared to control subjects, all the other comparisons showed a
significant heterogeneity (all p<0.001). Interstudy differences in gender distribu-
tion 2, 11 and prevalence of cardiovascular risk factors3, 6 in some of the included
studies might be responsible for the observed heterogeneity. Furthermore differ-
ences in diagnostic criteria and presence of the mix pathologic states as well as
differences in the applied methods to measure hemodynamic parameters might
be considered as other potential sources for heterogeneity of findings among the
studies.
Publication Bias
No indication of publication bias was found for the studies included in this
meta-analysis except for the set of studies used for the comparison of cerebral
blood flow velocity in Alzheimer‘s disease patients and healthy controls. In this
set of studies the funnel plot was asymmetric and there was borderline evidence
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Discussion
This meta-analysis shows that patients with Alzheimer’s disease and vascu-
lar dementia, in comparison with healthy aged matched subjects, have a pro-
nounced disturbance in their cerebrovascular hemodynamics. The severity of
disturbances in cerebral hemodynamics is significantly lower in Alzheimer’s dis-
ease compared to vascular dementia.
Recently, the cerebrovascular hypothesis of dementia has received consider-
able attention13. This hypothesis implies that chronic cerebral hypoperfusion,
in the presence of vascular risk factors leading to vascular and metabolic dam-
ages of the brain, is the main drive of neuronal dysfunction and cell death with
consequent cognitive disability14. While the most common form of dementia,
Alzheimer‘s disease, was first introduced as a primary neurodegenerative dis-
order, there is ongoing debate whether this entity should be recognized as a
primary vascular disorder15. By the introduction of various neuroimaging tech-
niques, a large number of studies have assessed whether Alzheimer‘s disease
and vascular dementia have different patterns of vascular and hemodynamic
characteristics16.
Cerebral blood flow velocity, detected by ultrasound, has been used exten-
sively as a proxy for cerebral blood flow17. Our results are in line with previ-
ous findings showing a state of cerebral hypoperfusion in dementia18. How-
ever, comparison of patients with Alzheimer’s disease and vascular dementia
revealed that Alzheimer‘s disease patients have significantly less impairment in
their cerebral perfusion than vascular dementia patients, suggesting a potential
spectrum of hemodynamic disturbances in different types of dementia. This
difference between Alzheimer‘s disease and vascular dementia may be a reflec-
tion of differences in type, load or even location of vascular pathology. For
instance, histological investigations have shown that amyloid angiopathy is the
main vascular pathology in Alzheimer‘s disease, whereas atherosclerosis with
consequent micro and macro vascular infarcts are the major pathologic features
of vascular damage in vascular dementia19. In addition to the type of vascular
damage, the severity of vascular changes might underlie this difference. For
instance, although it was shown that patients with Alzheimer’s disease have
cerebral white matter lesions and microbleeds, as signs of small vessel disease,
the severity of these pathologies are reported to be significantly higher in vascu-
lar dementia20, 21. Finally, different locations of vascular changes in the brains of
patients with Alzheimer’s disease and vascular dementia 22 might contribute to
variation of cerebrovascular hemodynamics in these two types of dementia. In
a large autopsy series of demented patients, evaluation of topographic patterns
of brain vascular lesions showed that subjects with pure vascular dementia had
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higher frequency of small subcortical lesions while cases with a definite diag-
nosis of Alzheimer’s disease with vascular encephalopathy showed more lobar
and cortical infarcts23.
Significant increase in pulsatility index in both Alzheimer‘s disease and vas-
cular dementia patients indicate a remarkable increase in cerebrovascular stiff-
ness associated with decline in intracranial vascular compliance. A diffuse injury
to micro-vascular structure imposed by atherosclerosis and amyloid angiopathy
can be a potential explanation for this phenomenon24. However, most of the in-
cluded studies in this meta-analysis have not provided detailed information on
vascular pathologies proximal or distal to the middle cerebral artery. Further-
more, increased cerebrovascular resistance might highlight the role of chronic
cerebral hypoperfusion not only as a consequence of neuronal loss and lower
metabolic demand but also as the primary factor in development and promotion
of dementia. The combination of high level of vascular resistance and low per-
fusion state suggests a global vascular pathology which could start from small
vessel disease in both types of dementia and extend to larger vessels in the vas-
cular type of dementia23. Collectively, it seems that hemodynamic disturbances
and neurodegeneration act in concert in development and progression of de-
mentia and no single mechanism can fully explain common mixed pathologic
findings in the brains of patients with dementia.
Although dementia is a slowly progressing medical condition and pathogenic
mechanisms may start working decades before apparent clinical symptoms25,
there is a limited data on hemodynamic changes in pre-clinical stages of de-
mentia and mild cognitive impairment. Sun et al investigated the mean cerebral
blood flow velocity in mild cognitive impairment patients and demonstrated
that those patients had significantly lower cerebral blood flow velocity com-
pared to age-matched controls26. While decrease in cerebral blood flow velocity
and increase in pulsatility index are well-described phenomenon in ageing27, the
findings of our review highlight the intensified disturbances of cerebrovascular
hemodynamics in aged people with dementia.
This meta-analysis has certain limitations. First, we could only include out-
comes measured in the middle cerebral artery. Even though middle cerebral
artery is the main vessel responsible for perfusion of parietotemporal areas in
brain, there might be regional variations in hemodynamic disturbances through
development and progression of dementia which we could not address. Never-
theless, recent studies among demented patients confirm that most of intracra-
nial arteries follow similar hemodynamic pattern we presented for the middle
cerebral artery28. Second, the studies were small and despite statistical analysis,
there is concern of publication bias as small negative studies were unlikely to be
published because of a lack of power compared to small positive studies. Finally,
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transcranial doppler sonography cannot provide any estimation on the extent of
brain atrophy. Therefore, neuronal loss and decrease in metabolic demand can
be considered as an alternative explanation for reduction of cerebral blood flow
in patients with dementia in comparison with healthy elderly. In this setting, in-
terpretation of cerebral hemodynamic parameters before correction for the level
of brain atrophy needs caution.
Regulations of cerebral blood flow and other hemodynamic measure follows
complex mechanisms29. Though great achievement has been made in recogni-
tion of these mechanisms in physiologic states, our knowledge concerning the
impairment of regulatory pathways in dementia is limited and needs further
investigation. In future work, using pooled data of other hemodynamic indexes
such as cerebral autoregulation and vasomotor reactivity measured at a regional




1. Zlokovic BV, Deane R, Sallstrom J, Chow N, Miano JM. Neurovascular pathways and
alzheimer amyloid beta-peptide. Brain Pathol. 2005;15:78-83
2. Cacabelos R, Fernandez-Novoa L, Lombardi V, Corzo L, Pichel V, Kubota Y. Cere-
brovascular risk factors in alzheimer’s disease: Brain hemodynamics and pharmacoge-
nomic implications. Neurol Res. 2003; 25:567-580
3. Gorelick PB. Risk factors for vascular dementia and alzheimer disease. Stroke. 2004;35:2620-
2622
4. Viswanathan A, Rocca WA, Tzourio C. Vascular risk factors and dementia: How to
move forward? Neurology. 2009;72:368-374
5. Reed BR, Mungas DM, Kramer JH, Ellis W, Vinters HV, Zarow C, Jagust WJ, Chui HC.
Profiles of neuropsychological impairment in autopsy-defined alzheimer’s disease and
cerebrovascular disease. Brain. 2007;130:731-739
6. de la Torre JC. Alzheimer’s disease is a vasocognopathy: A new term to describe its
nature. Neurol Res. 2004;26:517-524
7. Altman R, Rutledge JC. The vascular contribution to alzheimer’s disease. Clin Sci
(Lond). 2010;119:407-421
8. Panerai RB. Cerebral autoregulation: From models to clinical applications. Cardiovasc
Eng. 2008;8:42-59
9. Wagshul ME, Eide PK, Madsen JR. The pulsating brain: A review of experimental and
clinical studies of intracranial pulsatility. Fluids Barriers CNS. 2011;8:5
10. Baumgartner RW. Transcranial insonation. Front Neurol Neurosci. 2006;21:105-116
11. van Beek AH, Sijbesma JC, Jansen RW, Rikkert MG, Claassen JA. Cortical oxygen
supply during postural hypotension is further decreased in alzheimer’s disease, but un-
related to cholinesterase-inhibitor use. J Alzheimers Dis. 2010;21:519-526
12. Claassen JA, Diaz-Arrastia R, Martin-Cook K, Levine BD, Zhang R. Altered cerebral
hemodynamics in early alzheimer disease: A pilot study using transcranial doppler. J
Alzheimers Dis. 2009;17:621-629
13. Doepp F, Valdueza JM, Schreiber SJ. Transcranial and extracranial ultrasound as-
sessment of cerebral hemodynamics in vascular and alzheimer’s dementia. Neurol Res.
2006;28:645-649
14. Marcos A EJ, Barquero M, Fernandez C, De Seijas EV. Full range of vasodilation tested
by transcranial doppler in the differential diagnosis of vascular and alzheimer types of
dementia. Cerebrovascular Diseases. 1997;7:14-18
15. Biedert S, Forstl H, Hewer W. Multiinfarct dementia vs alzheimer’s disease: Sono-
graphic criteria. Angiology. 1995;46:129-135
16. Ries F, Horn R, Hillekamp J, Honisch C, Konig M, Solymosi L. Differentiation of
multi-infarct and alzheimer dementia by intracranial hemodynamic parameters. Stroke.
1993;24:228-235
17. Biedert S, Forstl H, Hewer W. The value of transcranial doppler sonography in the
123
Chapter 8 – Cerebrovascular Hemodynamics in Alzheimer’s disease and Vascular Dementia
differential diagnosis of alzheimer disease vs multi-infarct dementia. Mol Chem Neu-
ropathol. 1993;19:15-23
18. Provinciali L, Minciotti P, Ceravolo G, Angeleri F, Sanguinetti CM. Transcranial
doppler sonography as a diagnostic tool in vascular dementia. Eur Neurol. 1990;30:98-
103
19. Biedert S FH, Hewer W. Transcranial doppler sonography in the differential diagnosis
of alzheimer’s disease and multi-infarct dementia. Journal of Cardiovascular Technology.
1990;9:153-155
20. Foerstl H, Biedert S, Hewer W. Multiinfarct and alzheimer-type dementia investigated
by transcranial doppler sonography. Biol Psychiatry. 1989;26:590-594
21. van Beek AH, Lagro J, Olde-Rikkert MG, Zhang R, Claassen JA. Oscillations in
cerebral blood flow and cortical oxygenation in alzheimer’s disease. Neurobiol Aging.
2012;33(2):428.e21-31.
22. Vicenzini E, Ricciardi MC, Altieri M, Puccinelli F, Bonaffini N, Di Piero V, Lenzi GL.
Cerebrovascular reactivity in degenerative and vascular dementia: A transcranial doppler
study. Eur Neurol. 2007;58:84-89
23. Lee ST, Jung KH, Lee YS. Decreased vasomotor reactivity in alzheimer’s disease. J
Clin Neurol. 2007;3:18-23
24. Caamano J, Gomez MJ, Cacabelos R. Transcranial doppler ultrasonography in se-
nile dementia: Neuropsychological correlations. Methods Find Exp Clin Pharmacol.
1993;15:193-199
25. Tierney MC, Fisher RH, Lewis AJ, Zorzitto ML, Snow WG, Reid DW, Nieuwstraten P.
The nincds-adrda work group criteria for the clinical diagnosis of probable alzheimer’s
disease: A clinicopathologic study of 57 cases. Neurology. 1988;38:359-364
26. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Ama-
ducci L, Orgogozo JM, Brun A, Hofman A, et al. Vascular dementia: Diagnostic crite-
ria for research studies. Report of the ninds-airen international workshop. Neurology.
1993;43:250-260
27. Zaudig M. A new systematic method of measurement and diagnosis of "mild cogni-
tive impairment" and dementia according to icd-10 and dsm-iii-r criteria. Int Psychogeri-
atr. 1992;4 Suppl 2:203-219
28. AP A. Diagnostic and statistical manual of mental disorders, 4th ed.: Dsm-iv. Wash-
ington, d.C. 1994.
29. Nakagawa S, Cuthill IC. Effect size, confidence interval and statistical significance: A
practical guide for biologists. Biol Rev Camb Philos Soc. 2007;82:591-605
30. Khoshdel A, Attia J, Carney SL. Basic concepts in meta-analysis: A primer for clini-
cians. Int J Clin Pract. 2006;60:1287-1294
31. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods
to detect publication bias in meta-analysis. JAMA. 2006;295:676-680
32. de la Torre JC. Is alzheimer’s disease a neurodegenerative or a vascular disorder?
Data, dogma, and dialectics. Lancet Neurol. 2004;3:184-190
124
33. de la Torre JC. Critically attained threshold of cerebral hypoperfusion: The catch
hypothesis of alzheimer’s pathogenesis. Neurobiol Aging. 2000;21:331-342
34. de la Torre JC. Alzheimer disease as a vascular disorder: Nosological evidence. Stroke.
2002;33:1152-1162
35. Tartaglia MC, Rosen HJ, Miller BL. Neuroimaging in dementia. Neurotherapeutics.
2011;8:82-92
36. Sorond FA, Hollenberg NK, Panych LP, Fisher ND. Brain blood flow and velocity:
Correlations between magnetic resonance imaging and transcranial doppler sonography.
J Ultrasound Med. 2010;29:1017-1022
37. Ruitenberg A, den Heijer T, Bakker SL, van Swieten JC, Koudstaal PJ, Hofman A,
Breteler MM. Cerebral hypoperfusion and clinical onset of dementia: The rotterdam
study. Ann Neurol. 2005;57:789-794
38. Kalaria R. Similarities between alzheimer’s disease and vascular dementia. J Neurol
Sci. 2002;203-204:29-34
39. Cordonnier C, van der Flier WM, Sluimer JD, Leys D, Barkhof F, Scheltens P. Preva-
lence and severity of microbleeds in a memory clinic setting. Neurology. 2006;66:1356-
1360
40. Barber R, Scheltens P, Gholkar A, Ballard C, McKeith I, Ince P, Perry R, O’Brien
J. White matter lesions on magnetic resonance imaging in dementia with lewy bodies,
alzheimer’s disease, vascular dementia, and normal aging. J Neurol Neurosurg Psychia-
try. 1999;67:66-72
41. Zarei M, Damoiseaux JS, Morgese C, Beckmann CF, Smith SM, Matthews PM, Schel-
tens P, Rombouts SA, Barkhof F. Regional white matter integrity differentiates between
vascular dementia and alzheimer disease. Stroke. 2009;40:773-779
42. Jellinger KA. The pathology of "vascular dementia": A critical update. J Alzheimers
Dis. 2008;14:107-123
43. Kalback W, Esh C, Castano EM, Rahman A, Kokjohn T, Luehrs DC, Sue L, Cisneros
R, Gerber F, Richardson C, Bohrmann B, Walker DG, Beach TG, Roher AE. Atheroscle-
rosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic
alzheimer’s disease. Neurol Res. 2004;26:525-539
44. Stern Y. What is cognitive reserve? Theory and research application of the reserve
concept. J Int Neuropsychol Soc. 2002;8:448-460
45. Sun ZW, Zhu YX, Liu HY, Liu J, Zhu XQ, Zhou JN, Liu RY. Decreased cerebral blood
flow velocity in apolipoprotein e epsilon4 allele carriers with mild cognitive impairment.
Eur J Neurol. 2007;14:150-155
46. Bakker SL, de Leeuw FE, den Heijer T, Koudstaal PJ, Hofman A, Breteler MM. Cere-
bral haemodynamics in the elderly: The rotterdam study. Neuroepidemiology. 2004;23:178-
184
47. Roher AE, Garami Z, Tyas SL, Maarouf CL, Kokjohn TA, Belohlavek M, Vedders
LJ, Connor D, Sabbagh MN, Beach TG, Emmerling MR. Transcranial doppler ultrasound
blood flow velocity and pulsatility index as systemic indicators for alzheimer’s disease.
Alzheimers Dement. 2011;7:445-455
125
Chapter 8 – Cerebrovascular Hemodynamics in Alzheimer’s disease and Vascular Dementia
48. van Beek AH, Claassen JA, Rikkert MG, Jansen RW. Cerebral autoregulation: An
overview of current concepts and methodology with special focus on the elderly. J Cereb
Blood Flow Metab. 2008;28:1071-1085
126
9
Cognitive Impairment and Risk of
Stroke
Manuscript based on this chapter has been published as:
Sabayan B, Gussekloo J, de Ruijter W, Westendorp RG, de Craen AJ. Framingham stroke
risk score and cognitive impairment for predicting first-time stroke in the oldest old.
Stroke. 2013 ;44(7):1866-71.
127
Chapter 9 – Cognitive Impairment and Risk of Stroke
Summary
Predictive value of the conventional risk factors for stroke attenuates with age.
Cognitive impairment has been implicated as a potential predictor for stroke in
older subjects. Our aim was to compare the Framingham stroke risk score with
cognitive functioning for predicting first-time stroke in a cohort of the oldest-
old individuals. We included 480 subjects aged 85 years old from the Leiden
85-plus Study. At baseline, data on the Framingham stroke risk score and the
Mini-Mental State Examination (MMSE) score were obtained. Risk of first-time
stroke was estimated in tertiles of Framingham and MMSE scores. Receiver op-
erating characteristic curves with corresponding areas under the curves (AUC)
and 95% confidence intervals (CI) were constructed for both Framingham and
MMSE scores. Subjects with high Framingham risk score compared to those
with low Framingham risk score did not have a higher risk of stroke (Hazard
Ratio (HR): 0.77, 95% CI: 0.39-1.54). Conversely, subjects with high level of cogni-
tive impairment compared to those with low level of cognitive impairment had a
higher risk of stroke (HR: 2.85, 95% CI: 1.48-5.51). In contrast to the Framingham
risk score (AUC: 0.48, 95% CI: 0.40-0.56), MMSE score had discriminative power
to predict stroke (AUC: 0.65, 95% CI: 0.57-0.72). There was a significant differ-
ence between AUC for Framingham risk score and MMSE score (p=0.006). In
the oldest-old, the Framingham stroke risk score is not predictive for first-time
stroke. In contrast, cognitive impairment, as assessed by MMSE score, identifies
subjects at a higher risk of stroke.
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Introduction
Oldest old subjects form a growing part of the stroke population in developed
countries1. Since stroke in very old age puts a great burden on patients and
health care systems, novel strategies for early identification of very old subjects
at high risk of stroke is crucial2.
With advancing age, conventional vascular risk factors such as hypertension
and hypercholesterolemia lose their predictive value for stroke3, 4. This phe-
nomenon has raised doubt whether well-established predictive models such as
Framingham stroke risk score, which were constructed based on such factors
in middle age and younger elderly, can accurately identify very old subjects at
high risk of stroke5. Cognitive impairment is common in old age and is strongly
associated with brain vascular pathologies and disturbances in cerebrovascular
hemodynamics6. Some studies have shown that impaired cognitive function is
a potential predictor for first-time stroke in middle aged and younger elderly
people7, 8. Whether these findings can be extrapolated to very old subjects is
unclear.
The Framingham stroke risk score has been validated in subjects younger
than 85 years old9 and there is a lack of evidence on the predictive value of cog-
nitive impairment for first-time stroke in the oldest old. The aim of our study
was to investigate the performance of Framingham stroke risk score and cogni-
tive impairment in predicting five-year risk of first-time stroke in a population-
based sample of very old subjects. We hypothesized that level of cognitive im-
pairment better predicts risk of stroke in the oldest old.
Material and methods
Study design and participants
The Leiden 85-plus Study is an observational, prospective population-based co-
hort study of inhabitants of Leiden, the Netherlands. Between September 1997
and September 1999, all inhabitants of 1912-1914 birth cohort (n = 705) were
contacted in the month of their 85th birthday. There were no selection criteria on
demographic features or health status. Fourteen people died before enrollment;
a total of 599 (397 women and 202 men) subjects agreed to participate (85%).
As described previously, there was no significant difference between the demo-
graphic features and health status of those who participated and those who did
not10. In this analysis we excluded 61 subjects who had a previous stroke. In
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addition, 58 subjects were excluded because of missing data for the components
of Framingham risk score or cognitive function, leading to a final sample size of
480 subjects. All participants were visited at their homes, where they underwent
face to face interview, physical examination, blood sampling, electrocardiogra-
phy and cognitive assessment. The Medical Ethical Committee of the Leiden
University Medical Centre approved the study, and informed consent was ob-
tained from all subjects.
Vascular risk factors included in the Framingham stroke risk score
Blood Pressure
Blood pressure was measured at baseline in the seating position, using a mer-
cury sphygmomanometer. During the home visits, two blood pressure mea-
surements were done two weeks apart and average of these two measurements
were used in the analyses. Blood pressure measurements were recorded after at
least 5 min of rest and no vigorous exercise in the preceding 30 min. The sys-
tolic blood pressure (SBP) was measured at Korotkoff sound 1, and the diastolic
blood pressure (DBP) was measured at Korotkoff sound 5. Use of antihyperten-
sive medication was extracted from pharmacy records.
Diabetes mellitus
Diabetes mellitus was considered present when present in the records of the pri-
mary care physician, when non-fasting glucose concentrations were greater than
11.0 mmol/l, or when a participant was taking antidiabetic medication accord-
ing to their pharmacy records.
Smoking
All participants were interviewed about present and past smoking habits. Cur-
rent and past smokers of cigarettes, cigars, and pipes were judged to have a
history of smoking.
Cardiovascular diseases
Data on history of cardiovascular diseases including coronary artery disease,
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heart failure, or peripheral vascular disease were obtained through interviewing
individual’s general practitioners or nursing home physicians.
Electrocardiogram based left ventricular hypertrophy and atrial fibrillation
Electrocardiograms were recorded on a Siemens Sicard 440 (Erlangen, Germany)
and transmitted to the electrocardiograms core laboratory in the Glasgow Royal
Infirmary for automated Minnesota coding 11. All electrocardiograms were re-
viewed to exclude coding errors due to technical causes. Left ventricular hyper-
trophy was defined by Minnesota codes 3-1-0, 3-3-0, or 3-4-0. Atrial fibrillation
was defined as the presence of Minnesota Code 8-3-1.
Cognitive assessment
At baseline, global cognitive function was assessed in all participants using the
Mini-Mental State Examination (MMSE). The MMSE assesses five areas of cog-
nitive function: orientation, registration, attention and calculation, recall and
language. The MMSE has a maximum score of 30 in which higher scores indi-
cate better cognitive function. We categorized participants based on the tertiles
of MMSE score to low (MMSE >27), intermediate (MMSE =25-27) and high
(MMSE <25) levels of cognitive impairment.
Stroke
In the Netherlands detailed information on health status, emergency events and
patients’ hospitalizations are all recorded with general practitioners. Occurrence
of clinically recognized stroke during five years of follow up was assessed by
annually interviewing general practitioners (for subjects living independently)
or nursing home physicians (for subjects living in a nursing home). We used
the World Health Organization definition of stroke of “rapidly developing clin-
ical signs of focal (at times global) disturbance of cerebral functioning lasting
> 24 hours” to identify subjects with stroke events.12 To obtain exact date of
fatal stroke events, we retrieved specific data on causes of death from Statistics
Netherlands, which assigns codes for all national death certificates according to
the International Classification of Diseases and Related Disorders, 10th revision
(ICD-10). Death due to stroke was classified as ICD-10 codes I60-I69.13
Statistical analysis
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Characteristics of the study participants are reported as mean (standard devia-
tion) for continuous variables and number (percentage) for categorical variables.
Differences in values of continue parameters between participants who devel-
oped stroke and participants who did not were tested by independent samples t
tests. Differences in frequency of categorical parameters between the two groups
were evaluated using Chi-Square tests. To assess the performance of Framing-
ham risk score and MMSE score in prediction of stroke we used following analy-
ses. First, incidence rate of stroke with corresponding 95% confidence intervals,
in each tertile of Framingham and MMSE score was estimated by dividing the
number of events by the person-year at risk. In addition, we compared cu-
mulative incidence of stroke in tertiles of both Framingham and MMSE scores.
Kaplan-Meier method was used and strata were compared with log-rank test.
In the next step, hazard ratios with corresponding 95% confidence intervals for
stroke outcomes (second and third tertile of Framingham and MMSE score ver-
sus first tertile as reference) were calculated using Cox regression models. Fi-
nally, receiver operating characteristic (ROC) curves with corresponding areas
under the curves (AUC, neutral value 0.50= risk prediction by pure chance) and
95% confidence intervals were constructed for the Framingham risk score and
MMSE score. Significant difference between area under the curve for the Fram-
ingham and MMSE scores was tested using Chi-Square test. All analyses were
carried out using SPSS software (version 20.0.0, SPSS Inc., Chicago, IL) except
for the comparing of the AUC of ROC curves which was performed by STATA
version 10.0 (Stata Corp., College Station, TX).
Results
Table 1 summarizes baseline characteristics of the participants. During five years
of follow up 56 subjects developed a stroke (incidence rate: 30.3 per 1000 person-
year). At age 85 years, prevalence of cardiovascular diseases, diabetes mellitus,
smoking, atrial fibrillation, left ventricular hypertrophy and use of antihyperten-
sive medication was not statistically different in participants with and without
stroke events in subsequent years (all P>0.05). Moreover, systolic and diastolic
blood pressure at age 85 years was also similar in participants with and without
stroke events in subsequent years (both P>0.05). In contrast, subjects who de-
veloped stroke had significantly lower MMSE score at age 85 years (P<0.001).
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Figure 1. Cumulative incidence of fatal and nonfatal stroke during five years of follow-up
according to level the Framingham risk score (1-A) and cognitive impairment (1-B)
MMSE scores. There was no significant difference in cumulative incidence of
stroke among subjects with low, intermediate and high Framingham risk scores
(log-rank p=0.39). In contrast, there was a significant difference in cumulative
incidence of stroke among subjects with low, intermediate and high levels of
cognitive impairment (log-rank p=0.004).
Number of stroke events and risk of stroke in tertiles of Framingham and
MMSE scores are presented in table 2. Incidence rate of stroke was 23.3 (95%
CI: 11.1-35.5) per 1000 person-year in subjects with high Framingham risk score,
37.1 (95% CI: 21.9-52.3) per 1000 person-year in subjects with intermediate Fram-
ingham risk score and 30.2 (95% CI: 16.6-43.8) per 1000 person-year in subjects
with low Framingham risk score. Incidence rate of stroke was 49.5 (95% CI: 31.2-
67.8) per 1000 person-year in subjects with high level of cognitive impairment,
27.8 (95% CI: 13.7-41.9) per 1000 person-year in subjects with intermediate level
of cognitive impairment and 17.4 (95% CI: 8.1-26.8) per 1000 person-year in sub-
jects with low level of cognitive impairment. Furthermore, subjects with high
Framingham risk score did not have a higher risk of stroke compared to those
with low Framingham risk score (HR: 0.77, 95 % CI: 0.39-1.54) whereas subjects
with high level of cognitive impairment had a higher risk of stroke compared
to those with low level of cognitive impairment (HR: 2.85, 95 % CI: 1.48-5.51).
We further explored whether cognitive performance predicts risk of first-time
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Figure 2. Receiver operating characteristic (ROC) curves showing area under the curve
(AUC) of Framingham risk score and Mini Mental Status Examination (MMSE) for pre-
dicting five years risk of first-time stroke.
stroke independent of socio-demographic and cardiovascular factors and found
similar associations between cognitive impairment and risk of stroke (table S-1
http://stroke.ahajournals.org/content/44/7/1866/suppl/DC1).
Figure 2 shows the ROC curve for Framingham risk score as well as MMSE
score in prediction of stroke events. Framingham risk score did not predict
stroke (AUC 0.48, 95%CI: 0.40-0.56). Conversely, MMSE score had discrimina-
tive power to predict stroke (AUC 0.65, 95%CI: 0.57-0.72). The AUC for MMSE
score was significantly higher than the AUC for Framingham stroke risk score
(p=0.006). In addition, to explore whether the association between cognitive im-
pairment and risk of stroke was not only dependent on subjects with very low
cognitive function, in a sensitivity analysis, we excluded subjects with MMSE
score 16 or less (n= 42) and found similar outcomes (data not shown). In an-
other sensitivity analysis, to test whether our findings are not due to short term
stroke events, we excluded subjects who developed stroke in the first year of
follow-up (n=14). This sensitivity analysis showed that the predictive value of
MMSE score for stroke is not dependent on short term stroke events (table S-2
http://stroke.ahajournals.org/content/44/7/1866/suppl/DC1 ).
Discussion
In a cohort of very old individuals without a previous history of stroke, we ob-
served that Framingham stroke risk score, composed of conventional vascular
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risk factors, did not predict risk of stroke. In contrast, impaired cognitive func-
tion assessed by low scores on the MMSE, identified subjects at higher risk of
stroke.
A growing body of evidence indicates that the predictive value of conven-
tional vascular risk factors for mortality and cardiovascular events attenuates
with age.3, 14-16 Previously, we reported that in very old people from the gen-
eral population with no history of cardiovascular disease, risk factors such as
hypertension, hypercholesterolemia, diabetes mellitus and left ventricular hy-
pertrophy did not predict cardiovascular mortality.5 Consistently, results from
the current study suggest that conventional vascular risk factors included in the
Framingham stroke risk score may not predict higher risk of stroke in the old-
est old. Well-established prediction models for stroke are basically designed for
middle aged or younger elderly people.17 The Framingham stroke risk score is
not an exception as it was constructed in a study population with an average age
of 65 years and is validated for subjects younger than 85 years old.9 This might
explain why the Framingham risk score in our study population consisting of
very old age subjects did not predict risk of stroke.
Cognitive impairment is common in old age and has a clear association with
brain vascular pathologies and disturbances in cerebrovascular hemodynamics.18-20
Thus, cognitive assessment has been proposed as a tool to identify younger el-
derly subjects at risk of stroke.8, 21 In a population-based study including 9451
subjects aged 65 year and older, cognitive impairment was associated with a
twofold increased risk for fatal incident stroke.22 Similarly, a recent large study
on 30959 individuals older than 55 years at increased cardiovascular risk showed
that impaired cognitive function is associated with a graded increase in risk of
stroke.23 Findings of our study extend this evidence to the oldest old population
and show that in very old age when the association between conventional vascu-
lar risk factors and cerebrovascular events is weak, cognitive assessment might
be considered as a tool for identifying subjects at high risk of stroke. Given that
the population of very old subjects is rapidly increasing worldwide and partic-
ularly in developed countries24, our findings highlight a need for development
of new prediction models for stroke in this age group and suggest that cognitive
performance can be considered as a potential component in future prediction
models.
We performed our analysis in the Leiden 85-plus study which is a population-
based cohort with a relatively large number of participants, low attrition rate and
a long follow up period. However, limitations of this study should be kept in
mind when evaluating the results. Lack of neuro-imaging data to determine type
of stroke can be marked as a limitation of this study although it is previously
reported that the majority of strokes in very old age are of the ischemic type25.
137
Chapter 9 – Cognitive Impairment and Risk of Stroke
Moreover, silent strokes are frequently observed in older subjects26. Therefore,
there is a possibility that subjects in the group with high cognitive impairment
had more clinically unrecognized strokes which predisposed them to the sub-
sequent stroke events. In addition, we assessed level of cognitive impairment
only based on MMSE scores. Since there is no single criterion or definition for
cognitive impairment, MMSE may not be the optimum tool to evaluate level of
cognitive impairment. Despite this limitation, MMSE is commonly used in clin-
ical settings and no expertise is involved in its application which makes it an
appropriate candidate for identification of the oldest old subjects at high risk of
stroke27. It is possible that cognitive tests such as Montreal Cognitive Assess-
ment (MoCA) which are more sensitive to vascular cognitive impairment might
better predict stroke events in old age28.
In conclusion, we showed that the Framingham stroke risk score is not pre-
dictive for first-time stroke in a general population of the oldest-old individuals.
In contrast, low cognitive function predicts higher risk of stroke in the oldest
old. Assessment of cognitive function can be considered as an easily accessible
tool to identify very old subjects at risk of stroke. Findings of this study need to
be validated in the other cohorts of the oldest old people.
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Summary
We investigated the association of two markers of endothelial dysfunction, tis-
sue plasminogen activator (t-PA) and von willebrand factor (VWF), with cere-
bral blood flow in 541 older participants at high risk for cardiovascular disease.
Serum levels of t-PA and VWF were measured at baseline. Participants under-
went two successive brain MRI scans, first at baseline and the second after a
mean follow-up of 33 months. Total cerebral blood flow (CBF) was determined
in each scan and also standardized for brain parenchymal volume. At baseline,
higher t-PA was associated with lower CBF (p = 0.034). In the longitudinal anal-
ysis, higher levels of VWF were associated with a steeper decline in CBF (p =
0.043). There was no association between t-PA and decrease in CBF. These as-
sociations were independent of socio-demographic and cardiovascular factors.
In conclusion, elevated markers of endothelial dysfunction are associated with
lower cerebral blood flow in older adults at risk for cardiovascular disease.
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Introduction
Endothelial cells play a crucial role in maintaining vascular homeostasis1. These
cells contribute to regulation of vascular tone and the development of throm-
bosis and vessel wall inflammation2. Long-lasting exposure to cardiovascular
risk factors results in activation of endothelial cells and consequently release of
circulating markers reflecting endothelial cell injury3.
Endothelial dysfunction is a systemic phenomenon involving vascular beds
in different organs including the brain4. Elevated markers of endothelial dys-
function are related to impaired brain functioning5. However, the exact patho-
physiologic mechanisms behind this association remain to be elucidated. En-
dothelial cells are actively involved in regulation of cerebral circulation6. In
response to humoral, neuronal and metabolic stimuli, these cells produce and
release relaxing and contracting factors that adjust vascular tone and change
cerebrovascular hemodynamics7. Since regulation of cerebral blood flow (CBF)
depends on proper functioning of vascular endothelial cells8, endothelial dys-
function might lead to impaired brain functioning through changes in CBF.
Endothelial cells release t-PA in response to a range of factors mainly re-
lated to the activation of coagulation cascade9. Upon release, t-PA catalyzes the
conversion of plasminogen to plasmin which facilitates thrombus dissolution.
While acute release of t-PA contributes to prevent intravascular thrombosis, sev-
eral studies have shown that elevated serum t-PA concentration is associated
with higher risk of cardiovascular events10, 11. Hence, it has been suggested that
high serum t-PA in people at high risk of vascular disease might reflect pres-
ence of long-lasting endothelial injury and subsequent endothelial dysfunction.
On the other hand, VWF is a glycoprotein released from activated endothelial
cells and plays a key role in thrombus formation12. Given this role, several
studies have shown that higher levels of VWF predict vascular events11, 13. Dif-
ferent lines of evidence indicate that plasma VWF levels may also show a state
of endothelial activation, which in itself may contribute to the pathogenesis of
vascular events beyond the direct effects of released VWF14. Given this back-
ground and considering the pivotal role of endothelial cells in cerebrovascular
regulation, we hypothesized that elevated levels of t-PA and VWF, as markers of
endothelial cell injury and dysfunction, are associated with lower cerebral blood
flow in older adults at high risk for cardiovascular disease.
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Methods
Setting and participants
Participants were included from the nested MRI substudy of the Prospective
Study of Pravastatin in the Elderly at Risk (PROSPER), a large randomized
controlled trial assessing the benefits of 40 mg pravastatin daily on vascular
outcomes15. Study participants were men or women aged 70-82 years with
either preexisting vascular diseases or with increased risk of vascular disease
because of smoking, hypertension or diabetes mellitus. Participants with con-
gestive heart failure and arrhythmia were not included in this study. Inclu-
sion and exclusion criteria of the PROSPER study have been described in detail
elsewhere16. A total of 553 Dutch participants in the PROSPER study under-
went two successive MRI scans of the brain. In this report we included 541
participants for whom data on t-PA and VWF was available. Participants were
included from both pravastatin and placebo groups since we previously showed
that treatment with pravastatin does not influence level of CBF17. The Leiden
University Medical Center institutional ethics review board approved the proto-
col for the MRI study and all participants gave written, informed consent.
Markers of endothelial dysfunction
Venous blood samples were obtained at baseline and stored at -80◦C in the
Haemostasis and Thrombosis Laboratory, Glasgow Royal Infirmary18. Level of
tissue plasminogen activator (t-PA) antigen was measured by enzyme-linked im-
munosorbent assay (ELISA) from Hyphen BioMed (Paris, France). Level of von
willebrand factor (VWF) antigen was measured by an in-house ELISA using an-
tibody from DAKO (Copenhagen, Denmark). Measurements of t-PA and VWF
were done before the start of statin treatment. All laboratory analyses were con-
ducted by technicians blind to the identity of samples.
MRI Scanning
All imaging was performed on an MR system operating at field strength of 1.5 T
(Philips Medical Systems, Best, The Netherlands). Dual fast spin echo [repetition
time (TR) = 3,000 ms; echo time (TE) = 27/120 ms; flip angle = 90◦; slice thick-
ness = 3 mm; 48 slices; no interslice gap; field of view (FOV) = 220×220 mm;
matrix = 256×204] were obtained from all participantss. The SIENAX technique
was used to obtain estimates of total brain parenchymal volume. In summary,
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SIENAX starts by extracting brain and skull images from the single whole-head
input data. The brain image is then afne-registered to Montreal Neurological
Institute (MNI) 152 space (by using the skull image to determine the registra-
tion scaling), done primarily to obtain the volumetric scaling factor to be used
as normalization for head size19. In addition, single slice phase contrast MR
angiography (TR/TE = 16/9 ms; flip angle = 7.5◦; slice thickness = 5 mm; FOV
= 250; RFOV = 75%; scan percentage = 80%; matrix = 256; 8 signal averages)
with a velocity encoding of 100 cm/s was used for flow measurements20. The
scans were performed in a plane perpendicular to the left and right internal
carotid artery and the vertebral arteries, at the level of the vertical segment of
the petrous portion of the internal carotid artery.
Total CBF
Level of CBF was analyzed by application of an in-house developed software
package (FLOW; Division of Image Processing, Department of Radiology, Lei-
den University Medical Center) by using a workstation (UltraSparc 10; Sun Mi-
crosystems, Santa Clara, Calif)21. With this software, the blood vessel is identi-
fied manually, after which delineation of the vessel is performed automatically.
For this method a region of interest (ROI) was manually drawn around the ves-
sel in the magnitude image and copied into the phase images. For triggered
measurements a vessel contour was drawn in one heart phase and the software
copied this contour to the other phases. Visually, all phases were screened for
correct positioning of the ROI. If required, the ROI was adjusted. Then flow
volume is calculated by integrating the flow velocity values within this contour,
multiplied with the area. Total CBF was calculated by adding flow from the left
and right internal carotid arteries and the flow in both vertebral arteries. We
standardized level of total CBF by brain parenchymal volume through dividing
total CBF by each individual’s brain volume (ml) and multiplying the obtained
result by 100. Changes in levels of CBF were defined as the follow up measure-
ment minus the baseline measurement.
Statistical analysis
Characteristics of the study participants are reported as mean (standard devia-
tion) for continuous variables and number (percentage) for categorical variables.
Participants were grouped based on t-PA and VWF tertiles. Baseline levels of
total CBF were calculated for each tertile of t-PA and VWF. Similarly, we cal-
culated changes in total CBF for each tertile of t-PA and VWF. The association
between markers of endothelial dysfunction and CBF was tested using linear
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regression models. We performed our analyses in two steps. In the first step,
analyses were adjusted for age and sex. In the next step, further covariates were
added to the statistical models based on their biological plausibility and their po-
tential role as a confounder on the association between endothelial dysfunction
and changes in CBF. The covariates included in the multivariate analyses were
age, sex, body mass index, serum triglyceride, high density lipoprotein (HDL)
cholesterol, history of diabetes, history of hypertension, smoking, alcohol intake,
statin treatment and history of cardiovascular diseases (coronary, cerebral, or pe-
ripheral) at baseline. Associations between markers of endothelial dysfunction
and changes in CBF were further adjusted for baseline CBF measures. All the
probability values were estimated from normally transformed continuous data.




Baseline characteristics of the participants are presented in table 1. Mean age
was 75.0 years and 43.6% of participants were female. Mean values for t-PA and
VWF were 11.3 ng/ml and 127.3 IU/dL respectively. At baseline, average of un-
standardized CBF was 523.6 ml/min and average of standardized CBF for brain
parenchymal volume was 49.3 ml/min/100 ml. The mean duration between the
baseline and follow up MRI scans was 33±1.4 months.




Age, years 75.0 (3.1)
Women, n (%) 236 (43.6)
Current smoker, n (%) 110 (20.3)
Alcohol intake, unit per week 6.7 (8.3)
Cardiovascular factors
SBP, mmHg 157.3 (21.6)
DBP, mmHg 85.8 (11.1)
Diabetes mellitus, n (%) 90 (16.6)
BMI, kg/m2 26.6 (3.6)
Serum triglyceride, mmol/L 1.6 (0.7)
HDL cholesterol, mmol/L 1.3 (0.3)
History of vascular disease, n (%) 235 (43.4)
History of Stroke or TIA, n (%) 87 (16.1)
History of myocardial infarction, n (%) 67 (12.3)
Statin treatment, n (%) 269 (49)
Markers of endothelial dysfunction
Tissue plasminogen activator, ng/mL 11.3 (3.8)
von Willebrand factor, IU/dL 127.3 (41.3)
Cerebral blood flow
Unstandardized CBF, ml/min 523.6 (95.8)
Standardized CBF, ml/min/100ml 49.3 (8.9)
-All the values are presented as mean (standard devia-
tion) except as noted. Abbreviations: SBP: systolic blood
pressure, DBP: diastolic blood pressure, BMI: body mass
index, HDL: high density lipoprotein, TIA: transient is-
chemic attack, CBF: cerebral blood flow
Table 2 shows baseline and changes in CBF in relation to tertiles of t-PA.
In the cross-sectional analysis adjusted for age and sex, baseline CBF was sig-
nificantly lower in participants with higher t-PA circulating (p=0.008). Further
adjustments for socio-demographic and cardiovascular factors did not materi-
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ally change the results. In contrast, in the longitudinal analysis, there was
no significant association between level of t-PA and changes in CBF. Associa-
tions between covariates and CBF from the multivariate analysis of t-PA with
CBF are presented in the supplemental material (Table S-1 and Table S-2 http:
//www.sciencedirect.com/science/article/pii/S0197458013003540).
Table 3 shows baseline and changes in CBF in relation to tertiles of VWF. In
the cross-sectional analysis, there was no association between level of VWF and
baseline CBF. However, longitudinal analysis adjusted for age and sex showed
that participants with higher VWF at baseline had a higher decline in CBF (p
= 0.014). Further adjustments for sociodemographic and cardiovascular factors
did not materially change the results. Associations between covariates and CBF
from the multivariate analysis of VWF with CBF are presented in the supplemen-
tal material (Table S-3 and Table S-4 http://www.sciencedirect.com/science/
article/pii/S0197458013003540).
Figure 1 shows percentages decline in CBF over a 33 months follow-up pe-
riod dependent on tertiles of baseline t-PA and VWF at baseline. In the whole
study population average decline in CBF was 1.6 ml/min/100ml. Between two
MRI measurements, 26 participants developed stroke and 14 participants devel-
oped coronary artery events. To test whether the association between markers of
endothelial dysfunction and CBF measures was independent of these events, we
performed a sensitivity analysis excluding these participants and found similar
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Von Willebrand factor
Figure 1. Longitudinal changes in cerebral blood flow in tertiles of tissue plasminogen
acitivator and von willebrand factor. Each bar represents mean (standard error) for per-
centage decline in cerebral blood flow.
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Discussion
This study shows that higher levels of t-PA and VWF, as circulating markers
of endothelial dysfunction, are associated with lower cerebral blood flow in a
cohort of older people at risk for cardiovascular events. We observed that high t-
PA was cross-sectionally associated with lower cerebral blood flow, while higher
levels of VWF were associated with a steeper decline in cerebral blood flow.
The capacity of endothelial cells to maintain vascular homeostasis decreases
with advancing age8. Advanced age, on the other hand, is associated with a
decrease in cerebral blood flow and increase in cerebral vascular resistance22, 23.
Accordingly, it has been suggested that lower cerebral blood flow in older adults
may be partly related to impaired endothelial cell functioning in the brain vas-
culature 24. Exposure to cardiovascular risk factors activates endothelial cells
which results in expression and release of inflammatory cytokines and coagula-
tion factors into the circulation 25. It has been demonstrated that t-PA and VWF
are released from activated endothelial cells and they can serve as the markers
of endothelial dysfunction 14, 26. In this study, we found different associations
of t-PA and VWF with cerebral blood flow measurements. While higher t-PA
was associated with lower cerebral blood flow at baseline, VWF was associated
with a steeper decline in cerebral blood flow. The reason for these differential
associations is not clear. These findings might suggest that various circulating
markers of endothelial dysfunction, probably because of their different biolog-
ical properties, have different predictive values for CBF measurements. t-PA
is a measure of activated endogenous fibrinolysis9, a process that might carry
counter-regulatory protection against reduction in CBF. VWF in contrast potenti-
ates platelet activation 27, and elevated levels might then affect CBF change over
time.
The observed association between circulating markers of endothelial dys-
function and lower cerebral blood flow can be explained in different ways. First,
markers of endothelial dysfunction could represent higher loads of cardiovascu-
lar risk factors and disease 28 which may independently decrease level of CBF 29.
However, we showed that the association of the circulating markers of endothe-
lial dysfunction with CBF measures did not essentially change after adjusting
for established cardiovascular risk factors and diseases. A second explanation
could be that higher degrees of endothelial dysfunction were associated with
a loss of parenchymal brain volume due to previous neurovascular injuries 30.
Hence, those with higher t-PA and VWF might have required less CBF to meet
the metabolic demand of their brains. Nevertheless, we found similar associ-
ations of the markers of endothelial dysfunction after standardization of cere-
bral blood flow for brain parenchymal volume. As a third possible explanation,
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elevated t-PA and VWF could reflect presence of endothelial dysfunction not
only in the systemic circulation but also in the brain vasculature which led to
an increased cerebral vascular resistance and ultimately dysregulation of CBF.
In line with this explanation, previous studies showed that medical conditions
associated with endothelial dysfunction such as diabetes mellitus and cerebral
microangiopathy are linked to disturbances in cerebrovascular hemodynamics
31, 32. Further studies are needed to test whether elevated markers of endothelial
dysfunction are associated with impaired functioning of cerebrovascular regula-
tory mechanisms such as cerebral autoregulation.
Increasing body of evidence shows that long-lasting exposure to cardiovas-
cular risk factors with consequent cerebrovascular damage is associated with
higher risk of cognitive impairment in older adults 33. In line with this evidence,
a recent systematic review and meta-analysis showed that individuals with ele-
vated serum markers of endothelial cell injury including t-PA and VWF are at a
higher risk for developing vascular dementia 5. Although the exact mechanisms
behind this association remain to be elucidated, it has been suggested that en-
dothelial dysfunction might lead to cognitive impairment through changes in
CBF 34. Findings of our study support this hypothesis and might imply that
strategies to prevent endothelial dysfunction can be considered as potential tools
to reduce risk of cognitive impairment and dementia in older adults.
Our study has certain strengths and limitations. Major strengths of this study
include a relatively large number of older participants and measurement of de-
cline in CBF in two subsequent MRI sessions. As a limitation, our study popula-
tion consisted of participants at high risk for cardiovascular disease which might
reduce the generalizability of our findings to community-dwelling older adults.
Nevertheless, this restriction provided us with an opportunity to investigate our
research question in a homogeneous group of participants at high risk for devel-
opment and progression of endothelial dysfunction 35. As a second limitation,
we assessed endothelial dysfunction indirectly using serum levels of t-PA and
WVF antigens. Although different methods are available to assess endothelial
dysfunction, no single test fulfills all the requirements for comprehensive assess-
ment of impaired endothelial functioning 3. Circulating markers of endothelial
dysfunction including tPA and VWF are no exceptions and they cannot serve
as the optimum tools to assess endothelial dysfunction. Therefore, our findings
need to be replicated in future studies assessing endothelial dysfunction with
other methods.
In conclusion, our findings suggest that endothelial dysfunction associates
with lower levels of cerebral blood flow in older adults at risk for cardiovascular
disease. Future interventional studies are needed to test whether strategies to
maintain optimal function of endothelial cells can lead to preservation of CBF
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and ultimately conservation of brain functioning in older adults.
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Chapter 11 – Cerebral Blood Flow and Survival in Old Age
Summary
The objective of this chapter is to examine the association of total CBF with all-
cause, non-cardiovascular and cardiovascular mortality in older subjects at risk
of cardiovascular disease. We included 411 subjects with a mean age of 74.5 years
from the MRI substudy of the Prospective Study of Pravastatin in the Elderly at
Risk (PROSPER). Total CBF was measured at baseline and occurrence of death
was recorded in an average follow-up period of 11.8 years. For each participant,
total CBF was standardized for brain parenchymal volume. Cox regression mod-
els were used to estimate risk of all-cause, non-cardiovascular and cardiovascular
mortality in relation to CBF. Mortality rates among participants in low, middle
and high thirds of total CBF were 52.1, 41.5 and 28.7 per 1000 person-years re-
spectively. Compared to participants in the high third of CBF, participants in the
low third had 1.88-fold (95% confidence interval (CI): 1.30-2.72) higher risk of all-
cause mortality, 1.66-fold (95% CI: 1.06-2.59) higher risk of non-cardiovascular
mortality and 2.50-fold (95% CI: 1.28-4.91) higher risk of cardiovascular mortal-
ity. Likewise, compared to participants in the high third of CBF, participants in
the middle third had 144-fold (95% CI: 0.98-2.11) higher risk of all-cause mortal-
ity, 1.29-fold (95% CI: 0.82-2.04) higher risk of non-cardiovascular mortality and
1.86-fold (95% CI: 0.93-3.74) higher risk cardiovascular mortality. These associa-
tions were independent of prevalent vascular status and risk factors. Low total
CBF is linked with higher risk of all-cause, non-cardiovascular and cardiovascu-
lar mortality in older people independent of clinical cardiovascular status.
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Introduction
Structural and functional integrity of the brain depends on adequate supply
of nutrient and oxygen through blood flow.1 The brain is a demanding organ
and consumes about 20% of the oxygen inspired at rest while accounting for
only 2% of the body weight.2 This high metabolic demand renders the brain
tissue vulnerable to low cerebral blood flow (CBF) as several animal studies
have shown that long-standing cerebral hypoperfusion leads to neuronal loss,
microvascular abnormalities and cognitive deficit.3, 4
Decreased cerebral perfusion in patients with acute traumatic brain injury
and cerebrovascular accidents has been linked to adverse clinical outcomes and
shorter survival.5, 6 Likewise, clinical conditions with a state of chronic reduction
in CBF, such as heart failure and carotid stenosis, have been associated with an
increased risk of mortality.7, 8 Despite this evidence, the independent role of CBF
in the maintenance of health and survival in old age has not been thoroughly
investigated.
In a cohort of older subjects at risk for cardiovascular disease, we investigated
whether lower CBF is linked with a higher risk of all-cause, non-cardiovascular
and cardiovascular mortality. We hypothesized that lower total CBF is indepen-
dently associated with higher risk of mortality in old age.
Methods
Setting and participants
Participants were included from the nested MRI substudy of the Prospective
Study of Pravastatin in the Elderly at Risk (PROSPER), a large randomized
controlled trial assessing the benefits of 40 mg pravastatin daily on vascular
outcomes.9 Study participants were men or women aged 70-82 years with either
preexisting vascular diseases or with increased risk of vascular disease because
of smoking, hypertension or diabetes mellitus. Subjects with congestive heart
failure (NYHA class III/IV), arrhythmia and cognitive impairment (MMSE score
<24) were not recruited in the PROSPER study. Inclusion and exclusion criteria
of the PROSPER study have been described in detail elsewhere.9 A total of 554
Dutch participants who completed the trial underwent MRI scans of the brain.
In this study we included 411 participants for whom data on baseline total CBF,
brain parenchymal volume and mortality was available. There was no signifi-
cant difference between characteristics of the included participants and subjects
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with missing values except for higher prevalence of coronary artery disease in
subjects with missing values. Since we previously reported that treatment with
pravastatin does not influence level of CBF, participants were included from both
pravastatin and placebo groups.10
Standard Protocol Approvals, Registrations, and Patient Consents
The institutional ethics review boards of all participating centers approved the
study protocol of the PROSPER study. The protocol was consistent with the
Declaration of Helsinki. The institutional ethics review board of the Leiden
University Medical Center approved the protocol for the MRI substudy. All par-
ticipants gave written, informed consent.
MRI Scanning
All imaging was performed on an MR system operating at field strength of 1.5 T
(Philips Medical Systems, Best, The Netherlands). Dual fast spin echo [repetition
time (TR) = 3,000 ms; echo time (TE) = 27/120 ms; flip angle = 90◦; slice thickness
= 3 mm; 48 slices; no interslice gap; field of view (FOV) = 220×220 mm; matrix
= 256×204], FLAIR (TR = 8,000 ms; TE = 100 ms; flip angle = 90◦; slice thickness
= 3 mm; 48 slices; no interslice gap; FOV = 220×176 mm; matrix = 256×153) and
susceptibility weighted images (multislice gradient echo sequence; TR = 2593
ms; TE = 48 ms; flip angle = 60◦; slice thickness = 6 mm; 22 slices; interslice gap
= 6 mm; whole brain coverage; FOV = 220×198 mm; matrix = 256×176) were
obtained from all subjects. The SIENAX technique was used to obtain estimates
of total brain parenchymal volume, gray matter and white matter volume. In
summary, SIENAX starts by extracting brain and skull images from the single
whole-head input data. The brain image is then affine-registered to Montreal
Neurological Institute (MNI) 152 space (by using the skull image to determine
the registration scaling), done primarily to obtain the volumetric scaling factor to
be used as normalization for head size.11 Segmentation of white matter hyperin-
tensities volume was performed automatically using software for Neuro-Image
Processing in Experimental Research (SNIPER), an in-house developed program
for image processing.12 This segmentation was based on the T2-weighted and
FLAIR images. Cerebral infarcts were defined as parenchymal defects seen on
FLAIR images with the same signal intensity as CSF and a surrounding rim
of high signal intensity following a vascular distribution. In addition, single
slice phase contrast MR angiography (TR/TE = 16/9 ms; flip angle = 7.5◦; slice
thickness = 5 mm; FOV = 250; RFOV = 75%; scan percentage = 80%; matrix =
256; 8 signal averages) with a velocity encoding of 100 cm/s was used for flow
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measurements.13 The scans were performed in a plane perpendicular to the left
and right internal carotid artery and the vertebral arteries, at the level of the
vertical segment of the petrous portion of the internal carotid artery.
Total CBF
CBF was assessed using an in-house developed software package (FLOW; Divi-
sion of Image Processing, Department of Radiology, Leiden University Medical
Center) on a workstation (UltraSparc 10; Sun Microsystems, Santa Clara, Calif).14
For this method a region of interest (ROI) was manually drawn around the ves-
sel in the magnitude image and copied into the phase images. For triggered
measurements a vessel contour was drawn in one heart phase and the software
copied this contour to the other phases. Visually, all phases were screened for
correct positioning of the ROI. If required, the ROI was adjusted. Flow vol-
ume is calculated by integrating the flow velocity values within these contours,
multiplied with the areas within the vessel contours. Total CBF was calculated
by adding flow from the left and right internal carotid arteries and the flow
in both vertebral arteries. Total CBF was expressed in milliliters per minute
(ml/min). We standardized level of total CBF by brain parenchymal volume
(ml/min/100ml) by dividing total CBF (ml/min) by each individual’s brain vol-
ume (ml) and multiplying the obtained result by 100.
Mortality
Participants were followed for occurrence of mortality until January 1, 2012 in
an average follow-up period of 11.8 years. We obtained dates of deaths from the
Dutch civic registry and specific data on causes of death from Statistics Nether-
lands, which assigns codes for all national death certificates according to the In-
ternational Classification of Diseases and Related Disorders, 10th revision (ICD-
10). Death due to cardiovascular mortality was classified as ICD-10 codes I00-I99
and death due to other reasons were recorded as non-cardiovascular mortality.
Other variables
At baseline a research nurse interviewed all the participants and data for their
demographic characteristics and medication use were obtained. Information
about history of vascular diseases was provided by each participant general
practitioner. Diabetes mellitus was defined by self-reported history, a fasting
blood glucose concentration of 7.0 mmol/L or self-reported use of antidiabetic
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medication. Blood pressure was measured in sitting position using a fully au-
tomatic electronic sphygmomanometer (Omron M4 R⃝). Body mass index was
measured using standard protocols. Global cognitive function was assessed us-
ing mini-mental state examination (MMSE).
Statistical analysis
Baseline characteristics of the study participants are reported as mean (standard
deviation) or median (interquartile range) for continuous variables and number
(percentage) for categorical variables. Differences in characteristics of study par-
ticipants in thirds of CBF were tested by analysis of covariance or Kruskal-Wallis
for continuous variables and pearson chi-square test for categorical variables. To
compare cumulative incidence of all-cause, non-cardiovascular and cardiovascu-
lar mortality in thirds of total CBF, Kaplan-Meier graphs were made and strata
were compared with log-rank test. We used Cox proportional hazard models to
estimate risk of all-cause, non-cardiovascular and cardiovascular mortality asso-
ciated with level of total CBF. Cox regression models were fit with time to death
as the outcome variables and total CBF as the determinants. We performed
our analyses in three steps. In the first step, analyses were performed unad-
justed. In the second step analyses were adjusted for age and sex and finally
analyses were adjusted for age, sex, cardiovascular risk factors and diseases in-
cluding body mass index, smoking, serum cholesterol, mean arterial pressure,
antihypertensive medication use, diabetes mellitus, statin treatment and history
of vascular disease (coronary, cerebral, or peripheral) at baseline. In the multi-
variate analyses, body mass index, serum cholesterol and mean arterial pressure
were entered as continuous variables and the other parameters were entered as
dichotomous variables. In addition, we performed a series of sensitivity analyses
to test whether our results were consistent in different subgroup of participants.
In these sensitivity analyses, we separately excluded subjects with diabetes mel-
litus, hypertension, high body mass index (>25 kg/m2), elevated serum levels
of N-terminal pro-brain natriuretic peptide (NT-proBNP) (>400 ng/L)15 as a
marker of impaired cardiac function, coronary artery disease, cerebrovascular
accidents (stroke or transient ischemic attack), brain infarcts, high load of white
matter hyperintensities (>5 ml) and impaired cognitive function (MMSE score
<28 points). All the analyses were carried out using SPSS software (version
20.0.0, SPSS Inc., Chicago, IL).
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Results
Table 1 shows characteristics of the study participants in whole study population
and in thirds of total CBF. Mean age of participants was 74.5 years and 55.5%
of them were female. Mean values for total CBF and total CBF by parenchymal
volume were 522.6 ml/min and 49.3 ml/min/100ml respectively. There was
no significant difference in socio-demographic, cerebrovascular and cognitive
characteristics of the participants in thirds of total CBF except that participants
with lower total CBF were more frequently male (p=0.016) and had higher body
mass index (p=0.041).
During follow-up period 195 subjects (47.4%) died, of whom 129 subjects
(66.2%) died due to non-cardiovascular reasons and 66 (33.8%) died of cardio-
vascular causes. Numbers of deaths in low, middle and high thirds of CBF were
80 (41.0%), 66 (33.8%) and 49 (25.2%) respectively. All-cause mortality rates in
subjects with low, middle and high total CBF were 52.1, 41.5 and 28.7 per 1000
person-years respectively. Non-cardiovascular mortality rates in subjects with
low, middle and high total CBF were 32.6, 27.0 and 21.1 per 1000 person-years
respectively and cardiovascular mortality rates in subjects with low, middle and
high total CBF were 19.5, 14.4 and 7.6 per 1000 person-years respectively (Fig 1).
Table 2 shows the risks of all-cause, non-cardiovascular and cardiovascu-
lar mortality in relation to total CBF. In the multivariate adjusted model, com-
pared to participants in the high third of CBF, participants in the low third had
1.88-fold (95% confidence interval (CI): 1.30-2.72) higher risk of all-cause mortal-
ity, 1.66-fold (95% CI: 1.06-2.59) higher risk of non-cardiovascular mortality and
2.50-fold (95% CI: 1.28-4.91) higher risk of cardiovascular mortality. Likewise,
compared to participants in the high third of CBF, participants in the middle
third had 144-fold (95% CI: 0.98-2.11) higher risk of all-cause mortality, 1.29-
fold (95% CI: 0.82-2.04) higher risk of non-cardiovascular mortality and 1.86-fold
(95% CI: 0.93-3.74) higher risk cardiovascular mortality. We found similar as-
sociations between lower CBF and higher risk of mortality when analyses were
performed using CBF as a continuous variable (data not shown). The corre-
sponding Kaplan-Meier survival curves showed that subjects with low total CBF
had highest cumulative incidence of all-cause, non-cardiovascular and cardio-
vascular mortality (Fig 2).
165
Chapter 11 – Cerebral Blood Flow and Survival in Old Age










































Figure 1. All-cause, non-cardiovascular (Non-CV) and cardiovascular (CV) mortality
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Table 2. Risk of mortality in relation to level of total cerebral blood flow
Total CBF, ml/min/100ml
Low Middle High
9.7- 45.7 45.8- 52.2 52.3- 84.8 P for trend
HR (95%CI) HR (95%CI) HR (95%CI)
All-cause mortality
Unadjusted model 1.98 (1.39-2.83) 1.51 (1.05-2.19) 1 (ref) <0.001
Age and sex adjusted model 1.82 (1.27-2.61) 1.41 (0.98-2.06) 1 (ref) 0.001
Multivariate adjusted model∗ 1.88 (1.30-2.72) 1.44 (0.98-2.11) 1 (ref) 0.001
Non-cardiovascular mortality
Unadjusted model 1.71 (1.11-2.62) 1.35 (0.87-2.11) 1 (ref) 0.014
Age and sex adjusted model 1.57 (1.02-2.42) 1.27 (0.82-1.99) 1 (ref) 0.040
Multivariate adjusted model∗ 1.66 (1.06-2.59) 1.29 (0.82-2.04) 1 (ref) 0.026
Cardiovascular mortality
Unadjusted model 2.74 (1.43-5.25) 1.96 (0.99-3.87) 1 (ref) 0.002
Age and sex adjusted model 2.52 (1.31-4.85) 1.76 (0.89-3.51) 1 (ref) 0.005
Multivariate adjusted model∗ 2.50 (1.28-4.91) 1.86 (0.93-3.74) 1 (ref) 0.007
Abbreviations: HR: hazard ratio, CBF: cerebral blood flow
∗ Adjusted for age, sex, body mass index, smoking, serum cholesterol, mean arterial
pressure, antihypertensive medication, diabetes mellitus, Statin treatment and history of
vascular diseases (coronary, cerebral or peripheral)
- Number of participants in each third is 137
We performed a series of sensitivity analyses on the associations of total CBF
with all-cause, non-cardiovascular and cardiovascular mortality separately ex-
cluding participants who had diabetes mellitus, hypertension, high body mass
index, impaired cardiac functioning, coronary artery disease, cerebrovascular ac-
cidents, brain infarcts, high load of white matter hyperintensities and impaired
cognitive function (Fig 3). We found that exclusion of subjects with cardiovas-
cular risk factors, cerebrovascular diseases and impaired cognitive function did
not essentially change the results. In another sensitivity analysis, to test whether
our findings are not due to short term death events, we excluded subjects who
died in the first two years of follow-up (n=12). This sensitivity analysis showed
that the associations were not dependent on short term death events (data not
shown).
Discussion
In this study we showed that lower total CBF is associated with higher risk of
all-cause, non-cardiovascular and cardiovascular mortality in older subjects at
high risk of cardiovascular diseases. These associations were independent of
168













































Figure 2. Kaplan meier curves for all cause, non-cardiovascular and cardiovascular mor-
tality in thirds of total cerebral blood flow (ml/min/100ml).
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prevalent vascular diseases (coronary, cerebral, or peripheral) and cardiovascu-
lar risk factors such as hypertension, diabetes mellitus, obesity, smoking and
hypercholesterolemia.
Despite the fact that multiple systemic and cerebrovascular mechanisms act
in concert to maintain optimal CBF, total CBF decreases with increasing age.16
Decrease in CBF has been implicated in the pathogenesis of neurodegenerative
disorders such as dementia and certain cerebrovascular events such as low flow
infarcts.17, 18 A recent study showed that lower total CBF is an independent risk
factor for mortality and adverse clinical outcomes in patients with heart failure.19
However, little is known about the independent role of CBF in the maintenance
of health and survival in older people. In the current study, we observed that
lower total CBF in older subjects at risk of cardiovascular disease is associated
with higher risk of mortality.
Different explanations can be proposed for the association of lower CBF with
higher risk of all-cause, non-cardiovascular and cardiovascular mortality. First
explanation could be that lower total CBF in older subject is related to lower
metabolic demand of the brain due to parenchymal atrophy which indepen-
dently puts subjects at higher risk of mortality.20 Since in each participant we
normalized level of total CBF for brain parenchymal volume, this explanation
seems unlikely. In addition, we observed that exclusion of participants with im-
paired cognition, which is closely related to a decreased in number and activity
of neurons in the brain20, did not materially change the associations between
CBF and mortality outcomes.
A second explanation might be that lower total CBF reflects the presence
of vascular risk factors and pre-existing vascular pathologies in the brain and
heart21-23 and that themselves rather than decreased CBF are responsible for in-
creasing risk of mortality in older subjects. In line with this explanation, we
found that subjects with lower CBF tended to have higher blood pressure and
body mass index. Previous studies also showed that vascular risk factors such as
hypertension can lead to a decline in CBF.24 We observed that the adjustments
of the analyses for cardiovascular risk factors and diseases did not essentially
change the estimates and the sensitivity analyses showed that the associations
between total CBF and mortality outcomes were not dependent of presence of
impaired cardiac functioning, history of coronary artery events, cerebrovascular
accidents, cerebral infarcts and white matter hyperintensties. Nevertheless, the
possibility of residual confounding from unmeasured cardiovascular risk fac-
tors cannot be excluded. We observed that correction of all analyses for various
well-established cardiovascular risk factors only slightly influenced the associa-
tions. Therefore, we expect that if we could account for potential unmeasured
confounders, this would result in minor changes of the measures of association
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between lower CBF and higher risk of mortality.
A third possible explanation involves the critical role of adequate CBF in
maintenance of brain structure and function.1 There are different lines of ev-
idence indicating that lower CBF is associated with structural and functional
abnormalities in the brain.17 Since the brain is a vital organ in regulation of
homeostasis25, it is likely that suboptimal CBF, via neuronal injury and cell
death, independently alters normal function of the brain leading to an increased
risk for mortality.26 It has been shown that neuronal damage is not only asso-
ciated with structural and functional changes in the brain but also with distur-
bances in the immune system, energy homeostasis, autonomic stress response
and endocrine regulation.27-30 As it is not possible to make a causal inference
solely based on our observation, this hypothesis needs to be tested in future
studies investigating the long-term consequences of suboptimal CBF on major
homeostatic mechanisms.
The main strengths of this study include a long follow-up time of 12 years
and availability of extensive data on various socio-demographic and cardiovas-
cular factors. A possible limitation is the inclusion of older subjects with or
at high risk for cardiovascular disease which limits the generalizability of our
findings to a general population of older subjects. However, the study popula-
tion represents a substantial part of the aging subjects given the high prevalence
of cardiovascular diseases and risk factors in the elderly. As another limita-
tion, we only assessed total CBF and were not able to investigate the association
between regional CBF and mortality outcomes. Future studies, using arterial
spin-labeling MRI perfusion techniques, might unravel whether there is any as-
sociation between regional CBF and cause-specific mortality in old age. In addi-
tion, we assessed total CBF with an in-house developed software package which
needs further validation in the future studies.
Our findings show that lower total CBF standardized for brain parenchymal
volume, independent of cardiovascular diseases and risk factors, is linked with
higher risk of all-cause, non-cardiovascular and cardiovascular mortality in el-
derly subjects at high risk of cardiovascular diseases. These findings need to be
replicated in future population-based studies with larger number of participants.
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Increasing life span and decreasing birth rate have given rise to a rapid in-
crease of the aged population in many countries, both in absolute and relative
terms1. This demographic transition has resulted in increasing number of older
people with disorders linked to the accelerated brain aging such as dementia2.
Different lines of evidence from epidemiological, pathological and neuroimaging
studies indicate that exposure to cardiovascular risk factors are closely related
to structural and functional changes in the brain3. This cumulative evidence
on the role of vascular factors in acceleration of brain aging has been reflected
in the statements by the American Heart Association / American Stroke As-
sociation (AHA/ASA) and the National Institute of Health (NIH) emphasizing
that cardiac diseases and vascular pathologies should be considered as poten-
tially modifiable risk factors for cognitive impairment and dementia4. Despite
achievements in the understanding of the brain structure and function, the mech-
anisms by which cardiovascular factors contribute in brain aging are not fully
understood.
The aims of this chapter are to (1) review the key findings of this thesis in
the context of current knowledge and evidence (2) present pathophysiological
models on potential contribution of cardiovascular and hemodynamic factors in
development and progression of brain aging, (3) address the methodological is-
sues and (4) provide directions for future research.
176
Lowering blood pressure: a double-edged sword for the aging
brain
Higher midlife blood pressure increases risk of cognitive impairment and stroke,
whereas studies on late-life hypertension have shown mixed findings5, 6. There
is a complex interaction between blood pressure and the brain. Long-lasting
hypertension damages cerebral vessels through hemodynamic stress and puts
subjects at high risk for cerebral small vessel disease and stroke7. Once vascu-
lar pathologies are established and the brain tissue is extensively damaged, the
brain fails to play a central role in regulation of blood pressure8. If this situa-
tion coincides with a decrease in cardiac function, a drop in blood pressure may
further decrease brain perfusion and accelerate brain aging9. In line with this no-
tion, life course studies have shown that men who develop dementia experience
a steeper increase in systolic blood pressure from midlife to late life, followed by
a steeper decrease in late life10. The dynamic connection between the brain and
blood pressure has made it difficult to give a single answer to the clinical ques-
tion whether lowering blood pressure can protect the brain in late life. A limited
number of clinical trials investigated the effect of antihypertensive medications
in prevention of dementia and stroke in the oldest old. Most of these studies
showed some benefits11, 12. However, such trials generally recruited healthy par-
ticipants with low levels of co-morbidities and frailty. This has raised a concern
whether findings of these studies can be generalized to general populations of
very old people in which functional disability and multi-morbidity are relatively
common13. In the second and third chapters of this thesis the association of high
blood pressure with risk of cognitive decline and stroke in very old subjects is
examined. The findings indicate that higher blood pressure is not associated
with adverse brain outcomes. In addition, in subjects with disability, high blood
pressure might be even beneficial. These results possibly imply that the biolog-
ical age rather chronological age should be a basis for treatment of high blood
pressure in older people. In very old people with higher degrees of frailty and
morbidities, higher blood pressure might be needed to ensure perfusion of dif-
ferent organs including the brain14, 15.
Limitations of the hypertension hypothesis in old age: signifi-
cance of variability
Although hypertension has been recognized as a strong risk factor for cere-
brovascular damage, current evidence shows that the predictive value of high
blood pressure for stroke attenuates with age6. Based on the common hypoth-
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esis of hypertension, the main determinant of blood pressure-related end organ
damage is higher levels of blood pressure. However, recent data suggest that
other parameters such as blood pressure variability also contribute in increas-
ing risk of vascular events16. Blood pressure fluctuates around average values
over short and long period of times. Exaggerated minute-to-minute and di-
urnal blood pressure variability has been mentioned as a cardiovascular risk
indicator17. Apart from short-term blood pressure variability, a substantial vari-
ation in blood pressure exists when a subject is observed over months with
repeated clinical visits18. Recent studies have shown that visit-to-visit blood
pressure variability, independent of average blood pressure, is associated with
higher risk of stroke, carotid artery atherosclerosis and cerebral small vessel dis-
ease in older subjects19. In the fourth chapter of this book, it is demonstrated
that higher visit-to-visit blood pressure variability has a strong relationship with
cognitive impairment, manifestations of cerebral small vessel disease and lower
hippocampus volume. Higher blood pressure variability might reflect a long-
term hemodynamic instability that puts stress on the vascular endothelium and
leads to alterations in brain structure and function. Furthermore, increased fluc-
tuations in systemic blood pressure might result in repeated episodes of cerebral
hypoperfusion causing neuronal injury and accelerated brain aging19. Increase
in age is associated with a decrease in cardiac function, alternations in the me-
chanical and the structural properties of the vessels and diminished activities
of blood pressure regulatory mechanisms20. Therefore, it seems that standard
blood pressure measurements are not adequate for the evaluation of cardiovas-
cular risk in older people18. Most of the current guidelines put emphasis on
reduction of blood pressure in older subjects and less attention has been paid
to management of blood pressure variability16. Further studies are needed to
evaluate whether strategies to lower blood pressure variability can contribute in
preservation of the brain structure and function in older subjects.
Blood pressure dysregulationn, cerebrovascular dysfunction and
brain aging: A pathophysiological model
Normal regulation of blood pressure is necessary for adequate organ perfu-
sion and prevention of vascular damage. In the presented pathophysiological
model, hypertension, hypotension and blood pressure variation contribute in
cerebrovascular damage and promote cerebral hypoperfusion (figure 1). Hemo-
dynamic stress imposed by hypertension damages large and small cerebral ves-
sels and results in endothelial dysfunction. Impaired function of the vascular
endothelium leads to efflux of abnormal proteins and waste metabolic products.
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Figure 1. Pathophysiological model on the role of blood pressure dysregulation in brain
aging
In addition, neurovascular unit loses its capacity to adjust the regional perfusion
according to the metabolic demands of neurons. Long-lasting cerebral hypop-
erfusion results in neuronal enrgy crisis which ultimately lead to neuronal cell
death. Extensive brain tissue damage may perpetuate the situation by further
dysregulation in blood pressure and cerebral blood flow.
Impaired cardiac function: an emerging risk factor for brain ag-
ing?
Experimental studies in animal models have shown that chronic cerebral hypop-
erfusion results in neuronal energy crisis, glial cell activation, accelerated amy-
loid beta accumulation and blood brain barrier disruption which all contribute
to development of neuronal dysfunction and injury21. Likewise, human studies
have revealed that lower cerebral blood flow is associated with higher risk of de-
veloping white matter lesions and brain atrophy22, 23. It is known that the heart
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plays a pivotal role in generation and regulation of cerebral blood flow24, 25.
Despite activities of multiple regulatory mechanisms, it has been shown that
patients with New York Heart Association (NYHA) class III/IV heart failure
have about 30% lower total cerebral blood flow compared to healthy controls26.
On the other hand, interventions to improve cardiac functioning such as car-
diac transplantation have been shown to restore cerebral hemodynamics to the
normal levels24. Patients with congestive heart failure frequently present with
cognitive impairment27. Decline in cerebral blood flow and hemodynamic ab-
normalities have been suggested to mediate the association between congestive
heart failure and cognitive impairment25. A large prospective study showed
that congestive heart failure in older people independent of cardiovascular co-
morbidities associates with higher risk of dementia28. Recent reports suggest
that not only presence of congestive heart failure but also a graded decrease
in cardiac functioning might be a risk factor for brain aging29. Findings of the
chapters five, six and seven of this thesis show that the association between car-
diac function and impaired cognition is not limited to patients with heart fail-
ure. These data suggest that a graded decrease in cardiac function as reflected
in cardiac hemodynamics and serum NT-proBNP level, a marker of ventricular
dysfunction, is associated with cognitive decline in general populations of old
and very old subjects as well as in older subjects at risk of cardiovascular disease
without heart failure. In line with these results, role of the heart-brain axis in
brain aging has been suggested30. Long-lasting decline in cardiac functioning in
interaction with pathologies in the systemic and cerebral circulations results in
chronic brain hypoperfusion (figure 2). Chronic brain hypoperfusion gives rise
to neuronal energy crisis and this ultimately leads to neuronal cell death. This
cascade of events may put subjects at risk of accelerated brain aging.
Cognitive impairment in old age: a red flag for future stroke
Postmortem and neuroimaging studies have confirmed that not only patients
with vascular dementia but also patients with Alzheimer’s disease carry a high
load of brain vascular pathologies31. In this thesis, it is demonstrated that pa-
tients with Alzheimer’s disease and vascular dementia have a pronounced dis-
turbance in their cerebrovascular hemodynamics (chapter eight). Accordingly,
it has been suggested that cognitive impairment might reflect covert brain vas-
cular pathologies, predisposing subjects to higher risk of stroke32. A number
of longitudinal studies have investigated whether cognitive impairment is as-
sociated with increased risk of stroke and whether cognitive assessment can
be considered as a tool for identification of subjects at high risk of stroke33, 34.
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Figure 2. Proposed pathophysiological model on the link between abnormalities in the
heart-brain axis and accelerated brain aging. Long-lasting decline in cardiac functioning
in interaction with pathologies in the systemic and cerebral circulations results in chronic
brain hypoperfusion. Chronic brain hypoperfusion gives rise to neuronal energy crisis
and this ultimately leads to neuronal injury and cell death. This cascade of events renders
subjects vulnerable for development of accelerated brain aging.
181
Chapter 12 – Key Findings and General Discussion
Most of these studies reported that middle aged or younger elderly subjects with
lower cognitive performance were at a higher risk for developing stroke. In the
ninth chapter of this thesis, we showed that lower cognitive function measured
by mini-mental-state examination (MMSE) was associated with risk of first-time
stroke in the oldest old. Furthermore, MMSE score appeared to be a better
predictor for stroke when compared to the well-established Framingham stroke
risk score. Collectively, available data suggest that older subjects with cognitive
impairment should be considered among high-risk groups for development of
future stroke.
Vascular endothelium; roles in regulation of cerebral blood flow
Cerebral autoregulation is the inherent ability of the brain to maintain a rel-
atively constant level of cerebral blood flow despite fluctuations in perfusion
pressure35. Changes in cerebral vascular tone play a key role in regulation of
cerebral blood flow. Vascular tone in the cerebral circulation is regulated by
several mechanisms36. One major mechanism involves endothelial factors37. En-
dothelium produces and releases potent relaxing and contracting factors that
regulate tone of underlying vascular muscle and may also influence vascular
growth38. Cardiovascular risk factors such as hypertension and diabetes have
been linked to a decline in cerebral perfusion and it has been postulated that en-
dothelial dysfunction due to chronic exposure to these risk factors is responsible
for a decline in cerebral blood flow39. In line with this hypothesis, data pre-
sented in the tenth chapter of this thesis demonstrate that two serum markers of
endothelial activation (von willebrand factor and tissue plasminogen activator)
are associated with lower levels of cerebral blood flow. Given the critical role of
cerebral perfusion in the maintenance of brain structure and function, preserva-
tion of the vascular endothelium can be a potential approach for delaying brain
aging.
Cerebral blood flow; a determinant of survival in old age
The brain has an extraordinary metabolic demand40. This high metabolic de-
mand is met by adequate and constant levels of cerebral blood flow that de-
liver energy, nutrient and oxygen to the brain41. Normal function of the brain
is crucial for maintenance of health and homeostasis42. The brain is involved in
regulation of stress response, circadian rhythm, endocrine system, fluid and elec-
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trolyte balance, body energy expenditure and several other key pathways that
act in concert to keep our body in a steady state43, 44. It has been shown that
animal models with a state of hypoperfusion live shorter and develop weight
loss45. In human, development of stroke is associated with disturbances in auto-
nomic control, impaired sleep cycles and immune response46, 47. In the eleventh
chapter of this thesis, the association between cerebral blood flow and 12-year
survival in older people at risk for cardiovascular disease is investigated. The
observed associations of cerebral blood flow with all-cause; cardiovascular and
non-cardiovascular mortality might highlight the importance of cerebral perfu-
sion in maintenance of health and survival in older people. Interestingly, all
these associations were independent of socio-demographic and cardiovascular
risk factors. There are a limited number of studies investigating the link be-
tween decreased brain blood flow and mortality. For instance, a recent study
showed that lower cerebral blood flow is a strong predictor for mortality in pa-
tients with heart failure48. This finding might further highlight the importance
of sufficient cerebral blood flow in maintenance of health and survival. Strate-
gies to slow down decline of cerebral blood flow might decelerate rate of brain
aging and improves survival in older people.
Methodological considerations
Scientific background, accurate observation, experimentation and applicability
have been regarded as the fundamental elements of clinical research49. In this
thesis, we build up our hypotheses based on the current evidence on the link be-
tween cardiovascular factors and age-related disorders of the brain. While find-
ings of this thesis are in line with growing evidence exist supporting a role for
vascular factors in brain aging, cardiovascular aging can be a cause or an epiphe-
nomenon for brain aging50, 51. Hence, further life-course studies are needed to
show the temporal relationship between dysregulations in cardiovascular sys-
tem and changes in the brain structure and function. Such studies might unravel
how early life events influence the susceptibility of the brain to cardiovascular
and hemodynamic abnormalities. Findings presented in this thesis come from
three well-establsihed cohorts of older subjects. Despite strengths in the design,
inclusion of participants and availability of a wide range of variables, observa-
tional nature of these studies limits causal inference from the results. Therefore,
interventional studies are needed to test whether correction of cardiovascular
and hemodynamic abnormalities can decelerate process of brain aging.
It is important to keep in mind that the translation of findings from clinical
studies to clinical practice has been always a challenge52. While clinical studies
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usually look at outcomes in a population under study, in real life clinicians need
to make decision for individual subjects. In this thesis we emphasized on the
associations independent of sociodemographic and cardiovascular factors which
might serve as potential confounders. Nontheless, large proportions of older
subjects have multiple cardiovascular risk factors and co-morbidities53. These
cardiovascular factors might individually or in interaction with each other con-
tribute to brain aging. Further sophisticated analyses are waranted to account
for cumulative contribution of multiple factors in development and progression
of brain aging.
Future directions
Despite major efforts have been made, our understanding about etiology of ab-
normal brain aging is still limited. Current evidence indicates that the brain
aging is a complex and multi-facet phenomenon54. This complexity has been
reflected in the etiology of age-related disorders of the brain like dementia. It is
well-described that a combination of factors act in concert in the pathogenesis of
cognitive impairment and no single mechanism can explain the pathologic fea-
tures observed in the brain of patients with dementia55. In this setting, studies
which targeted specific brain pathologies, such as amyloid β deposition, have
failed to show any improvement in cognitive function56. Future studies might
be needed to focus on strategies which cover multiple aspects of brain aging.
It has been shown that long-lasting cerebral hypoperfusion promotes oxidative
stress, activation of inflammatory pathways, endothelial dysfunction, and amy-
loid β deposition21. Therefore, optimization of brain perfusion by prevention
of pathologies in the heart-brain axis and neurovascular unit might modulate
pace of aging in the brain30. In addition, findings of this thesis suggest that the
association between cardiovascular factors and features of brain aging, like cog-
nitive performance, might be not only age dependent but also functional status
dependent. This calls for future studies investigating individualized approach
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Chapter 13 – Summary/ Samenvatting
Summary in English
The structural and functional integrity of the brain depends on the adequate and
constant supply of energy and oxygen through cerebral blood flow. Hence, fac-
tors playing role in generation, delivery and regulation of brain blood flow may
contribute in the pace of aging in the brain. Accelerated brain aging presents
with pathological changes which impair cognitive function. This thesis aimed to
show that cardiovascular and hemodynamic factors are related to the structural
and functional features of brain aging. Findings of this thesis might open new
avenues in prevention and progression of the accelerated brain aging.
Chapter 1 provides a background on the demographic, biologic and cardio-
vascular aspects of brain aging. In Chapter 2, we showed that higher blood
pressure is associated with lower cognitive decline in very old age. This associa-
tion was more prominent in older people with higher disability in their acticities
of daily living. This has brought us to the next step to test whether levels of
cognitive and functional disability moderate the association between high blood
pressure and stroke in very old age. The findings presented in the Chapter 3 in-
dicate that higher blood pressure is associated with lower risk of stroke in very
old subjects with higher degrees of disability.
Chapter 4 expands our current knowledge on the association of higher visit-
to-visit blood pressure variability with impaired brain structure and function.
Previously it has been shown that increased blood pressure variability is related
to higher risk of stroke. Consistently, we showed that visit-to-visit blood pres-
sure variability might put subjects at a higher risk for accelerated brain aging.
In Chapters 5, 6 and 7, we focused on the association between level of cardiac
function and brain aging. We observed that a strong association exists between
a graded decrease in cardiac function and lower brain volumes and cognitive
performance. Furthermore, we observed that in very old age, subjects who have
both low blood pressure and left ventricular dysfunction have a higher risk for
cognitive decline. These findings support the hypothesis that strategies to pre-
serve cardiac function might also prevent abnormal brain aging in older subjects.
Disturbances in cerebrovascular hemodynamics have been implicated in the
pathogenesis of cognitive impairment. Several studies have investigated whether
patients with dementia have a lower cerebral blood flow and higher cerebrovas-
cular resistance. In a meta-analysis (Chapter 8) we demonstrated that in patients
with two most common forms of dementia; Alzheimer’s disease and vascular
dementia have profound disturbances in their cerebrovascular hemodynamics.
However, the severity of disturbances was higher in patints with vascular de-
mentia.
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Chapter 9 deals with the identification of very old subject at risk for stroke
using cognitive assessment. This chapter shows that in late life, conventional
cardiovascular risk factors loss their predictive value while impaired cognitive
function better predicts risk of stroke. This finding highlights that the assess-
ment of cognitive function might be an easily accessible tool to recognize older
subjects at risk of stroke.
In Chapter 10, we showed that increased serum markers of endothelial dys-
function are associated with lower levels of cerebral blood flow in older subjects
at risk for cardiovascular disease. This is in line with previous lab findings in-
dicating that endothelial cells play an important role in regulation of cerebral
blood flow. Furthermore, it supports the hypothesis that cardiovascular risk
factors accelerate process of brain aging, through ptomotion of the endothelial
dysfunction and decrease in cerebral blood flow.
The brain is a key regulator of homeostasis. Previous studies have shown
that subjects who carry a higher load of cerebrovascular damages have a shorter
survival indepenet of cardiovascular risk factors and diseases. Given the signifi-
cance of cerebral blood flow in the maintenance of brain structure and function,
in Chapter 11, we showed that older subjects with lower cerebral blood flow
have a shorter survival. This observation merits future studies investigating
how preservation of cerebral blood flow influence health and survival in old
age.
Chapter 12 reviews the key findings of this thesis and discusses them in the
context of current knowledge and evidence. Based on the findings of this thesis,
we suggested pathophysiological models on the contribution of cardiovascular
and hemodynamic factors in development and progression of brain aging.
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Samenvatting
De structurele en functionele integriteit van de hersenen is afhankelijk van een
adequate en constante aanvoer van energie en zuurstof via de cerebrale bloed-
toevoer. Factoren die een rol spelen in de productie, afgifte en regulatie van
cerebrale bloedtoevoer kunnen derhalve bijdragen aan de snelheid van hersen-
veroudering. Versnelde hersenveroudering presenteert zich met pathologische
veranderingen die de cognitieve functie beperken. Dit proefschrift heeft als doel
om aan te tonen dat cardiovasculaire en hemodynamische factoren gerelateerd
zijn aan structurele en functionele kenmerken van hersenveroudering. De bevin-
dingen in dit proefschrift kunnen mogelijk nieuwe paden openen in de preventie
van versnelde hersenveroudering.
Hoofdstuk 1 verschaft een achtergrond van de demografische, biologische en
cardiovasculaire aspecten van hersenveroudering. In Hoofdstuk 2 laten we zien
dat een hogere bloeddruk geassocieerd is met een lagere cognitieve achteruit-
gang op zeer hoge leeftijd. Deze associatie was meer uitgesproken in oudere
mensen met ernstigere beperkingen in hun dagelijkse activiteiten. Dit bracht
ons tot de volgende stap, waarbij we testten of het niveau van cognitieve en
functionele beperkingen de associatie tussen hoge bloeddruk en beroerte op
zeer hoge leeftijd beïnvloedt. De bevindingen, zoals gepresenteerd in Hoofd-
stuk 3, tonen aan dat een hogere bloeddruk geassocieerd is met een lager risico
op beroerte in zeer oude personen.
Hoofdstuk 4 verbreedt onze huidige kennis over de associatie tussen een
hogere variabiliteit in bloeddruk, gemeten op meerdere momenten, en beschadigde
hersenstructuren en functie. Eerder was reeds aangetoond dat een toegenomen
bloeddrukvariabiliteit gerelateerd is aan een hoger risico op beroerte. Overeenkom-
stig deze bevindingen hebben wij aangetoond dat bloeddrukvariabiliteit mo-
gelijk een groter risico geeft op versnelde hersenveroudering.
In Hoofdstuk 5, 6 en 7 hebben we de aandacht gevestigd op de associ-
atie tussen het niveau van cardiale functie en hersenveroudering. Onze obser-
vatie was dat er een sterke associatie bestaat tussen een graduele achteruitgang
in cardiale functie en lagere hersenvolumes en slechtere cognitieve prestaties.
Daarnaast vonden we dat op zeer hoge leeftijd personen met zowel een lage
bloeddruk als linker ventrikel dysfunctie een hoger risico hebben op cognitieve
achteruitgang. Deze bevindingen ondersteunen de hypothese dat strategieën die
gericht zijn op het behoud van cardiale functie mogelijk ook preventief werken
tegen abnormale hersenveroudering in oudere personen.
Verstoringen in cerebrovasculaire hemodynamiek zijn betrokken bij de patho-
genese van cognitieve beperkingen. Meerdere studies hebben onderzocht of
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patiënten met dementie een lagere cerebrale bloedtoevoer en hogere cerebrovas-
culaire weerstand hebben. In een meta-analyse (hoofdstuk 8) laten we zien dat
patiënten met de twee meest voorkomende vormen van dementie, de ziekte van
Alzheimer en vasculaire dementie, uitgesproken verstoringen hebben in cere-
brovasculaire hemodynamiek. Echter, de ernst van de verstoringen was meer
uitgesproken in patiënten met vasculaire dementie.
Hoofdstuk 9 behandelt de identificatie van zeer oude personen met een ver-
hoogd risico op een beroerte, door gebruik te maken van cognitieve beoordelin-
gen. Dit hoofdstuk laat zien dat, op hogere leeftijd, conventionele cardiovas-
culaire risicofactoren hun voorspellende waarde verliezen, terwijl een beperkte
cognitieve functie juist het risico op beroerte beter voorspelt. Deze bevinding
onderstreept dat de beoordeling van cognitieve functie mogelijk een eenvoudig
beschikbaar middel kan zijn om oudere personen met een verhoogd risico op
beroerte te identificeren.
In Hoofdstuk 10 laten we zien dat verhoogde serum markers van endotheel
dysfunctie geassocieerd zijn met lagere niveaus van cerebrale bloedtoevoer in
oudere personen met een verhoogd risico hebben op cardiovasculaire ziekte. Dit
komt overeen met eerdere bevindingen uit laboratoriumonderzoek, wat aangeeft
dat endotheelcellen een belangrijke rol spelen in de regulatie van cerebrale bloed-
toevoer. Daarnaast ondersteunt het de hypothese dat cardiovasculaire risico-
factoren het proces van hersenveroudering versnellen door het bevorderen van
endotheel dyfunctie en een afname in cerebrale bloedtoevoer.
De hersenen spelen een sleutelrol in de regulatie van homeostase. Voor-
gaande studies hebben aangetoond dat personen met een hogere accumulatie
van cerebrovasculaire schade een kortere overleving hebben, onafhankelijk van
cardiovasculaire risicofactoren en ziekten. Uitgaande van de importantie van de
cerebrale bloedtoevoer in het onderhoud van hersenstuctuur en functie, laten
we in Hoofdstuk 11 zien dat oudere personen met een lagere cerebrale bloed-
toevoer een kortere overleving hebben. Deze observatie vraagt om toekomstige
studies, waarin onderzocht wordt hoe het behoud van cerebrale bloedtoevoer
van invloed kan zijn op gezondheid en overleving op hoge leeftijd.
Hoofstuk 12 vat de belangrijkste bevindingen van dit proefschrift samen en
bediscussieert deze bevindingen in de context van de huidige kennis en bewi-
jzen. Gebaseerd op de bevindingen in dit proefschrift hebben we suggesties
gedaan voor pathofysiologische modellen, waarin de bijdrage van cardiovas-
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